var title_f38_17_39184="SCLC normal CT";
var content_f38_17_39184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT negative PET positive Paraneoplastic disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 71-year-old man presented with a polyneuropathy thought secondary to a paraneoplastic syndrome as he had a high PQ type calcium channel antibody present in serum. CT showing a normal sized hilar node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39184=[""].join("\n");
var outline_f38_17_39184=null;
var title_f38_17_39185="CMV pneumonitis 1";
var content_f38_17_39185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Cytomegalovirus pneumonitis in an immunosuppressed patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 175px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A and B) Acute cytomegalovirus pneumonitis in an immunosuppressed patient. Patchy ground-glass opacities are&nbsp;visible bilaterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Webb WR, Muller NL, Naidich DP. Infections. In: High-resolution CT of the Lung, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39185=[""].join("\n");
var outline_f38_17_39185=null;
var title_f38_17_39186="Sulfanilamide: Drug information";
var content_f38_17_39186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfanilamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/29/32211?source=see_link\">",
"    see \"Sulfanilamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10360990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AVC&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10501437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Vaginal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10501478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Vulvovaginitis due to",
"     </b>",
"     <b>",
"      <i>",
"       Candida albicans",
"      </i>",
"     </b>",
"     : Intravaginal:  Insert one applicatorful intravaginally once or twice daily; treatment should continue for a period of 30 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AVC&trade;: 15% (120 g) [~6 g/applicator]",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F247519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of vulvovaginitis caused by",
"     <i>",
"      Candida albicans",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10501475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Local: Sensitivity reactions (burning, discomfort)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F247521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfanilamide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F247510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Blood dyscrasias: Severe reactions, including agranulocytosis, aplastic anemia, and other blood dyscrasias, have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic reactions: Severe reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic necrosis: Fatalities associated with fulminant hepatic necrosis have occurred with sulfonamides (regardless of route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Topical antifungal agents or oral fluconazole are generally considered to be the preferred treatment for uncomplicated vulvovaginal candidiasis (Reef, 1993; Pappas, 2009; Sobel, 2007). Sulfanilamide is not recognized as a preferred or as an alternative agent for the treatment of uncomplicated vulvovaginitis candidiasis in the available literature.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10571867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F247514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10501438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies with sulfonamides, including sulfanilamide. Sulfonamides cross the placenta and distribute to amniotic fluid. The fetal concentration is 50% to 90% of that measured in the maternal blood. Because of the theoretical increased risk for hyperbilirubinemia and kernicterus, neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10501439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10501440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorbed sulfonamides are transferred to breast milk and have caused kernicterus in the newborn.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (AVC Vaginal Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15% (120 g): $184.06",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F247508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with microbial folic acid synthesis and growth via inhibition of para-aminiobenzoic acid metabolism; exerts a bacteriostatic action",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, &ldquo;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/17/39186/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reef SE, Levine WC, McNeil MM, et al, &ldquo;Treatment of Options for Vulvovaginal Candidiasis, 1993,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 20(Suppl 1):80-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/17/39186/abstract-text/7795112/pubmed\" id=\"7795112\" target=\"_blank\">",
"        7795112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sobel JD, &ldquo;Vulvovaginal Candidosis,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 369(9577):1961-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/17/39186/abstract-text/17560449/pubmed\" id=\"17560449\" target=\"_blank\">",
"        17560449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sobel JD, Faro S, Force RW, et al, &ldquo;Vulvovaginal Candidiasis: Epidemiologic, Diagnostic, and Therapeutic Considerations,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1998, 178(2):203-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/17/39186/abstract-text/9500475/pubmed\" id=\"9500475\" target=\"_blank\">",
"        9500475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15617 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39186=[""].join("\n");
var outline_f38_17_39186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10360990\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501437\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501478\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247518\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247519\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501475\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247521\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247510\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300095\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10571867\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247514\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501438\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501439\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501440\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323471\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247508\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/29/32211?source=related_link\">",
"      Sulfanilamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_17_39187="Pyoderma gangrenosum early";
var content_f38_17_39187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early lesion in pyoderma gangrenosum presenting as a pustular and violaceous plaque with incipient breakdown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39187=[""].join("\n");
var outline_f38_17_39187=null;
var title_f38_17_39188="Bilevel airway pressure";
var content_f38_17_39188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilevel positive airway pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Philips Respironics V60 (Murrysville, PA) is a bilevel positive airway pressure ventilator designed for acute administration of noninvasive ventilation. It has a graphic screen, an alarm system, an oxygen blender capable of delivering high inspired oxygen concentrations, and an internal battery that lasts up to 6 hours. It can deliver up to 40 cm H2O airway pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Philips Healthcare. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39188=[""].join("\n");
var outline_f38_17_39188=null;
var title_f38_17_39189="Med bronchogen cyst CXR V";
var content_f38_17_39189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56360%7EPULM%2F53262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56360%7EPULM%2F53262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a mass in the right tracheobronchial angle that mimics an enlarged azygos vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a low attenuation, non-enhancing cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39189=[""].join("\n");
var outline_f38_17_39189=null;
var title_f38_17_39190="Intraosseous cannulation technique";
var content_f38_17_39190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Intraosseous cannulation technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 631px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJ3AioDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6K8YeJ4fDFvYSSWF9qEt9dfZIYLPy95fypJCSZHRQAsTd/SsVPH9y/wB3wX4kP/bSw/8AkqoviwcT+Df+w03/AKQ3dYehR+INautfex1fRtOsdMvFtQLrTZJ2I+zwzF2cXCADMpGMcAdaTGjpP+E7vMZ/4QrxJj/rrYf/ACVVX/hZL7Qf+EO8SYPH+ssf/kmsLwVfah4306e98L+NfDt9bQymGRh4euYyr4Bxte6BxgjnGD+BpdGnk1XwnoWuTxRpNfWUNzOsQIRWeNWOASTjJPc1E5SSuioKLdmdCvxCnZdw8GeJNvr5lh/8k04eP7kjI8F+Jcf9dLD/AOSqy4Zg7CKP7g/Wru/5hGp4HWs/ayNPZIsDx9dEZHgrxL/38sP/AJKpP+FgXP8A0JfiT/v5Yf8AyVSudiqo6mmKuWxR7Vi9miQePLsjI8FeJMf9dbD/AOSqT/hPrrP/ACJfiT/v5Yf/ACVUrkImKgByaFVkHs0L/wAJ9df9CX4k/wC/lh/8lUf8J9df9CX4k/7+WH/yVQSKCRT9qw9mg/4T66/6EvxJ/wB/LD/5Kpf+E9uv+hK8S/8Afyw/+SqQU4nil7Vh7NCf8J7df9CV4k/7+2H/AMlUf8J9df8AQleJP+/th/8AJVITTR1pe2kHs0PPj66HXwV4k/7+2H/yVTf+FgXP/Ql+JP8Av5Yf/JVOxkc03aKPbSD2aD/hYFz/ANCX4l/7+WH/AMlUo8f3J6eC/Ev/AH8sP/kqkxT0Tmj2zD2aAeO7w9PBXiX/AL+2H/yVTh45vT/zJPiX/v7Yf/JVWIkzgVYEeO9ZvEyRSpIof8Jvff8AQkeJf+/th/8AJVNbx3eL97wT4lH/AG0sP/kqtNVHrTJwoU8ZrP63Psh+xRln4g3A6+C/Ev8A38sP/kmk/wCFhz/9CZ4l/wC/lh/8k1FcsASPyqsXwMmq+tTfQHRii7/wsSf/AKEzxJ/38sP/AJJpp+I0o6+DfEv/AH3Y/wDyTVSLJznvT2jJHSpeLmuiD2MR4+JxM4hHg7xKZMZxusv/AJJqldfGOztbmS3m8LeJFmjOGUGyOD9RcYrO1ueXT7W4uLZQZkjOMjOPevNLVmlcu7FnY5YnqT6124WTrJyl0OPFT9i0o9T2C2+Ldvctth8J+JGP1sh/O5qyfifjr4P8Sf8Afdj/APJNcB4eULcDjtW5K3BBrqjTTOV4mSOgPxSUdfCHiT/vqy/+SaT/AIWon/Qo+JP++rL/AOSa5joMk0ytFQizJ4ya6I9P8FeKrfxZZ301vY31i9ldfZJobwR7w/lxyZHlu6kbZF7+tcpYfF22v7G3vLTwp4lkt7iNZonzZDcjAEHBuMjgjrU3wW/1Xi7/ALDQ/wDSK0ryzw5NcxeAPCqWDwx3NzHplmkk0ZkRPOeGIsVDKTgOTjI6da87FVJUmow6u2p7ODpxrRcp9FfQ9U/4Wkv/AEKPiT/vqy/+SaUfFFT/AMyh4k/76sf/AJJrz/XpYtB1W/0/U/HGnR3WnrHJd7PCt7KlurgFGeRJyig5HJNaV/Y6pomu6Ta3mq6dqlpqVlcXUclrYvblfLaADkzSBgRMfToKwnUxEIuTSN4U8NOSim/6+R1x+KKjr4Q8Sf8AfVj/APJNMPxXiHXwl4k/76sv/kmuamPymqUh4rn+v1Oy/r5nUsvp93/XyOub4uW6/e8J+JPzsv8A5JqBvjPYKMt4W8SD8LP/AOSK4ybkGse7TBNNY6o+iD+z6Xd/18j1zSviZ/atuJtP8IeIpo923PmWCkH0INyCPxrVXxZqjdPA3iT/AL/6f/8AJVeB6frF14f1JbyzbK5HmRHpIPT61774V8T2Ou6fDc2cnDjlW4ZT6GuqliXPc4q+G9m9Nhs3i3VIYXlk8C+JQiKWY+dp5wB1/wCXqsib4oiGISSeD/EojP8AEDZEfpc13Nw2+0lUHcWRl/SvMNKIezRXAPy4INbOo0ZQpqW5rw/E8ToHi8IeI2X1D2P/AMk1IfiU44Pg7xL/AN92P/yTXOXWly2ztPpjhGPJiflG/wAKdaXon/dzRtBcL1jb+YPcVPtWaOgt0bM/xWjg/wBb4R8Sr+Nkf/bmkT4sQyEBPCXiQ5/2rL/5JrIu7dZ1OR9awArWlx5Tfd6qar2jJVKLO/T4ku/3fB3iQ/8AA7H/AOSalHxBuD08F+JP+/lh/wDJNc3ps27mtmJ84pe0YexiX18eXbdPBXiT/v7Yf/JVPHji9P8AzJPiT/v7p/8A8lUyE9KuxDdyTxSdVh7GJVHje+PTwT4k/wC/un//ACVQfG98vXwR4k/7+6f/APJVaAA/hAHvSlkToNzVDryH7GJn/wDCbX+M/wDCEeJcf9dbD/5Kpp8cXo6+CfEn/f2w/wDkqtBmlccJgepqLYehO4+1T9YkP2ESn/wnd5jP/CE+JMf9dbD/AOSqgn+Is1uMzeDfEijp/rLE/wDtzWjNtiXLnnsK5/xBk2hcjBDA4/GlLEzS0RUMPBtJlg/FAf8AQoeJP++rH/5Jph+KiDr4R8S/99WX/wAk1zudy5qvL3rm+vVOy/r5nWsvp93/AF8jp2+LMC9fCXiQfjZf/JNRt8YLVevhTxJ+dl/8kVxs9Z1xTjjqj6Iby+n3f9fI78/GWxHXwt4k/wDJP/5IpjfGrTl6+GPEn5Wf/wAkV5pKapy8nAruo1XUdmctXDQgrps9Sb446UsgjPhrxIHPbbaf/JFWo/jFaSDKeFfEp/8AAP8A+SK8Wgj87UixGQDj8q6m1GBzx6V7UcFTau2zwKmMnGTSSseteEviHaeJNfGkLo+r6fctayXaNeeQUdEeNWAMcrnOZV6gd67avEfhr/yVOz/7A17/AOj7Ovbq4a9NU5uKOyjN1IKTPP8A4uHEng4/9Rpv/SG7ri57bX9R8AfEjTvCVp9p1W/1ZLVR5qRCON7G0EjksR0Xd05yRXafFtDJL4OVcZOst1/68buuXGg2q3tzOZ9XtpblxJMLPVrq2R2CKgYrHIq52oozjsKwur2N7O1xPhR8Ptf+HfxAuoYktLvwzqOmwrNcWsYt1huYRsXMTSuxLKCWYcFmzgYrV+Gq7vhx4TBAIOkWuf8AvylLb+HLCZfl1LxJn/sYb/8A+PVt6ZY2+l6fbafYxeVZ2cSQQx7i21FUKoyeTgAdaG7glYoX1q9qXlt0Hlt1A/h/+tTbL5I/MlIx1+tbUnzxFWGVPBFc/f27WjqGctCTx7VhOFtUbQlfRl6F/MLStwO1WYQQpdup6VnWcwlIBGI05PuatvPuPH3azKY6Qlj7U5FwMmmbwoy3SgO8x4GFpiA8mnBaY7BeAcmjccdaAJMYNLxUO807PGaWoElCjNRBvWnFxRYZKfakA9aarcdaXcM0WAkVaftwQaj8xVBJxUSzPOSI+F9TQMvxShTjPNSNMAM5rOkKQcscseg9ajaRyMsNq+lZuBaNAXIPeopJ8jrWb5hYkL+dG4jkk/QVDplWFueTmoFXJBI57D0qUsXP9KnDwWUBmuSPYdz7Cs7comLb2uE3yEKo5JNVpdUshlYJBO44xH81ct4tXWdXVWikaDT15a2XhmHqT3+nSodOdIYlRNwQDHFCi5b6Iajpc2r1vMdjKACwxsznA9689WzNrqE0IGFVzj6dq7RX3HI6fzqrNZ20t0Hk3CV8Dg8cV04Wp7KTT2Zx4ylzxTXQq6UhSUMPStRlZmBClvoKnS3ijGIl6dc12uiW8U1jG6ovp0r0HiPZrRHnRw/tHqziIrKaZtqrhvRu9aEPhm7cZeWFPzNXp1a2v3KjAVv610infGr54bmsZYyp0Oupl1OCT3MT4U2hsbjxlblw5TWV+YDGc2Fof615D4Y/5EvwN/186J/6U21e0fD3/kL+N/8AsNJ/6b7OvHvCVjDqHw+8PQXPmbPsNnIDFK8Tq6KjqyuhDKQygggjpXNi525Jy73O/Awupwj2sX/iL8P9e1bxv49u4fD+pX9trFjbQadNbalFBCJkjA3TxmZd6BgDtZHzg4HOa6HxVa31nqvgO11aSGXUYNCvI7mSFdqNIrWIYqOOMg9h9BWQNNb/AKC/iT/wf33/AMeqSDSoYL1Lx7jUrq5SN4Ue91G4utiMVLBRK7BclEzj+6Kzq4yFSDikzWlgqlOak2ixcH5apSGrdyegqjKeTXnHqoryms66XOavy81TuBlaaFcw7iMOSCK7HwBLaxaXKimWK9gJCsAdpBOck/jXKyD95XX+CohJHd22zLylTnsB3r0MKrux5+N+G6PVdNu7lbZDdLgcjI9vWuE0hj5QJOSSSfzr022hUWscTc/L3715jbwm0Yqd23PGa6ZKyOOm9TbjIPBqG902O5ToNw5BHakt3U45NX4mA75rO9josc25uLF9twrPF/fxyPr/AI1FqFvHd25eMgnqpFdRPGkqkOMiufvNNkt5Glsmxk5Mbfdb/CqT7EOJnaNMQCr/AHgcGuitnziuUEwS8OVMb/xIf8810NjJuANKLuElY3oWzir8ZAFZUL45zWjakEgmhgi4AXwoGBVhEVAB1psJLnCLU7BIRmU5bso6ms2DdiJkZ+OgqpNKkRKRDzJfQdvrUt1K0ikM3lR+ink/jWfvCgrAojX+8RzUDSEk2x/vLhtz9h6Vja03mWU2eDjNaDlFYnmSSqOqwsLGTf8AfdSQPQUNXGnZmBaJ5iU6a24OKXSDuJFaU0fHSuOUbM9BTOZuoCAayLoFSQa6u5jHOa5S9ffKzDpnj6URWpd7oz5TyahK7YpJT0UZqaTrUi2TXluI0cICwLE9xXq4Wykrnm4yTUHYoaJDmUuRk4rdBwOvStXSPDEUa/NcSHdyQq9K6K30LTY1HmRFj6u+K+hWKpxWp8y8LORj/DJ93xSs/wDsC3v/AKPs69wrzHw/DbQfFDR0tEjQDRdQyF/672XWvTq82vUVSbkjvo0/ZwUWcP8AExN+oeClPfWX/wDSC8qvc2uQRzVz4ijOq+CB/wBRp/8A033lW5IsjpXBXdpI7qPwnMgy2z5/h9RWtaXiyj5uuKS5tjyQKzniZGynyn07GlGt3HKl1Rvbz0HcZ4qrewJcQiJhnNVrS72sFc8jjBrSyHRSoGM9a3TuYapnISNLYBozG0nzYUDvV61dgA8wzJ2jB6fWretQLOUSM4kBzms60kSEFZchwcYAyTXPOPKzeMro0o0aRt0p/wABT3lJ+SDp3NQ+aZAPMPlr2jHLH60uXcbUGxP1pLUYpKxnn5nNGSeW4poCpwPmalCk8twKoQ4NSGTJqF2x0+7UbyD1osIslvSkD4qqshY4HNWB8o560ASeYaQzelQMxJqOW4jiIH3m7AUnoUkWQGkOXOF9Kf8Aaiw8q0TJ7nsKzvMMpzKxIPRE/qanBbZtDiFfRep/Giwy2WitTumYyXB5x1qNmmuTukBUdlqFJ4LdeCC3sMk/jSm4nlHyRlF/vGkUifBUdQo9KA3oPxqrvCfeYu/tUsdtPc4MmY4uuKTQ7iiX59luvmS9+eF+pppiLXC7yJrj1I+WP6CrccWR5Fmv1Iq2EgsItpw0p5OOpNZtpA2VGh2pjqO5PeuY1Wx+zSGaLIjY/MPQ+tdUxeQ7n4HoKpXKBlKsMg8EGsW7O41oc5H0Heqd1OEukIzhcZIPIqxqJ+xMQxwh5Un0rGjfzm3K5Ys/QetXFXdznxE7Rsdem1jkMTkDv2rsPCshazdGUrsbgE9jXHxbxEABhsAGt/wpMwv5o2ONw6H1FejOPunl0p2mO8SJ5d3nqHHStTS3EumxMD0GPpVbxTAWSKYA5B28e9N8MOptpoMFWU7iD71hKOh7c/eoJ9hvw9/5C/jf/sNR/wDpvs68u8E28kHgTw00i/K+mWzKfrEtepfD7jV/G/8A2Gk/9N9nXOfD+2jn+GPhMSKGB0i06/8AXFKjFQ5qcURhKnJJsyV609qmvrRrScryUJ+U1Wc4BzXlNOLsz2E1JXRWmOWNUZTyasyHOaqSGhFkD81BOPlNTOcE1XmbitEiG7GVPxKK9E+GkG+MPjmaTk+qr0rzbUpfJjeTGWA+UepPAH51674Etvsen2YP3o4Vz9TXfhotJyODFyTSR6PbxkHOBjHFcJH5E1zcxp80ayttJ7jPB+ldRr2qx2ekTSo37xx5ceP7zcA/h1/CuMslZYUCZJUcE9a2qPTQ4oQb1LMtgYjuiztPalQEDkVcsrxJiYnwsyjlD1+o9qllhU8qOa51I6FJrRlIOQOaikIbrVh4jnpUUkRHatEwepga7p8c8Ykx8685HWq2kTlcRsfmH61uzJwQRxXN38T2tz5iZ20PR8yLWqszqbZjNIFTnHWuhtIEjTdMwAHvXI+HrxTDuJy7E4H9a6OJ9+GkOT2HYUNt7EKLbsbCT7hthGxR/FjrSMowck5PU1Wgcv0PFTnG3nk1NrFOKRXmZF6LuaqbEsxaTr0Cirki5PHyj1qFdqBmhUHHWRugqA6EJVLWJppsbuw9/Ss2QNcF2fkkc+wqSffdXACksB3P86mvAltbLDHzK/J+lBCOW0ZdtwynscVvTR/LWbYKDqE7JyN56VsS/drCotTrizndYHlWczd8YrjZ67fX1zp8v4H9a4e4qEtTeD90ptycVPZ3jpd+TCqnbySagHD5PbmptDhZ7gyYzmTBz7GvUoRucVWPO7M7IvP9iaV3Y4GSBxV7wzbCa2a4cbnLYyafqMSppEpxyBwBWh4URW0hVQgncc47V2Ne7c8dv95Yo+GX3fFyxAzhdHv16f8ATeyr1avK/DyFPjHar2/si/I/7/2deqVB0VElKy8vyON+IIzrHgf/ALDT/wDpvvK1CtZnj/8A5DPgf/sNSf8ApvvK18cVy1/iNKWxXaMHtVC6tQwOBzWoRUUi57VgzdM5m5t2+jDoaksb0geVJwRxWtcwAjOK5/UoWhk81e3X3FaU6ltGRUhzao0bFRJeyMRu9KydaRf7TOCw2rkhTjitLRbhQ0hYjkDBp1pBHPfyyzlcOCASegreS5lYwT5XczbOZdmIx+NW8s33jx6VT2rb3skSOGjz8pBzxVvcAOMn61gb7kqKAMngU123dfu00vx81Rs+TxTE0JJ0NVCrO4VeprSigaVd3Cp3Y9KrXDqmUtvxc96OboITcluNq/M/c0ivu5JquQEjaSZgqKMlj2qvYXB1F5NilLVTtXPV/f2HtSlJRdupcIOWqLMksk7FLVc9i56D/GiLSWY7pZGZj1xxWvZQquAAAPStNYV9OetXGKauym+XRHJz6dLGMpNID6E5FUpBKrfMJZB3wwrtp7cOhworn7yAxuQVNKSitUVF33M6K+igwHtZl/2sZq4moQyDJSXb7g0wAHg0gjWJweQvcr1FZp+Y5RtsaNvdQkDykjB/2jgVZa5gx++uDJ/sRLkfnVWFWZA8Ukcq+pUGrKysvBiT8Kq1zK44X7GPy7SHyl9epNJDbyyPuKNn1YUv2twMK7J9BVWaRnPzyuw92qHEpF66mgtoyu8PKewrNLFh83WmExqPlXmmPJ1I5rKUQMzXIhNaTLjLYyK53R086YPtYJGQQpFdPetkKPU1k6YsrFoGCoY3IzjGR2rbCRTlZnDjrqKaNhZmYqBF06Zq5ok62+qJIXLZ6j0zVBWWNfm3Fx71LENxBxh8cD1r0nG6seUpWdzvdYhE+nSj0G4Y7YrnvDtwF1Lbu3b8ruIrodOlFzp0LOQS6cj3rlGi/s/UCVBVUk7DqK5raH0OFaqU5Q7mx4BGNa8cg/8AQaT/ANN9nWB8OG/4tp4SH/UItP8A0SldB4CYNrXjdhyDrMZH/gvs65b4byY+G/hXn/mE2n/olKisrxRjR3ZuXVusyNuUMD1rmNTs3tRkfNH2Pp9a6+JuOlQXVskgKkAq3auOpSUkdtKq4PyOAk6VWkPWtfWrA2UgK5MTdPY+lY0veuJpxdmekpKSuitIeKrSHippD1qtIa3grmc9DGu1+1a3YWYzt3iV/wADwPz/AJV7ro8fk2e4LwSFz9AK8X8OxrNrbXbc/vCq/ReP55r1/wDtHZpXlRriWUYXHb3r1eT2cEjyKk+eTsVb6Y6heKyM6xQkqoU5DHPWrVrxgFj+IqC0hESj19BWgisRllwPeuaUjaOgy4tVmCyIQJUO5SOoNS210WCrLwSOG7H/AOvQ8iRj3rIS/B1J7cwlrUrudx1R88YrJyKcXI6AgHmonAPeoY5ihCSNuU/cf+9/9enk/NVR1MtURSxgjGKytQtN8TLWwZE3BWYAn1qKePI9q0Uh8xymikQXbIcnPQCu1sUL4Pluf+Amuf0+2Uak7Ddx6HFdpp5AUcNn61mp2Rcp2ehNBBIV4jKj34qRoFQEyOo/WrixKy9W/Oo3gj/uHP1pN3MvaXZlXLRjs0gHY8Csq6nlnZY+ufuxoOPrXQzQRngx5+rGsfWNTi0uILEiLK3AwvT61O+xad9Bh22EIaUjzD0TPJNZcrSBZbmYb/4mwRwKgjc3EvmSvvdu7H+VRaw3l2TKrY3kIRVWtoaKFtx2hbpAXPVjmtt/nXa3XsaoaNGI7davP7VTV9B9TH1SHzLWaP8Ai2kV59c9K9NvRnDevBrzzW4fIvZU7ZyPoa5bcsrHVTd0zHPXHdjitaC3W3uyr8Yw3171Ss1DXcAIyDIBXQ6xAq3aPkqWXGR04r2cNG6bOOMv3vKzr50E+kSBed0ZOfTik8GODazx5HDAgD0p+iN5+lJ0wUx/SqPhOQ22qy2zEbWyBnrkGt94M8equSqvuL9jFs+L+ltgDfol+f8AyPZV6NXCRrj4q6G3rouo/wDo+xru6zZs3c4z4hHGr+CCP+g0/wD6b7ytaN6yPiKSuq+CCOv9tP8A+kF5WsgEi5HDVy1l7x0Ul7pIVzyKYy8VImVbFOZeORWDRpcpsOCDWfd229TnkGtd0Ofaq8iEg1my07nGyo1nLsKsUJ+UgZx7VLG7sMmNivoRWvf2+4HjmktYA6BgPY1oqzSF7GMilL5E9rtVFWROQMVVjklYYCdP7pzWxNajdkdfWsqQGCQrNGCOxq3NT1RmoOGg9I5GI3FUHuatIkUK7iN59W4H5VXjmAHyKq+9OJ3HLEk1Luw3C4mkn6nCjoOlUppEhRnkYKijJJ7CrEr+lcT4y1F3misYj+7Pzyn19B/WhyUI3RdOm5yUR2o6rJqM+FJFsp+RP73ua6rSIvItkTuBz9a4nRU83UIVPRfm/IV3dlytctK8m5s9CtaEVCOxfWQrjFTRagVYZ65qqOuKqvlXPsa3nJqOhzqKb1N1r8kcYAqjeSiQ5PWqwfI60xmzWDqtlqmkQTYDcd6Ady0yQgyfTmpY1+UVdFvUJlSSMq++N2jb+8hxVK41m606NpLxvNhTq4XkD1IFacwxmsfV9raZd7gMbDitZrqiIpN2ZpWurR3USyRurIwyCpyDUxnyOK8evr2/0nM2myhSOTE4yj/h2+ortfC+svq+mQXQhCmQfMobO09xRTqc24VaPszqDJjGWy1Iznv8o96iRZFUu6+Wo6kjH6mqdxdjny8knofWrkjC5O0olvVXPCjOKqtbumqMy5KOgbGe4PNULO4YasuSSDlT7musfTy2mi4cZZDj8KjDX9ujmx0P3WpUUhQHCtyMHI7U2ZySoR+R0x3qSLLIu9vkXOM9qaFU/Ku3IOVavYseHfQ6rwhMz2brIRlH49s1W8RxBL/ec/MoI54qDwrM0V88LNlXGQM8ZrT8UKn2RHJA2nvXPJWkz2cvnZr7ir8K3Mlz4xYnJ/tiMflYWYrlPh0SPh74X/7Bdr/6JWuo+En+t8Y9P+QyvT/rxtK5b4dMD8PPDHtpdr/6JWsqmyNl/EkdVFLhfepVO6qSnmrcQz0rFo0GapZreWEkZHzY4Pp6V5tcK0cjo4wynBFep4O3FeeeKkWPWZgvcAn64rixEep24Se8TDlqpcNtjdvQE1ak71Uuh/o03rsb+VFHdG1XYm8F2ckvkhAfmG9m7AGvTrS3t41G4s7AYya5vwhaNa6PbBhskdAz+vTpXUwRsy4+6v8AOvSxFXmlpseXCnoWEkUHC8D2FSkiRcN0piIFHFU724eIhYwWY9AK45SNkrEGoS/Zg/BbjIx1PtTbCLyYxuVjI/zOcdzQInklDyE8dBV+Jdi9KhXLcrIBGHjYIAyn+Gqct8tuNtwsgI77Sc1ppg5deo+8B/OotRKJaySuAVVSavzJVnuYP/CT6fJdm0WG5kk25OI/lH4k1I946DfbJOq9djrkfz4pNF06OIPOyL50p3Nnt6CtGcBImyOcUeZo4RWxl+H9SW81IssbrtbY4Yev869AtAgAOa4XQYAJ2cActniu2tfuipS91GNSK5tDVjdQvWmyzRgHLVXDYGKrzvtGTk+wqrGSppsLu5VYzt6muVu2EtyWbkk1p38hkX5TjHUd6zWhYgSDlf5VUdGbRSTHKIsYkRSh68Vj6iImuooYJGdc7yCc7fStN32RO4AwqkmsHQ1aadpXHLHNRJ9TdI6C2PlqB6VcByKodGNXYjwKVJ3RM1qRzAFCD+FcV4wgKNDNjg5Q/wAx/Wu0uThTXLeL2zpKZ/56jH5GnOCepVOVnY5K2YrcW7KM4lXP0ziuw1WNWt0c/wALd64uM8H17H0Negwqt5pnY70zz616eEaaaOSteFVSLnhOUiOSLI2/fAB9abqSjT9cjm2ja53ZHHPes7w5J5eoInRWypx61teKIQ1rFMRnY2CfTit4btHHj4WlzL1L0B3fFHQW7HRdRI/7/wBjXeV5p4duTdfEHw8xIyui6ip+onsa9LrF6ERd1c4r4jf8hTwT/wBhp/8A0gvK04TjpWZ8RjjVPBOf+g0//pBeVoR8HrXNW+I66Hwl9PmAp/Iznn6VDC2asdRwazepTImG76VC6cVZK85HWmOBgZ4rJoaZn3EW4His5JPszuhHytyD6GtyRBWZfW+5Dx+NZs1iyv5gY5Ug1HcxiaFlYckcGqcUDq3DNke9XopGA/edu9Gq1Rckmc+jkHB7VYV+OafdW+4+ZEBz1FUySowciulo5YtMbfTlE2x8yNwPauB1xgNbdAchEUE+p5JrtLp8ZbPNcdrdmwmNyD1PP0rKovdOrDu0y7oPy6lGP7ysP0rsbR9vHeuU8Lp5s8jfxCPA/GukRgDhxtb9KilsbVn7xqCQYyahdg5J9uarhgR/rBUkcbScKCE7k962aTVmYp6jRIR05HqKGlJ6UT2fzEqCpPcHFR/Yycbix+pricdTe4MSB9anVwF4NViGjypXKenp9Kbuj/vEfUGumMeVWMm7j7h+OKxPETmLTggB/esAT6Ac1sAg/cUu3bjArM8RRH+zmDcsGDGlUdolUvjRwWpw+ZERiq3g8z2bXcZDfZvMypH8JI5/CtWVabpEstrqcgTaFeMcFcg81NHXc1xD906OBzPtUF3PYZJq24ELBWYGY9cfwD/GqjX07JsjZIwevlrj9aq2l7DJdG3tz5si8vjkfTPrWknbRHnt9yqhePVGhUkAS5A6/j+Ve0LCj6GFjz80WQffFedjSjFNHeum0ldv0ru9BuDNYKN2Ng2kHvXVh6XIuZ7jxjVSkpI5eNi8WwoFwe/WgZDc8FRgsOmKdqoEF3NETtdWynPGDzUKyBmVyAXI/A16B83Zp2J7JzFqsDx87HGSO4rs9WiWfT5UcLnGRmvPbqYxlXjGMHJxXb2s7Xdgi5zvXk+nFYVXZpnbg5cr0KXwiAEnjEDAH9tL0/68bSuH+H8rL4C8NAHj+zLb/wBFLXdfCaLyZ/GceMbdaA/8kbSvKvAbuvgzw/tyf+Jfb8f9s1qfZ853SqqFST8zuhPIDxxVi3vipwzj86x4FecgbGz6ZyKvxQR2w82cjd2A7Vm6fQr2y7GvLqK28QY5eRugri9Vtp7m4kn3bpHOSD/StiWUzSbjwo6D2poOeoDLSlh4TjZjp15QlzI4ydWjYq6lWHY0lrEJp44yMhmAP0rsJ7WK4Uo6q49G6j6Gs8aObedJbQlyrA+VIcH8DXMsM6b01R2/Wo1FZ6M6awjUIOK0kBA54rKtbgR43KVI7GrTTPcL+5X5fXpTkhKyRYeRj8sQyfXsKiMMi/NkMx6kinQWrAZZgPYVYFuO7MfxrJohu5XRsdVwalyNmamESJzt596zNWvBEFQHkmpbsJLmZKs5iJdTx3HtUEl6l5mFSBFnLEnr7CqyTM67YxkHqx6VPZWkUMMcYhUgfxHrmpWppZLVl6NQF+XFU9VcJAc8E1cSNMEbTuH8JNY2p3EbypANwbPKntVyfulRd2aGhJ8i+tdRb4ArC01QqrgVuQYxzV2toZbu5Y3noKq3LY78+tTPKAMLVKeQEGgRRv2zGAOpNVdPjW2YCJyiHrG5yp+meRUt2291C9qjmZNmD1pO1i0jM8UTtbKI4OBOcA+g703SYhDbjA5xWdqEz6hqMSRYaOAYz1yT1/pWvFFNtAyFHoBisqj6GsFZErZHXuc1YWQBeDVfJQbWUsvb1FMLR/3m/I1rCPKrEN3dyS4k3cCuZ8ZK/wBkt8Y8tXO7644/rXRAlv8AVKSfUjpWZ4kt92lTJ1YDf+I5pTdkVT+JHBrwa6/wle+ZZtC5yYjgeuK48nFWdEvvsWqBif3cg2N7VvhZtTRGLheDfY6ic/Y9QzDJ827eox2rspCl9pjjIO9M4HrXJ6jF59usiAM6nqO4rR8P365MDkA/wj+Yr0paO5y1f31JPqtyHwQ7n4o6fGxyF0e/I/GeyH9K9fryrw7a+R8YbJ1P7uXRb5gPQ+fZ5r1WoqW5tDgpJxjZnFfEf/kJ+Cf+w0//AKQXlXYyMbTVH4kf8hPwT/2Gn/8ASC8q0H9Otcdbc7qHwl2JvbircZDAVnRtuFXIjgVmjVosHAphYY6jn1p+Mik21MkZoruTnAHHoKgmxg5P6dKuleDiqsg5IOM9M1k0axZlGMCYj1qQxjPSpZ1CsGAxjrUe/caXQ2WxREA8xo/yqG609woJFXoxvvlA9K6AwqygMoNd9KPPG7PNqe7KyPP57BDkOgasPxFY28OjXMiRhXCjB/EV6hPpkLnIUVwnxFgS20ObbxudQPz/APrVFanyxbNaE26kV5nJ+FWKytg4Oz+tdasgYjegPvXEaBL5d0mTgN8tdjE6kckV5nPyvc9edNyd0i+hQf8ALOpt+RwMCqaSoP4l/On+fH/ez9BQ6vdmapS6InLmo3c9aaZ0x3/FTVX7bBNNLDFNG0sWPMRWBZMjIyO2RS509mN05LdFkyg8EZpoZCf9WKaqY5NHAp8zJshzyqnCqMmsXXW3WUxJ7D+dZ82jagXwPFetHHrFZ/8Axion8N31ypE3ifWTF15itOT/AN+Kb16iT5Xexhy96o3k/wBlkjl8kylU6Bsd6u674ZuLNEeLxDqzbmwQ0dr/AEhFYUmlXU155B1zUW2hQfktsjPP/PKtqUVbcmtUur2NnSNTn1i5FvawGIDrnniuh0rQRoOrJcSLnzT8wxxVDT/Dd3p11EqeI9WhIwMpDadD9YK39Y8Nak1n5n/CV61JsG4borPp+FvXqUqMYPueZjL7x0R2F5F9qsCseFYDcAK5Pwz4206TVGsFOrS3WF/cHS7lCu7OzcWQBQcHDMQODzwa0/BMFxFEXuNa1HURt2CK5S3VF9wY4lbP1JHtXPX+k3kHivxPcC3xDd2NvFbPvHzMvn7h14++vJ9frVvsVQl7SHIupsapqMOpazNbC2uba7toIJJ45gnyeaGKrlWILDYwODj0JqtamR1lUpLCI5Ci+ZtO8YB3LtY8c45weDx0zxF94K1SfTJIpfDjT30mjada2d/5sGLGeJGEjEl94IJU5QNnGOlV9W8PapPLeQT6Yt1aT6pLcvtitZptvkxqjIJ8oAWVgeN2Og5q1J2PNq01znoEx243fM3c9K6/wnd+fZhCv+rG3mvOfB1jdaf4U0u01AFbuCBUkRnDkYJwCRweMdK7jwfOBeSwgDlc4HsamaurhSfLOxs/DkY1Xxvxj/idIcf9uFnXmHgWbTrbwH4be5ukDHTbYlFOT/ql4wOa9S+Hv/IX8b/9hpP/AE32dfPfhGI/8InohHexgP8A5DWuerPkR6dCkqsndnp41iJkIskUJ/eP+FU5pZ/mlSQyHqQf8K5FDJE25GZT6irkeqTrgSfNjuOCKqlXg9JaBVwlSOsNfzOittRjfiQeU36Uup6ibOFJIVWZy6gxo3zuD12+/f8ACuTutf8AJ/dyW7ybzgO3y7fqQD/KsrQ9Pk1DUGe4sbbUEeQhpJNyui/3g4AVh2AHNdDh1Rzxv1PT1lSay+02g88Mm+PYQN/HAyema81Hxw8OQXUlpqljq9pPExjkSWBcow4I4Ynj6V3+kNZWlstpaxrBFESAqHIB6n+deefFj4YReJtUsNX05ALkzxRXyxkL5sJYAuD/AHlH5j6c5tDUux6L4U1+x8VaUL3SvPktGO1TcQtET67SevpkcZrooJkjIRgUxxg15NFYeMPAoRdKc+KPD8Q2rayYS8t0HQI3STA7dewArrvCXjzRvE6GKyn/ANKjz5tjdL5c8ZHXKHnj1GRWM6aZtCod4hDAENke1KzleFBY+prJSVeTay7HH/LOQ8H6N/jSS65FCRDcYglJA+fgc965Z03HU6ITjIsXV00YzIwAqilmt9eCe4GY1HyJ7+p/wrTgt45VEm8SE/x8H8qsQ2oiJbII+lc/K2bXtsVxFGoxtCj6UKFTgdKtZByD1BqOUADNWlYncido2UK7FWH3XFYt4qzaxG+QXRcMR3q7M3nKyqpJB4IHeqFhFIL+VpQAx7Zzik9WgWlzpbFcKK0kbAxVG3wqirikMOK2JTFkIxyKqySKc+gqw/TBqlqEojtyccngUmMoTSrvJXjbgYrG1q92r5MR/euOMdvepdQultomlc8cHjvWPp8cl1OZpeWY5+ntUyfKjWMTZ0W1SKEFhzWruC9BUUChYwKV3UDrXM3fUscZFPUCmlkzxGKiALEntT8YoU2FkEsuxeBWXqjbrWct08tv5Vcun4wOtV1TzDk/cHX3p3bBaHnM6PGoMiOuem5SM1Sk/wBYvavTNbthdabOhUMdhK57ECvMpe2fWumg7NMJv2kWjrfC2pGRPs0hJccAnuK0bmGSwuRLDwjHgjtXJWIkglSReqnORXotsBqOlIybSWAZfZhXt1I2fkzxcJXs7Mm8Lzi4+JWiyDvouocen7+yr1KvHfAhI+KGnoc4XR788+pns8/yr2KuZ7mlWPJNpHEfEr/kI+Cv+w0//pBeVOD3qv8AE04v/BR/6jT/APpBeVIDkCuWt8RtQ+Esxt0P6Vchk9OKzkbpzVuFqyub2NJGyOKcQSKghbFWRyKrdGMtGNOAMD8qryLnO7gVYK0xlwOetYyQ4uxnXCcHHpWX5wANbMwJB7CuSuJ9s8qn+FiKhbHQma+mPuvkNdVjiuQ0YkSxM3fmuxyNoPtXo0dI2POqu8myMrwa8y+LTFNNt0z96YH8ga9EvL6KBDkjP1rz7xnaf8JEtvFDcCFY3Ls2zdnjGBSxGsGkaYVfvE3sedWvEefxrqdHuvPgzn94vDD196WPwYUjxHqMhbHG+MYz+FZkSXOjakIr1ApI6r9119R/hXkyi47nt3jNWW51tu4dc1ZU1RgwDkHg1ZV+eTSMGTk8Vzuv+H4NRuo723lex1WNcR3kIG7H91weHT/ZP4YPNbxYEGqrS5JxRcLHOWWvzWd5FpviGNbK+kO2GZMm2uj/ALDH7rf7Dc+m7rW68jEdvwqvf2FvqdpLbX8EdxbSDa8ci7lYfSuKvLvUvDc5itmn1PRUblT89zAO4B6yp7H5x6t0pcqe2hopSfxK53MY3SgHp396sXGVUFao6Ze2up2MF7p08c9u/wB1kOR7j2PYjtVuV8rggg1N7aSE4c2sNTI8Rp5umq3911P9K47SUM3jKWMAYZlX64ArrNYugES1/iZgT7Cub8NLnxPFO5xtl3dOtd2HXMtDz8ZJ04q56Vr1gyQxzqACAFJFX9JC3WmhWJ3AFWBrU1OETaVIAMnbmsbwy582aIkbcZFem2ZfHR9Cho4NpqklrjG48E9K0dfhIgWUFhjg1V1yNrTU4LgDIJzWzdN9osyCAd68H0olo+Y5MLPknbsZ2l3Ba1aJnJZPfPBrB1DfDfPGpZnPIzwBV7SCVvRGP4xgin+JYkjdXKZLrtB9DTp7lY6HK7oxN7MrBnOSOdorU0S5W2vIHy3PB4x1rN3ZwyAfMuCMdKkOQMYQOuCMd61aurHmp2d0d38O23ar42JxzrMf/pvs68M8GID4O0L/AK8IP/Ra17Z8LJfPufGMmc7tXj/9N9nXjngmPPgzQT/1D7f/ANFrXm4nZHvYHVsvGIHtUb2wIrQ8qgw8VyXPSMWSArSLPJGNpZto7A4rWeDNVJ7b2rSnWlD4WZzowqfEi3Z6shVI5lUqowMcEfT/ACa1o71BtNo7PI3SIDDH8K4+WIqadBcyRHAPGc11wxSfxHFUwTWsDvortXOJAUcdcD+lYHi7wZoviRftN5A8V/GMxX9mfLuEI6YYdfoc1FY6zgqs4D+m48/ga0EvnZ3kVljhA+UZyfxPT8Bmt9HqjkcXHRlhY/I0uKJpZZTHEse+Y5kc4Ay3qx7+9Zmo3FsmlyQ6gFMAYLlgWAbn8R9RUj6nb3MqJOSFc/K6f4Vg+KoLq72R2BW8somLTGE5YH0I/wA9aPIi5vaZJeaRYNcaddeZbtLuCyNvQ5HTf/jg10mieMrHUH+zXYNnedNjn5WPsa8etNU1DSnaSAtDvYs0TDKkehB68U+fUdP1RsToNOuT0aPJjJ+nUfhXz9bE2qy5GfpOE4fVbCQ9tHVrdbr1XX8/Q97mP8SkUwv5sYyOO9ea+ANV1JNQTTNQl862cHypFbcDj3r00qNvHQeldFKftFdHy+Y4GeBrOlJ36prqis8oiB4wB0rM06QPdlj1dqreJfENnpSeW2Zbhukanp7k9qx/BuvDUdQmtpUWKUfvIwDncvf8v616CwVf2XtnH3V1PI+s0VU9lze8ej7SEHFPhBB61ZsZEmjCsBnFMuYPJfI6Vhc3GyMoPXisbWpRlcuFCc89K1ppCFwoxmvM/HOpTHV0tY3KxxgO2DySf/rVL0Kpx5pWJr2dtSuysXNqhyDjGTWzp0axJhVZj7CqOiRboI5S5dWHc5reVgFGK5JylJnWuSKsCvLj5YR/wJwKjl809Yk/B/8A61TBsc0yV8Dk9ai3mHOuy/H/ADIxMUX5o2H05phulPcj8DTJXJ4FU9TuhYWbScGQ/KoPrRZ9xpxfT8f+HLDtvJ25J+lW4gDEMdMVz/hq7luDOsj7pAd3zdwa3VdkXDRN+GCKpSt8QThr7o1Bhip715hq8QgvLiMdFkIH516Dq18LS3aUKQw4UHua89vSzlmc5Zjkn3rooyuZqLi9TYsFd4ouFI2k/UV1/gxiUlgOBzuUY6etclooDWkO3AY8ZPt2rp/D7CDU4GZiC+Uxj1r32+ammfMtuFZrzZraJafZvi7pzAALJot+3Hr59nmvTq4K2AHxS0PjH/El1H/0fY13tcrd2drfM7s4X4onbeeCyf8AoNP/AOkF3SxOCASeKj+K3/Hz4M/7DTf+kF3UcTdM4rlrbnTQ2LwI4Papon5qurZUClQ4PvWR1LU1YW981fiORWPA/I5rRgfPFCZnUiWiKjYZ681IDxTSOeKmaMEU5kyD6V5b441NtG8QKJYna1nQPuXqDnBx6/8A169ZlXI5rzj4rWrNp1rcIB+7kKNkdmH+IrpyyFOpiY0qqupaf5GOOq1KeGlUpOzjr/mT6J4m0q8AFrdxhxx5ch2N+RrR1PxhYadJ9mu9StIbkgFYHnVZGz0wCc4968PmhhY/vIzF6MOVqrrVhput6PLp2vRyXK4/0e6QZltfcZ6r/s5xX0GKyVwjzUG35HhYTOo1JKOISXn0PaJLue+YPK3yHlVXp/8AXqeJcDnivluJtX+Gl/YXWkeKZJ9BmkEc4a3L+Uf9qAtjHurA/TjP0ZqHiK0tdDg1AzRTxTRq8UkP3ZcjIKj0P6V4M8PUU+Rp37H1FHE0nDmi1b1OkgZGOAeaz/FtqlzoV0xUeZApmjbuCP8A62RXiGreM9WvbxzDdSW0Ib5UiO0/ieteg6V4hln8EXKXMzTXbSG2UsckhhnJ+gzW+NyirhaHt5tenqc2Ezmhi8T9Xpp33T72NPRJ/NsUJOccVejV53bYdqjjNY+gHakkXYAEfyrb09wu8Nxzwa8KOp7NRWbGS288KO4beMdKitT5kYNULzxG+kai8GuxRw2Ez4tb+Ikxc9I5c/cbsD91vUHitDT8MrsOm4kU5RsRGVwu5fItJWHBA4+tcrIuQa3tcfEKJ/ebP5ViYzx68VlI6qKsrlifQJFb+0tAnSw1NwGmVlzBdHHSVB37bxhh7jimQeJI5TJaahA+n6rEhdrSVs7wP4o26OvuOR3ANdNENsKiuV8b2drqOnrBdx7j5m6NwdrxkD7ysOVPuK1TvozjcddChaiS4uWkPzNyxOaf4UsZJL2aZgz7RheR3qn4ZgvrWG7jvJ0uVRf3M2MSMPRwOMj1HX0Fcd4eudKs9Pt5NR0zTL/xAbtVuUnujDfrIZFG6JQhZkGSeCq7V78134SNnc8/MnzWifUdgXn0pAyjJTaRmuZst9rqY+TIVirEelcbpOv61H4Vl1KXXprW2OsS6fNN9nhMdlbi5dfOOUPzAKqbmOwBslSRmsjWPE2uR20dzYagdRtbjULjSrO+EMf+ls6qYJztUKQrh0JUBWxnFdjIws/dcX1PXfEls0unCRACyHNL4ZuIb+w2xzRTPbMYZQjg7HAB2nHQ4IOD6ivIbvVtX8Q+H4bzXtUl0u00rWLLT55ljhRUmjVhPOS6EBS7pjPyjH1zP4QvL/StUvrzTdblms5vEttZvAY4WjuUlSFGkLBd2cMCNhVeOhBqrpxscrjy1Lnot7aSWuqGVQMbwVx6Va17ybmL7OJITdCPzxCHG/bnG7b1xnjNc/8AF7U203WfDkTa2uh2V2Z1uLlvJH3UBUbpVKg59q4628SXkWnDWtSNx9sHh/b50CxxMQ17sSY71ZEBUq7EqQBk44oUrO51137WmjqjCw52YkXrg4oeFlHKhiRkYIPNeTyatc6le2UmreIY47XT9aMP9p280Esao9ozBjKYVRvmYqDsA+bvw1bWn+I9Zl8ZtbPqljHFHqD2wsZJl82WAZCSLGId3zDa2/zNnPQdBrzHkOmezfBbd5Pi3d1/tkf+kNpXmHgcf8UV4f8A+wfb/wDota9Q+DJJTxeWGCdaBx/25WleX+Bf+RK8P/8AYPt//Ra152M6HtZdt8kbmKSnUhrgPUGEUx1BHSpTTDSGUJoQc8VRltwOgrVlHNV2FCk0Va5j3cR8rOPumq8d7LEQGbcg7HkgexreMAlUqe4xWDJaSB2THIOK93K2qqcH0PEzO9Jqa6jNRgu5YCNOfYG5JTlj9PSsvTnvNHuFkgaWGUctzyfrWqn2qzPAyvoRkVeivheOkN3axMrHbuJOR+PWqxmXYtxcaLXr1NcpzXL6VVVMXTb8un3dSWTX9N1qHy/EFqsUx6XMAwc+pFZGp+FlSMXEEy3dm3Img+Yr/vDtV7V/CciI0lrhl67X4I+lQaDo2q21wHjdoEP3iH7e4r5athq0JclWDufqGFzPA+x9vhK6Uf5W/wBN1/Whb8GadJp1rqF7NIQkcJSJ1Y8O/AxjoR1/Cotf1vW4NWksbi6mmsmTej7yrbccNxgg+xqzr/ia30FbeJ7SQwRElSeQ8hGCxHHPp6YqtBqtvdaYh1qEvOSBE8Tjz/Lw5HmN0PzFPfFfV5HhKlFxXL8Xo+vTyt1PyzirNY4+rUrN2S06rp+bbvYxXluGkLTu0snGWc5J9DmmRX81lqMF3aOYriI7lP8AnqCKuSmGafERCKMA59sk/lwKzNTiZEt9y4LZI/If4iv0B0Kc1ytfI/LaeJrRlpLrufQXhXXYNTsYLlW2sQBIo/gbuK6SacGPB+YdjXgXgzWrLS7prS6mnimm2bXVd0YABzu5/X2r0631K6iQNE0c0BHB3ZBr88zHLZYavKMF7vQ/R8uzCGKoRqSdn1N64kCoWJ7V4/qU4vtZurjOVaQ7T/sjgfoK6Hxhr9zLbraxIsKSg7ypyWHp9K5izTvXk1k4Xi9z28MlL30dF4cu/Jn+zuf3cn3fZv8A69dSWwmSeK4BSVYMpwQciu0imFxaRyjo6g1yI3qxs7k/nsV+VWI9hTJZt5UdK1YgBGuOmKoawi+R5gwHU5Bq+XQxTIwvANc34smLXMMIPCruP1NdLCd1ureorkNcfdqs+e2B+gqWaUviJvC7bdTI9UP8xXYOcLmuN8N/8hQf7h/pXXzHCGqSuTV0kcl4nmL3ccWeFXcfqa5u5HFbWtvu1Oc+mF/IVizHORWsNGUtjT0J/wDRlXeq4Y8mt21ytyJBuZlYYP0rA8PR7o2bIDKxxnvXSW6bITvGCevPWveo600fLYxWry9TrNPk874l+H5OPm0TUTj/ALb2Neg15Z4SmWT4g6Gilj5ekakuW6/6+xr1OuZqzsdUHzRTOB+LBxP4NP8A1Gm/9IbuqkT461Z+Lf8ArfBv/Yab/wBIbus9W4rlrP3jro7GjDJkjJq0hB5A4rHSTj5TyP1q/ay7hgn3wKxOmLNCI7eAKu28nt1rPX16d6sxNg9fpQy2ro143+Wlznr0qpE/AFTK3HNS2czhYkbBBweK5nxtpL6xoF3ZQtsmkUGNvRgcj+WPxroyc9KQxBjlug5NKFSVKaqR3TuS4RlFwns1Y+VlnvISykCYKcMF4YEdiKsWV0rFioEeew7+uRXsHibwVpmp3U1ylskN47FvMTK7if7wHXPr1rzHVPBOoWUjmDeEHTPzr/iK+zo8R4ao0qkXH5XX4f5HyVXhvEwTlSkn5Xs/x/zMLxHpttq2mz208agTIy5Xgg4yDj2OK5L4YXF7qfhA2ry+YllO0cSM3KAgNx7ZJrX8W38/h7T7iS9zG6oVjBOQ8hGABn86xfhhEbDwyGl+V7mUygZ524AGfyzXXGdLE4qEqbT0f6WOWpGvg8JNVE4u6/W/4GtNYSwyMXU5z3GK6vwqTICrE4UBwO2emaqfabd7SZbmWRSFzHhQwJ9D3H4VY8HnfMVUFmKEAAZ6Gtc6pKWAqq3T8mjHIa7WY0ZX3bX3pnc6McXLY7r/AFretFBLg9KwdFObk4/umugtuCa/M1ofqVV3ZV1S2gntpYZokkicbWR1BVgeoIPUVzdraah4Ti36fHNqOh/xWg+ae1HrET99B/cPI/hz92uruwCwHrTlOI8U7mTVzm59QtdVigubC4jntnTKuhyOvT2Pt1FQ26b7qJfVhWXr+lSw6vc6joLpb3jNmaBuIbrH98D7rf7Y59cjirXhbU11CW4b7HcC9tEJlsjtEgbHAUkhTns2cH1HOJcbu6OmM+WNmdi5woHotcr4ifdcRp/dXP5//qqRfFjXS6l5eh3dp9hcwzzahc28MEUgRX2u6SOwGGXkKw5+uMU69p2oa9qFlNLbwXlvdNbRwtcDzJQqqdwXg9z69K09mzlhUjcfLMbexkYA5YheOvWui0CaQaejSptySa47UtU0xLCzXUL3T7Z55X2hbwFWCsV4Y7cn144ORzjNdd4fvIp7zUtOEGwae0UW8ybvM3Rq+cY4xux36V6eEhbc8XMZ80tDufB92zTTxMBwAeKseJmKyQvtzuGM+lcn4C8XaFqWqzQ2l9apPHcPaNG8yB2cMVGBuOQxB2+tanjnxZpOl3mmQXVxZC2uJZ4prmS6VEt3jUHa3bcdwGCRit5fEVgZcrXMdTorh9OXHOMrWJo8u3Xpkb1Zc5p2leIdBsLK3F9rOnWyXbA2xmukQTZxjZk/N1HTNUbvVdGsPE7LJqlhHIrsZEa5QMu1QXyCeNoYE+gIzThs0Ri1apddzS8U2EFzPp97LEHurNnELliNu9cNxnByB3q14enMlpIhXaVeqOt+IfD1x4bfU01rS30wSCP7WLuMxb/7u/OM+2a56Hxvo/h8TXGo3didOc2wjliu1Zz50hQOynAEYwW3BjkK5x8vMvY7FZ0GizrRaPUZ1ZRw2ee4NUzOQMKM9MGr/iDVNFuiL2DUrCezJRDPHcoyBmClRuBxkhkIHfcPUVms0aTDBPljI4roTTR4VRNSZ0vwbBC+Lwzbj/bQ5/7cbSvLfAv/ACJfh/8A7B9v/wCi1r1D4LnMXi4n/oNDr/15WleX+Bv+RL8P/wDYPt//AEWteZjOh72XbfJG9RThRiuE9QjI4ppqYjiomGKQEMgqs45q43SqzipKQkJ5pZol8zdjrzTU4NTycopr08oq+zxKXR6Hm5vS9ph2+q1K5iRhyM1l6hbCM74+Mc1r1BdpviNfYnxx1NsE1Hw/HMACzR8j3HWs+2txHEWUUfD+4Lw3VjIfuHegPoetbE1i0Bwq7kzkA9vavBxtGXPoe9hKqcLs4PxVpV1dsstqIywGGSRQ6OPcHvXDXk89ncmK6g+zynoNgVcf7IHFe2eUd/K4HvXA+PtJ/tXW1SPavkRKCSOuckmvVyTFVoS9lNLl89zy85wlGtH2mvN5dTjheIiBncKvTr19h6+9T/a5L54FkA2pkKMc8nJzS6hoEViYSsnmTEHJ7Ae1WdGsleaRriQRJHGWXjJdugUDucmvrFUi1znx9SlyScI7hbWTPJcXuxZwzMgiDfMoUD5yOwywGfUGtrR/EFzpj4B8tG4IxuRvqP8ADmuXMh2japjmUncc9ee47UsdwyHnIB9eQawqUoV1aWpvTrVcNJculju76+TU0ikUAFSQdpyDn+X40+JQq4rjoJ1B3wSG3l/2Sdp/wrorHVoJFSO5zDPgAkjgn1r43Ochqc3tcOr911+R9tk2f03H2VfTs+hpV0mhOW0wr3RiB9OtebeI9Vu4H8q3DQxH/lsP4/oe386zNDvbhNRDLPL5jggNvOc9RXJhuGcRWo+1nJR7Ld/PsdeM4kw9KsqEYt66vZf8E98hlkS3UkbuO1ZuqXTyx7fLKZOOaseH7z7bo1pcHq8Yz9e9JfRiSZAfXNfPO60Z7KsSxLstVHoK4nVTu1G5P+2a7o/6sCuDv+b24P8A00b+dSa0t2XvDAzqJPoh/mK6m4OQ31rmfCy/6fIfRP6iujnPyZ960iZVXeRw9+2+8uG9XP8AOsuX71aEp3SyN6sT+tUJxzVx3NehpeHchWZSykPwRzz6V0O5nI3gjAwAe9c74d5EgDEHfnj6V0Q46sDk5BJr3KH8NHy+O/jyNPwTKZPiRpanHy6TqPQcf66xr1yvH/A5B+KOnBQABo1/0/672dewVlUVpM1ou8EeffF7h/B3/Yab/wBIbuslXyOK1fi/97wf/wBhpv8A0hu6x0964q/xHdR+ElQ4arVu4Vuf0qkeRx1qe34A3dayNkzbgfcoGelWI2A656cVlxSj+GrPmkHPNLc1TNOJsjIzVtGHHNYP2pgBjIzxirdrJIX3Mx+lHKZymmbkQBHPTuaJWDDav3f51DGzFcv+VSJ8zYA/ConbZGbWtyBoQz5PQc15Z8X/ABGPB3g++1CcqJZFaC0GeWmYHaMe33j7CvXJlCx7R1J5NY19oel6hewXGo6fa3U0GRDLPEHMOcZK56HgcilTlySKvzI+F9H0vxR4qa0uddg1K+0ixQ4kuJCqqvXgty34c4711ElpHAAbYlAOm04GK+qdV0a3n8yOaMEEFT7j0rwrxn4G1DRpmazhlurBjmORFyV/2W9CP1r6bI8ZScnCTtI8POMNUUFKCuupyCTuUAZicetdZ4L3eZ5mSu3OMHB+orM0HwpqmqXKJFaybScEkY/P0r0zUPCkXh3QoJQ+66EiiRh93BHQD2r1c5zKjSw06XNeUlay/NnkZNllari4VXG0Yu93+SEiv7hpcvA1w+Pvn5X/AO+h1/HNbFhdySZ3RSoADkyYznsAR1/IVk6Ud9yM+hreVAOQK/PubufoU4pPQezFuTQaSmynbEx9ATSJOenO+WRvViav+HVxdSuegUD9az8HBrU0VMQOx7t/KpW50VPgsYuseGrybw/4wtVmthJq1y1xCSzYVfJiT5uODmNumeMVyU2g38upXav9hWzuNUj1Hz1lYzAJsIQLsxklOu7ox4r0jW5fLsWA6v8ALXKgZmHp1rojUd7HL7JWbOKvPC+rXXk6TFc28ieTcIYxdyworySO4c7Fy/ysAVOBx3r0zwnpE2k3epSTyW8i3P2fb5bEkeXAkZzkDup/CsbSk36hNdgcY29O9bgmDAMqleOTmvYw6vDmPncU37RxMmDR9YtXZLcaYyw63/a1uZLl1MmZCxjcCM7OGIDDd9K35/CviKE22reTolzeR6jeX725u5EjCzIqqFfyicjB/hH+FT7Q6DcFHvx/Wu40fUGutMQSDnG0gVpOFtQwtRqVmeWaV8P72MmBDaagt1p/2Sa3l1S7sYkbzJHIAg/1sf70jY2OAMEZNbniLwXcxaPr8IayW41DUI7uFssyFIxCVjkyMkExsCOeG7nNbZ32WqDaCSpyvfiuh1K2l1DTW2r23qfepirM7sbTSXNA4W+8Ma3rTXerPBpSahdXkdyIre/mh+zhITEHScR5LkMwbdGQVwOoBrnx4R1qJ333envepDp4GT5SNLbXLTEHanCnIAYDOcnFeo+FlklheKTGF6AVW8R2EcV6rKeWGaTjbQMG1V0fU47XNAvtT8eW95cQmC0FrFf6gke6SF7qPckQSQqu4gEk8D/Vx5AzV9gzyuV+6vTjivRLARz6SmVB3R4rjLiNVlYLjb049qunax52Ki4yN74JZ+z+Ldxyf7ZGf/AK1rzDwN/yJfh//sH2/wD6LWvU/g193xfwR/xOV/8ASG0ryzwL/wAiXoH/AGD7f/0Wtedjenqevl23yR0SDNPxxTU6VJXntnqDGHFQP1qwaikFAEJqu45qyahkFA0QdDU45iI/GoW61ND6VdKfs6in2dya0PaU3DurEVDDINKRjiivvk7q6PgGrOzItBnOn+IYJD/q5Dsb8a9OChx0zmvJ9QUrh14KncK9K8OXf27S4Jh94rg/WuLHRtaaO/BT3gW3s0ccgVx/ivQb15he6XEs8oTy5IC20uByCpPGRk8HrXenoKiKZeuKhiJUpcyOupSjUjys8Ol8N+IbyUM+mSR9su6j+tdN4Z8IT2lyt1qRV5Y/9VEnIU+pPrXpnljBGKVEA7V21s3rVIOGiXkcFLKMPSqe11b8zhNb8M2epAtdW22U9Joxtcfj3/GuD1Twbf2pJtCLqPPG0bXH1HQ/hXvPlhjggEVRudPicn5efascNmFSi/dZ018HTrq01c+etT0i+0wgXUBj3dGByPzHenWmpGOMQXUSzwdMN95foa9R8a6er6bcwZIG0OD6EHNeXPYOdNM6ENKGYAHuBXs4TNXVqeyqR6XujysVkyhS9tRlaztZ/wBfmacUcV0pGmS+aCPmtp8Bse3Y1jyQi3uTJHG0RiYFkbtz2rH+2PDMBMjRN1H/AOutg3zz2p88l3bADN1Cj3r24Qs+ZHhYipPl5ZqzR658PrjzNImt+9vOyj/dPI/nXQXCbnQ96434ey7by4jzxcW0U6+5A2n9a7dvmYe1fleZUvZYqpDz/wCCfpmBq+1w8KndIiP3cVwl4f8AS5iP77fzrvD3rgbg/v5Sf7x/nXAehS1uavhX/j4nPoB/Ot68YLbk+ik1h+Exl7g/7o/nWtrDeXYTN6Rn+VaIzn8RxA5XNV7gVP0Sq8pzVR3NnsXPD+N0qnJBbGBXSHYMrs5AwSOa5zQAQkz8YD43enFbAdRnymY5GTjsPSvdw/8ADR8tj0/rEv66Gx4Dfd8TtMAAAGjX/wBT+/s69irxX4dHPxTsSBgnRb7POf8AlvZ17VWdX42aYf8Aho89+MBw3g//ALDTf+kN3WOik1s/F77/AIOz/wBBpv8A0hu6y04/hP4VwYh2kehQXuiqmKdz2p+P+mcn/fNOdHjXJjk+m3mufmXVm1n0HQZU1ejO7FZMd5EW27lV842vwa0I/PP3dn5mmpJ6oGnHcurECwOOlaMCKoUjr6msqB7hHBKxn25rSE8kuOEQD0qmxF9Y8t8z49Tmnh1VdseQvdu7VQB5xkg+vXNWISoGOSamwOPcnY5bk8YpHAMbAew/WnKm4dM0yTghc5IO5v8ACs5bCW+hRvBubcepXn61VMO6IkDtnHrVq5G7C9ycVKyBFx2xWXW5veySKKRxop2ooPfAxXDfEO8Ro7WzVsyvJ5hX0UDH8zXWa/qMWk6TcXs+dkK8gdW54H5kV5DbT3Gq6lNf3f35DkL2UdgKbd9WbUY31NzRVxcj/drezWVpihZCf9mtLcM1JpU1Y+oL5sWsn0xUm4etQ3pBtmHrigiK1MfotbOnpstIx3IzWXsBwB3OK2hwoA7cUGlR6WMXxHL88UfplqwGYiOV/RTWrr7brxv9kAVmMhdI4l+9I4Fa01qZ1HywOo8L6Tu0MnAJkOeao3MDI7ZALdMLxiu/0i1Flp8EQAJVRmuc1+GO3vHJAXzPmB7V7tD3YqJ83i037yMRbf5OnzdxnrXR+D8LcvE4IRlyBnvWKJlPIGcY5NXtLuTbXyMx2qTn6VtLVHJTlyyTN7xLEqSRSIoHbNaehXAn0xVJ+ZPlNV9ZC3Fgxj5YDcKp+FLlFeWMkjPIBPWud9z3tKmH80QaQ72niGWFhtRsgVoeJIgYUkPJU1T1uT7Lq0NwANrEZrX1KT7RYPsxkrkVUt7nDhJck7dmQeGmMlo6dlY4Hsa53XYzbX8iAqMnOMVe8O3ey+aMH/WL09xTfFkH7xJyoIYYPsamm9bFZlT1bRe+DQwni7nP/E5Xn/txtK8s8C/8iZoH/YPt/wD0Wteo/BYkxeLs9f7ZH/pFaV5Z4FOfBug/9g+3/wDRa1w43Zep2Zbt8kdLH0qTHFRxdKlrzmeoNNMYVIaaaEBXYVDIKsOKgemCK7DmpIjzTH4pYzzQULLw5/Om0+b7w9xTK+3wU+ehCXkfD42HJXnHzIrhN8ZFbfw8vdj3Nkzcr86j+dZB6GotLm+wa9b3GcIx2N9DW1aHPBxMqE+SaZ6puJX3pVJzz1pImBXI709Vy3HSvBeh7Q7JP40KvNJyKcfu5/GpAUdaR15zQQeKGz1pgcv4uh3Qtx95GH6V5TCwRHiJ5DF1HqD1r2PxGu+3XPrivHpbUStIhO11YgMO1bQxX1SrCs1dap+haw/1qlOjez0a9TG1GIGXIHynoCOlVvJZyAik5/KtkWV7H1S3nX3Yirdlpst3eW6X7Rx228booeMjPrX0kuIcHTheLu+1mfL/AOrONq1XzWS73Om+G0FxK6TOgFtaRNAkv/PUs2SPoK7x6gs444IUht0CQoNqqvQCpnOAK+CxuJliq8q0la59thMPHDUY0Yu6Qw/drgJz+9fn+I/zrvX/ANS59q8+k+831NctjupaXOh8Jr+7mb1cD9Kt+JW26dKPXA/WofCg/wBDc+rn+lHitv8AQwvq4FUjN6zOTf7tVZDVqX7tVJOlXA1Z1Hga1F3YaihXJ3rtOOhxS3UTRs6lWRF+U57ke1X/AIWgG3vySf8AWL0+lX/E1mEvy4bEbjIB9favZwr91Jnz2Yx99yRQ+HGT8UrJiTzo19xj/pvZ17XXjXgEY+KGnHGP+JLffj+/s69lpVfjZFD+Gjz74u/f8Hf9hpv/AEhu6q25wBgZqT403MVnF4RnnbbGutHJxnGbK7H9azdO1O3uEDW06OPVTk152JTun0PRw8la19TfiURAM4Bl7D0pxbIJPJNUI7hWPBzUwkHTNclzriiK90+C6jPmLlux7isSSPUdLy1vIZIR/CwyB/hXRq2SR6U8xggDHXk0nBPVaM1Uuj1Rh2fiiMNsvomi/wBtPmH5da6uzuIJ4g0MqOPY1h3ej21wcvHhj3HFR3mgslirWsrLLtAHOD+dTz1Y7q6InCm7cuhvyOufmI/OmJcHzQR0rjI7jVbJ9s6vIo7kZP51q22o/IXkimGOvyGqjXjLyJlSlHzOxW6LjCceppskgjUkniuXi1+JkBiSQD+8yECpVu/PIZpwfYdqTqRlsyfZuO6NkSAusjHgdB61XublpHwe/RRVYTRrG5Viz4yT1OK878TeLZpGks9HkGT8r3CnOPZf8aEVGLk9C38RtYWUpo1u6uSQ9yVOduDwn9T+FY+nxCOJQBis3TrLyhuclnPJJOSTW1D2pNnZCHIrFyElPu96lDt61EnSn96AH+a1JJIXXafrTaQ0CsQudjBvTmnC/wBv3uaZN0qjN3pFWuV7yQzSsx/iNWdDg+1a7axYyqYJqnjLgV0XgG2MupT3BHCnAP0rqw8byOPFytGx3hOxsHpWF4stDNZrKoy0Z7eldDLHvWqpXcrRS8gjHNesnZnjzjzKx5yCQcFvqBUqsVVfn5B6Yq7d232e4miYAEZwTWZdoyDfuBOQMAYFdG+x5mz1O10i8a608BvvL8prGic2Oq/MxGGzkehqnoF40N1sLYjb371f12MlROgORwcVi1rY9fB1dOV9TW1+P7RYhlbO0huPSp9DuPtFioJyV+U5NZ2mXX2uy8p+qjByag8Ps8GoTW7MOeRS3ic84unVEuP9E1XKDaEfPHcVu63A13pTbducblBrN8QwMpjlLHb6e9aOlz/adPAYdBtqL2dztxCVWkn8iP4JjbB4tHprQHX/AKcrWvK/Ah/4o7Qf+vC3/wDRa1638IEMb+MkPUa36Y/5crSvIfAp/wCKP0L/AK8IP/Ra1x43p6mmXK2nkdVCasdqqxHpVkdK81nqCGmGnmmmmgInqB+9WH6VA/U1QirL1pIj81OlFMj6ikUTS/dU1HUr/wCrqKvrcnlzYZLs2fI5vHlxLfdIKoaiCFyOo5FXqhul3JXqnlnoPhm7+26Pbyk5bbhvqK2A2Dx3rhPh3d/LcWbHBRtwHtXdKQFx3rw8TT5KjR7NCfPBMk7gU/ACVCXxg0okJzXNY2AthfelYkDPrQpyCMUvYA00Bka2pNm57g5ryS4G3Ublf+mjfzr2PWVzaSn2ryLV12axPjuQfzFRi9aafmdWBdqjXkKOlORtrqw7HNMU5Ap3avLPXPRraVTGrZ6ipJZRtFYFjcn7NH/uirD3GQOazloYqJoSzAQv9DXCv1P1rpJp/wB23Pauac8moRrBWOk8OyeXZL7sTVbxNN5ghXP8RNQafN5dsozjqaq6nL5kqewqyEveKMvSqknSrcnSqs3SrgWzuPhcQltfE8AyDn8K6HxFF9otGkxkx8jHX3rB+GSK2nXWepl/oK7FosoQQD25r1KD5UmeLi4qU5JnGfD19/xWsz2/sa+x/wB/7Ovaa8n8MWn2T4w2iBcK2jXzKc9R59nXrFaVdZM5qKagkzyv9oNd+j+F19da/wDbO6ryo2rA5TKn1U4r1z47LvsfCg9da/8AbK6rhlhUDkV24NXg/U4sZK1Rehl2eu6nYEB28+Idn6/nXTaZ4wtJtq3AMMpOArdPzrKktI37Cs670pWBKDFTWy2lV1tZ+RdHMatPRu68z023u0YDDByecA9a1IGGOfvHrXjmnarfaPKqu7va9CvcD2PWvQ9D1m3vYQ8MqkdCO4+orwsThKmHfvbdz3MPioV17u/Y6lVz0HNTXhASNB2qtZShiWzwozmkklDvwc8cVy31OlasXaGI9M08xKPLyPvNUW79BVlQJVAz0NDZbsQpAiWqKyjOcYIpxjjDBURQfpVHVtatbacJJMN46Ko3HP0FZj6lf3nyaZB5Ib708wy34L/jTjSnUeiMZVow3ZD8Sb1bDQZ0jfZcXS+SgXg7c/Mfy/nXmGkwhVU4rsfF2jGGya6up5Li5YhS7nPGeg9B9K5q0UAACnWp+zfKdGElzxci+gqxDxioFqePjFYnUy4nSnjmo4+lTLTIY0ikNPao36UAQTHiqEp61amNUpTwaRZCTtDN6Cu98A2nkaQsp+9Jya4GTmIj+8QteraFCINJt0/2BXoYRa3PKxstbGkmDUNxHzuHanRNtbHrVhlDoa7zgOK8XW5DRXSAkH5WFc67O4K8c8V3uq2v2iyuIMZOMj61w0kWxPkViSK2pvQ4cRG0rmePkckjkHg+hrtYit7pgwMlkwcetcj5O7JkUkdwD3rpvCcvmQPCVxsontcMPPllYoaC7RXzRSZBPy/jVrUibPWYZyp2Hr6Uy/tzba2rpwCwI5rQ8Twg2KyhCxQ5qFvY9DHK8VNepd1YefprsMEjDCs7w5cOrzQNgA/MMn860NOYXOmRnBI2bTmucV/supneSNrY9sVkzWhL2lJw+Z2fwrx9q8aY5H9tKf8AyRtK8Z8DH/ij9C/68IP/AEWteyfCggz+MipyP7ZX/wBILSvGfA5/4pDQv+vCD/0WtceM2RtgPiZ1MJ4FWlPFUoTVuM8VwM9EeaaacelIelJDIn6VC9TNUTVXQRVlqJetTSCoehqSiweYzUVSpyh+lRCvp8jlelKPZnzGeRtVjLugIprjchFONAr2zxCLw/cGx8QQydEk+Vq9Wj2lvY9K8fvcowdeCp3CvT9Huxd6dbTKc7kGfrXn4+F7SR6GCno4mkwGPxpqrkkU7HFOU4yB3ryzvANtIxTs4AJ5pMAnFPZMoDQBVvl320gx1BxXkXiRNmpg/wB5B+nFexvEXiI9q8k8Xx7LqFvdl/I0q2tF+RvhXasvMzYTlakAz0qGD7tWowCK8p6Hso1LSbbAgz2qbziRWfF0FWFGBUS1GkSSS8EGs51PNXGXNQstQkMiWUqoX0prtubNPZOKjxg1d9BW1Gv0qncVcfpVOboadMGeg/Dj5NDYjGWmY/yrqTJ1z+lcv4Hynh232jlmZvrzXQiFn5Jr1Kfwo8Su/wB4yroxB+KukEdf7F1D/wBH2VelV5ro0Rj+KekZHXRdQ/8AR9lXpVUzNHmnxw/49fCf/YaP/pFdVxJrt/jh/wAevhP/ALDR/wDSK6rh69PBfw36nl47+IvQOlKRRijOK7DjIJbdJR8wqibGa2l86ylaJx/dPX61q0VMoqSsxxk4u6ZnnXtbtXBmuf3X90IAK6611DURbxTCFZ45FDBlODXNXcKzW0iEduK7n4cCO78PQpMNxiJT8jXmYzB0uVNRsepg8XUbabIodSu3Hy2MxJ9SAKtxW2q34Ku32eI9VjPzH8f8K7O3s4IgMItF1EV+ePgj07158cPTi72PQlXnJWuc9p/hy2tlzsG7vnvWm1pHFH8igfSrkTiVcjhh1FDLuBFbmJ558QSBpjD/AG1H61wVqa7v4k/LY7f+moH864SzHFeVi/4h7eB/hF5e1Tx9RUK1NHXMdZci6VKKii6VLTIYGo5OlOJqOU8UAinL1NU5TVuWqU3WhFPYIU8y4t4x/E1etwL5NtEg/hUCvMNCi83WbZcZxg/rXqbD5cV6mFVlc8XFO8xjg43L0qaGTI61FA/VGpHXY/HSuo5h9wvzbhXC69H9k1KVT/q3+dfof/r13gbcvNc34xtN8UE68FTtJ9jVwdmYYiPNA5N5udu3Cnrn1rZ8MSn7f5W7ClTjI5NYkrYwoYE9fxq7pMu2+tySc7vyrSWqOOHuyTNrxHDieJhg54q9E4vNH2jklcY96h8TKWsQwPKMDxVHQ7tDBJHuOFORWHme1Jc9BeQ/w7cNiW3YZZT2NUfEUWy5EmMhhzj1qv8AajZa0THny2OSKn1y5WaAMHUFDnrQ07nPhJ8jszp/gtJ5sPix85zrC8/9uNpXj/gk/wDFIaF/14wf+i1r1j4DuH0/xWwIIOs9R/152teSeCj/AMUjof8A14wf+i1rgxmiR6GCtzysdTCeKuRGqEB4q3Ga4tzvZaprUiNTutRawyFu9RNUr1Ga0WwivIKrt96rUlVX+9UspE8XK1EKlhqM9/avoMil8a9P1Pns9XwP1/QDkCg8UDmj6V9AfPkFzHvWuj8AXn7iazc/NE2VHtWC3So9Juzp+uwyfwOdjfjWdaHPBo1oT5JpnrCNuBFO4ABPWoocFVKnginqN2favBa1PZJMgMCehFODDac1C3AUnmpGxuBFIBxYbRz1ry7x5DtYkfwzfzFenEDmuB8eQ5t7g46Yb9apq8JLyLpO1SL8zi7arsVUbYcg1oRivHke6ixEOKsDpUMQ4qwtZjAjio2GamqNhzQBA9RMKsOOKhfgUAV5OlUZz8rVdl6GqM/3Wq6YmeoeDotmg2Q/6Z7ufc11NsquuMVh+HE2aVZR46Qr/KteBtk2OetektEjwqjvJsqW6BPiloeABnRdR/8AR9jXe1wkX/JU9Cz1/sXUf/R9jXd1Qkea/HD/AI9fCf8A2GT/AOkV1XEZ4rt/jh/x6+Ev+w0f/SK6riRXqYL+G/U8vG/xF6Dc0uKKBXYcQdqKMe9KaBietdB8Mrnyp76zfgLJvX6Gueq34Yn+y+KYs8LOhX6kdKxxEeamzfDS5aiPYGl2IG9Ksxss0QI5BqghE1vx3FN0yUxO0L/hXjnsD3HkXGR0q4Iw2GU8dabdx70yOtNsZMrtPagDzj4nA/Zx/wBdv6GuDs+K7n4oS4VR/wBNj/I1wtm2TXk4r+Iz3MF/BRfWpkqJamWuc6yzEalJ4qCM1LnimZsCailNPJqKQ0DRWlqnKMtVqU4qoTlqa3HLY6DwTEH1Z2I+6MCvQj0NcV8P4sm4lPQsQK7Ruhr16CtBHg1nebIivIYdalBEi4PUUIuOtG0A5zitjIcBtFUdbhM2lzhRlgu4D6c1ceZEUszAAdzWFqvivSbFGEt0jt02J8xP5U4pt6EzatZnJOysvOBkelQST4Iki4xyax5NVlmkf7DZkqWO0t6Z4qL7LqVyf30oiX0BrtjQnI8pzjHdnb3WrQtp376VVDryCa48a35EzLZI07dOBxTrfRYFbdO7TH0Y1oRxRQjESKo9hWsMEl8Rcswmo8sTJddWvpPMkkWBT0A6imjRy7E3NzLIT1wcCtvPFMY4FdSowjsjjdWctWztvgFAltpnimGPOxdZ4z72dqa8k8Ff8ijon/XjB/6LWvYPgXzZeK/+wyP/AEita8e8FH/iktD/AOvGD/0WtfL5lpJ+rPqsq+H5I6aBquJWfCcVejPSvNR6rLKU/PFRpTjQxDXqNqkNRtVIRDJVV/vVbfpVV+tSy0SQU1hhj9afDTD1P1r3cjfvT+R4OefDD5/oJS0nFH06V9GfOBWdfxnJI6jkGtH+VV7tcrmmtxHfeF737ZpUL7ssBg/WtnO0/hXnvgO9+z3s1o5wHG5RXoKfMBXjYqnyTZ7GHnzwTHDJqRcY5pAAB70Acg1ym48Dr2rkvGsW+1mwOsZrqJWI5rB8Rp5lt9QR+daU1cTdtTy61+6ua0Yu1ZtrkfKeoOK0YeorxKi1PoY7FyOpxUEdTjpWYC0xutPpjdaAI3qF+lTNUL0DKk3eqMg3cepxV6fvVa2TzLyBP70ij9a0poUmexacFitoB6Io/SrqY88g1mWz52RjtitQAeZnNeoloeA3qU7XP/C0dCyc/wDEl1H/ANH2Nd9Xn9mwPxT0UDto2o/+j7GvQKQI81+OH/Hr4T/7DR/9IrquI5/Cu3+OH/Hr4T/7DJ/9IrquIya9TBfw36nmY7+IvQOhoPtRilANdhxiD3NIeKU0goAQ9OKimkNvNb3K9YZA34VMue9MuE8yB19RQ1dWBOzuevaLcK8SnOVYAj8amu4isgdeoNc54JufP0i0OckJsP1HFdeuGTD9K8OceVtHvRfMkx1rN50eG61CAYrnjuafGgR8rT51D4I61Azyn4puRJGPWVj+lcbY9K7L4pr++hP/AE0b+QrjrPgCvJxP8RnvYP8Ago0UqdagSp1rA6SdKmA4qGOph0pmbGP0qvIeasSVVfvQNFW4OAaqRt89T3LcGqasQHIGTiqgrtIVR2i2eh+Ak2aR5h/jYmujlmWNd0jqg9WOK8kh1XXFtEt7Wb7NAowNoAJqGS2vbts3t9NIPQsa+lpYKfKkz5Krj4czsel6j4m0mwB8+9jZ/wC5Gdx/Subu/HckxZdK05pPR5Tj9BXNw6dbRNkR7m9W5q7HHtXhQq+1dcMHFfEcs8dN/CVtQm1nWT/xMLvy4j/yyj4H5Cm2uk20BBK+Y3q1XwMHrS10RhGOyOaVSUt2JhVGFAA9BTGNSkZHFM2+taXMrCIwNI1PRKVk29aLhYhGTkU08Hrk1KR6Coyp7UXCx3nwK/48fFef+g1/7ZWteO+C+PCeiD/pxg/9FrXsXwKz9h8V56/21/7ZWteP+FBs8MaEOzadbH/yEtfLZjG7cvP/ADPq8rla0fL/ACOhhNXYjwKz4TV2M9K8tHssuIeKkqGM1KDTZIh6VG1SGo2poRBLVV+tW5OlVJOtSy0SQdaRuGP1og6ihuWP1r2sk/iS9DxM7/hx9RO9IOvNLg0nevpj5kDSMuVOe9L0+tJnPFAFCOV7K+huE6o3P0r1jTZhPbo6nIIBryy8jDIa7PwHfefppiY5eI7T9K5MbDmhzLodeDnaXKdaowaMHmm7icHtS8l8dj2ryD0xXj3Lk9Kx9aj/ANFf25rZwcYPas7U13wSA9cGtKb1Jex5HNH5N/cR+jkirMNP1mPZqbN/eUGo4e1eRiY8s2j3cPLmpxfkXY+tWB0qvF2qyK5zUKYafTTQBG3SoH4qdzVeSkMqT96foEIn12zQ9N+4/gM1HL3q/wCDk3a8H/55xsf6V00FeSRjWdoNnokChZSc4rSWUADPbjNY3nAYIP1qpe6vHbITK6oo9TivajSb0R4Lmupp6VKJPipo+Og0bUP/AEfZV6PXjngXU49R+Ktj5W5hHot9823AOZ7Pp+Vex1hVi4TcWVCSlG6PNfjhxa+E8/8AQaP/AKRXVcQSO1dv8cBm18JD/qNH/wBIrquJxivQwX8N+p52N/iL0Gg5pec0oGKCcV2HGN70hzkEU760uR3oASlxkUmcUhagDpPh1cYW5tieYpdw+hr0hRmMYNeTeCpxb+JJUP8Ay2jyM9yK9LOoxxJXk4mNqjPXw0uamjQUY704HFcnqHi3T7Rj595ChH8IO4/pXPX3xLsowwtY5pm7cbR+tZKlOWyNXUhHdj/ijHmNHx0m/mDXA23UVf1Txbd67ut5oIki+/8ALksMe9ULcjII6V5WOpunVsz3MuqKpRuu5op2qYHiq6ngVOhyK4zuJozUwbiqwOKdvpktEjtmq0hqQtULmkNIo3ZqG15kH1qS756UlgmZgPQZrqwceevBeZx4+fJh5vyZfVS3TpUhQ/hTo8KfanMwPfivtD4NIhK4NShgRz2puATkdKTO04NIY8DBzikL89OfalHIoIx05oGAyaDjoeTQucZHFJQA4EoDxTd+egpwUnrTSMcY4oAOCKZg5/rUgWlIB780rhY7T4GjFn4s/wCw0P8A0ita8k8Prjwh4Zf1023H/kNa9d+B/wDx6+LP+wyP/SK1ryfw+ufAvho+lhb/APopa8LFx5oVfL/M+gwUuWpS8/8AI0ITV6I8Cs6LrV+HpXgo+iZbjNTKagSpQasgeaY1LSNQhkMnSqkvWrcnSqknWpY0Og60Nw5+tJEcGnN/rDXs5I/30l5Hj52r0ovzGk4pCcCnHmmnivpz5cbndTlHFKAM0r9OKQFS8J2jFWfCl/8A2frao5/dT/KfrVa73eV8vWsuWRsqy/eQ5BpuKnFxY4ycJKSPbY5BsxTixJB9Kz9Jn+06dbS5++gP6VoYwBXz848rse4ndXHDJqG4iLRsT0xT0fDc0TSgoVHQ0K6YHl3iaPZeRP2OVqhD1rb8YR7VU/3ZP51hwckVwY5WqNnrYF3pJF+PpVhelV4xxU6dK4Udg41G1SkVC3WgRG5qCU8VM9QPzUlIpzGrfhy8jsZ7mWRZGJUKoQf17VVlHJzT9P5gmz/f/pXq5XTVSvGMjzszqOlh5Sia11rN3MP3QWBO38Tfn0rOkjEjrJLmSTrubk0vbilzyO9fYQpxh8KPjZ1JT+JnQfC8/wDF07Qdv7Gvf/R9nXuVeG/C7/kqdr/2Bb3/ANH2le5V8/j/APeJfL8kezg/4Mf66nmnxw/49fCf/YaP/pFdVxWK7b44HFr4S/7DR/8ASK6riCw/GujA/wAN+py47+IvQXBPejHGKSkLZNdhxi0uQKZyP/r0pGRxQAZ5oxjmjGBQMkYoERTRuZElgkaKdOVdeoqC5TUboH7RfzS+xY4q2oIqTGBScU3dlKckrJmEdIbrkE+9Z91bNCSCK6zb371n6vEGgZscgUml0KjJ9TB07KySOBnauDWlGhb54j+HY1S04YWc98ir9uSDlePbtXyeZSviJfL8j7PK42w0fn+ZciJCjcCDU6Gokk45U08FD2FcJ6BNmkLUzI96QkUXAeWqNzxRmmkgelK4FeRSx4GafYp+/kA5IHNEjuQQg/Gm2J8ucqTyw6+td2XO2Ijc4Mzi3hppdjQFLsGc0KT3FO56cYr68+IGYOaUrnnuO9O6U0tzx2oAcnFISAabnNMwc9ce9AiUkUnU0iipTwOKaAQnK00Ed6Q9eKGIwAfzoAUHml60gA/Cg+oFSUdt8EOLXxbj/oMj/wBIrWvLfDS7vh94fPpp9sf/ACGtepfBD/j18W/9hkf+kVrXmfgz954B0JSP+YdAP/IS15ip+09rDvc9T2ns/ZT7WCPqKvwnpWdGwyM8VoQ84wRXzKPrGW1qTNRr0pwNUiSQGmsaQmkzQA2TpVV+tWJGGMdfpULRu3OMD3pDRGDinbtx3DoaYyKpG47qfkHG30r1smdq9u6Z5Wcq+Hv2YDPWkPrTgM9KQ8GvqT5QTOfpRzjnpR0pu/OaAEK5Xisu4gCyHnitZe9VbuPJzRHcT2Ou8C3yyaX9mdv3sLEYPXb2rpzLtzuryC3nms7pZoHMci9x/KumtPFO8sdQXylAwrKcgn39K4q2Fbk5I78PiouKjLc7VZlYE7hUDXSDILD864a98Xwo+21SScdDtGB+ZrAk1nUryYhZRaoTkbRlsehNKGDnLWxdTF04dTpvFlyk1vKNyhtwwM8n3rn7RuBn8apNv+dpZXmkP8b9a0LNEmiXnB9q8nN6Dozjfqj18oxCrU5W6M0YcEVMKhiiK4G/j3q2qHHLLXio9cYelRMtWcL3OaDt7CmIqFM0xojVo7jwOlMeMnqwApDM25QIpYmq2nv8ssZGDnfWlPFGAcZZvU1ks/2e9Rz908N9DXoZdWVKvGT2OPMKDr0JQW/+ReHB9jT8cYB6Ukq84HPvSLkda+2ufDm/8Lf+SpWmf+gNe/8Ao+zr3OvDPhcc/FW1/wCwLe/+j7Svc6+cx/8AHl8vyR7mD/gx/rqeafHEZtPCY/6jJ/8ASK6riQuBXrHxCu/C1rpNoPGtnb3tjNdCOCGbT2vd02x2G2NUc52LJzjgZ55rhPt3wd/6FOy/8I+f/wCR6mji1RjytfiFbCOvLmT/AAMIA/hS7cc1ufbvg7/0Kdl/4R8//wAj0fbvg7/0Kdl/4R8//wAj1r/aUe34mX9my7/gYeM0o461ufbvg9/0KVn/AOEdP/8AI9Bvfg8OvhKz/wDCOn/+R6P7Rj2/EP7Nl3/AwqMDtW2dQ+DY6+FLH/wj5/8A5Hpp1P4Mjr4WsB9fCE//AMj0f2jHt+I/7Nl3/AxjjrikZsDGK1zrPwVHXw1po+vhKb/5Hq1az/CK7jWS08HW08bcBo/BtwwP0ItqazBdvxJeXNbv8DnNx6VHeLutpB7V2It/hcengMH/ALki5/8Akal+y/DD/oQv/LIuv/kan9f/ALv4/wDAF9Q/vfh/wTy3TR+9nTuQDV6JcGu/uE+FVsoa48DxxKxwC/gq5UE+nNtUEl18II13SeELRF9W8HXAH/pNXkYqiq9R1L2ue3hMS8PSVO17HJRnipMA11IufhCRkeELUj28G3H/AMjUG6+EA6+ELQf9ydcf/I1c/wBS/vHT/aP9z8f+AcuF9qcFNdF/aPwb3bf+EVsd3p/wh8+f/SenrefB9vu+EbM/Twdcf/I1H1L+8L+0H/L+P/AOb8sdwKkWJfSukE3wkPTwbbn/ALky4/8AkalD/CY9PBcB/wC5LuP/AJGp/U/7wfX3/L+P/AOXkjwKozgqysvUV3A/4VQengmL/wAIu5/+RqXb8Kv+hHj/APCKuf8A5GprC8rupCeOurOH4/8AAOWilEkasO4p9dOE+FRHHgeP/wAIq5/+RqQj4Ujr4IiH/clXP/yNXtrH2SuvxPn5YC7bT09DmSKQYPWumH/CqD08Ewn/ALku5/8Akagf8KoPTwTD/wCEXc//ACNT/tBdvxF9Qff8DmeKCQTzXQyXHwij/wBZ4OtV/wB7wbcD/wBtqYb74Ojr4Tsv/CPn/wDkel/aMV0/Ef8AZ0ns/wADByPSkc7uvSt06j8Gx18K2I/7k+f/AOR6adU+DA6+F9PH/coT/wDyPR/aMe34h/Zsu/4GJt44pQAwwa2DrHwWHXw1po/7lGb/AOR6adb+CY6+HNMH/cpTf/I9NZhfp+Inlz7/AIGV06UEkVpPr/wQQZfw/pKg8ZPhSYf+29PXW/gm33fDmmH6eEpv/kerWMk9of19xLwcVo5/1950HwPObXxYf+o0P/SK1rzfwMo/4Qjw+PXTrf8A9FLXtPw6vfCl7pF0fA9pbWdhFcmOeKDT2sgJtiMSY2RDnY0fOORjnij/AIVx4H/6E3w3/wCCuD/4muaniPZzlJrc6KmH9pCMU9jxZV8qVkbscVejWIgZAz7GvW/+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/ia8p4TXRnsLHO2sTyxRFjjNOxGPWvUf+FceB/+hN8N/wDgrg/+Jo/4Vx4H/wChN8N/+CuD/wCJo+qeYfXv7v4/8A8tJQdB+tNMijoBXqn/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNH1Tz/APr3938f+AeUNchRgYqu80jdAfxr1//AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaPqnmP69/d/H/gHj6R7z85z9KkcBSMdK9c/wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4munCReGqKpe5zYussTSdO1jyHJo6169/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE1639o/3fx/4B5H1D+9+B5CRtFIRkZr1//hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mj+0f7v4/wDAD6h/e/D/AIJ5EgBGD2ocBkweK9d/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImj+0f7v4/8APqH978P+CeHXClHORxUS8nkfUV7t/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E1X9p/3fx/4BH9nf3vw/4J4M8YJ6cGoWXaeK9//wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4mrjm1vsfj/wAAmWV3+1+H/BPAwMmrFixxg/pXun/CuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNefmFf67y6Wt8/8j0sug8EpK97/L/M8ihw2PnarKxDGd7GvVP+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/ia8v6p5npfXv7v4nl6RinbRXp3/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TR9V8w+vf3fxPMMY7VG4zXqf/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTR9U8w+vf3fxPIpVrJ1CIMpr3P/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mnHC8r3G8df7P4niNjK0luueWX5T+FWCmeP617N/wrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATXvUsycIKLje3n/wDwa2BVSbmnZPoebfC4AfFO1x/0Bb3/wBH2de51i6J4T8OaDdvdaHoGkabcuhjaWzso4XKEglSyqDjIBx7CtquKvV9tUc7WudNGn7KChfY83+Nf+o8I/8AYaP/AKRXdcNZHVtTuL6PRfDupajHZTC3lmhmtkTzDGkmAJJlY/LIvOMc13Pxs/1HhL/sMn/0iu64WePVpfg98U4/DyzNqLagAqw53lPsln5gXHOfL39K8yrSjVr2l2/U9KlVlSoc0e/6Fz+y/Ff/AEJer/8AgVY//JFU9JvY9U0uzv4FdYbqFJ0DgBgrKGAOM84Nd18LT4Bd7V/Bv9n/ANqHT0F19iGH2jbn7SE48zd/z0+f7+P4q838Bj/iifD/AP2D7f8A9FLXPisPCkk4nThMROq2pG8oqOY4U1Mo4NV7g8VxnatypIeKqTc9asyGqkx5qijJulwT6VJ4Z8Sy+F9VEz75LFz+9iXk/wC8B60XYzurHuYxJwRW1N6mdWKlFpn0roOuWer2cdzYzLJFIAymttZ9oPVu4xXh/gO6ih0aD7GZYryN1icEfI3OPzOa9YsrqXEa3I2sQCMdDXqxb6nhSSu7FHx1OJdNtW5UrcAY9cq1c8iLNHtcAg+tbHjvaLKzl3fL5+CPqprEtnG0YpS3NafwlKSzlsSWgBeHrs9Pp/hTkeO4XKHkdQeorajwwwRVK90pXPm25McvqO9Sn2LcbnPanYnPmR8MOR71Hp1xukUHgjgitJpmibyrxdjdA2PlP+FZl9B9mu0nj+4x+bFNvqJJ7M6W3fIFacB+UGsGyl3KvNbFu3AoA1YPWrBPc8n0qnAxYgDpV+ONQATUMdhER5Bydo9KR7eNBlssfc1ajVnwIwcetMneOLI5kk/ur/Ws2O5T8snsFUVUnmyfLt+T3bsKfcSM5P2hwF7Rp/U1SmlcrtiTy09T1qbBYyNbAWDrkg9a5+Rq6DUkL25xkjIrGkgOOlctZandh37plznrWfP3rTuYiM8VmTjBNZR3Om5Qm4zVCfrV24NVVjMj4Fenh9zirvQx9TyzwxDr94/yrodOgCKueSKw0Tz9W46Bto+grrIECjnk19ZQXLCx8binz1Wz0n4DjGn+Kh/1Gf8A2yta9PrzD4D/APIP8V/9hn/2zta9Prw6/wDEl6s9ej/Dj6IKKKKyNAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA83+Nn+o8Jf9ho/wDpFd1xuiaj4j8PT6p/Yd7pC21/dC7ZLzT5JnR/JjiIDLOgxiIHp3NeifEiGKfU/BMU6B4m1lwykZB/0C8rE8TeHlsozdWWfJH3o+u33HtXBilUjP2lPsd2FlTlH2VTuZY8ZeOD/wAv3hv/AMFM/wD8lVhaFY/2Vomn6d5vm/ZLeO38zbt37FC5xk4zjpmtOCzuJlzHESPfimTQSwNiaNk+vSuOpOrNe+d9OnSpv3Nxd2Biq07Z4qUmq0hyTWZuirKeaqyHmrEpqs3JpobZUuR8prKIzJj3rXuB8prJc4myeAOTWsVqZyeh3/gK1FxbpblOBciRmx2AGB+lev8AkrMNhAPYV558L7bNlE5AywMp46k9P0r0y3jKjJxmvYWiSPCn8TOT8RWLtHEk4OzcVB/DisHyJrM4fLR9mrpPFV75l5BahyuB5jEdj0AP61BbssqlHAJHUVzTlZmkLooQSZxjkVOGyOadJZCNi0X3fT0qMqRSUjdO6Ibu3SZCrgEGudv9Plgifyf3kPXyz1H0/wAK6ViaglwVORWi1Vidjl9IuVLbM9PXrXTQSYQGub1O1+y3IniHX0rV0i4W4ljHUdcVKlbRjklujp7CN3A2j8a14o4ocGU73PRRWbBcYUJFgD+96fSrMLAHIyWPVj1qHdiUWy1NJJIuB8i/3QapSJhSC21farRBIJJqrMvPcmk9BpFCQqGPkg+7GoBA8+S7kJVx4wvMzBV/ujqao390zfuoxsTue+KkGVborLIqxj92vA9/eqs0AA6VeCFYhIRhQRgetPnQEGsKyN6MrHM3cAOeK5W7P718dM4rtdRXy4pGHZSa4a4PBrFLU7Iu6KMxyTTAJFt5WgQvNjCqPWnSdafDMsMqqQScdBXp0NLM4MU3ayJfD3he/wBkc8ojXPQM3NddaeGmfBnukUeiAmjS7qSaICOFI1UYGeTVrTZri/v3i8+QRKMkDjNez9aqW0PBlhYRfvHS/By0FiPF9urlwmsr8xGCc2Nof616JXBfChPLuPGS88ayvX/rwtK72uCTcm2zrilFJIKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4z4hf8AIX8D/wDYaf8A9N95WhqDKunuzANhGOPUVm/Eckap4JI6/wBsv/6QXlQa5clLJ0L4d8Lj29KzlrKxrTjco25zjAx7VZkjSaIpIoIPY1QsXJI5rTIrOcDtlsclq9mbOXK5MTfdz29qyHPWu11S3F1bsh4NcTOCjMrdVODXnVqfI7rY68PV542e6Kkp/Kq7HFTyHiq5VpHCRqzsegUZJqIm8iCY5BrEu8vLFAnL3EgiH0PX9Aa7a28JaxeKGECRK3eV9v6davWHw6aPV7e8u9SjbyM7YkiOMn3J/pXZRp+8nLY4q1aMYtJ6naeE1WyijK8KuF/ICunutTjt4JJc5CqTgd/aufihNqixcHJJ3AdazNQmNxOsSfcjPzfX0rsb0ueclzMjSaS8u5LqZZFeQ52kfdHYfhVxoWKBomZJB0IqOKJRjkqfrVyIsO+RWEmnudCsSWtxvRVmwJOhPYmnyRA1TleJZdszBEkIAbOMN2q1Ezxt5U/X+FvWs1o9CWrbEbRLiq0kJI4q9IcVGRnpWifcSkYV7biRCrDisK032l+YwSA5xmuxnjBB4rndTtWN3EV5yQPSnNq1zSD6HS2LFlX5gBWxaoo6EsfzqjosMaIvypkDnIzXSwoxT5HCj2WocyXUsil5MjDIUge/FVbobBzIi/Tk1qTW5YfNIxP0rOubdcH5yP8AgP8A9epbuJSMae5CkiJG345lk/oKgtYRK3mScqOee/uauTQW0a5kMjgHODwDWTfX32kmGIFIBwQvG6krt2RW+w+7uvtUm2P/AFScDH8R/wAKnfPlA47VmXU0NrZSSFnTYpPbmr+n7hYw+Z94qCwpThzI1h7pm6iu63kHqpH6V5/c9DXpV3GAxH8JrzrUY/KmlQ9VYiudKzsddN6MzMZcD3pbGIzStNtySTgH0qK4kEacnlzsX6mt0Wv2eyshypKnn8a9fDQuzjm1Kokdd4ftFGnISNpK5OetP8IRhry7fqxXA9etXPDaxvpcYzuAyv15qv4WTydZuEIA4YfU5rr+yzyK7tVXqzo/hkpW/wDGgPUayn/pBZ13FcV8OBjU/G3/AGGU/wDSCzrta5mahRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcB8WZmt5vBsqHDLrLYP8A243YrnrmWWdt8j7vcdBW98X2dG8HtGSHGstjH/Xjd1hGeFv9eDE/Teg4/Ff8KiW5tT0VxbdyhBIx7g1qpeER9n9OxrORPk3fKydnTlT/AIUHK8ikzZTvoWJ7x93G3n0FYd5axTzO7FlZuuBxmrssgLe9GwOQMVm4RkveQKcoO8WY40SaW9EKt+7IBL/0rsdD0aDT0HlJmQ9XPU0ukW5dmlYcHgVuomBWMacYu6N5VZTSUgC4H0qocFic96mupNkTY6ngVWgG6QKOcdfrWm5zySsWCBJGUJK+hHY+tZkdkICVZiWzyQOtbXkgDk4NZ16gafOe3NPZGcHd2ESNADgHPqearzSOh2twO3vTnYRDJz+dUbq6+0KFiBbnr6fjWMmdMUVp4f7QuxEw3QxkM3oT2FbMeTEI5SSo+63dap2Nqsce05yTuJz1NX0G0gjlTwc9qI26hKSehGsp+6xBYHH1p5eTqqqwHaob6wjlG5S0beqnFcnDpE17qjSNdzi2hbAAkb5m/wDrVWqQo01I643ETna2Uf0bis3UoyrxyL1ByKU6YhjIMkh+rE1ixQ3UWtrCJ5HtMElGOcH2PaplqrFKnbZnoOlIksKSLgBhkit23woxkVz+kL5cYUfd9K2VIAocbsxcehYkdR1YCs+6mjw2Gye2KLhsA54FZV3J8h2cnpRyjULGZqszSl1j4C/zrMjhnRAfL8w9wp5/D1rRvV8q2QDlmbmqxkZAWXggd6pbG0EYOrzi5urKxUEebKC4IwQq84rrCBsAHQCuP0qdtV1yS/dcRQqY4vc9zXWRtuWpTT0LasQ3S7os91rhPFMPl3fmAcSD9RXfycA56GuW8WW+/TmkXnymB/A8VlOL5ro0pytocDdhQ9oz52/aEBx78f1rvdYgU2MTZxsYYIrgNUyLFmUkFXQg/wDAhXpRjFxpYDZy0YP417OE+E8+rLlrov8Ag991q0Ywdr9fqKZbf6F4oyw+WR+/bNVvC0hivFVSAkg2n69q1PEsAjltrvaOu0n9RWsd3E5cwjafMvU3Ph3/AMhXxv8A9hlP/TfZ12lcJ8LZhcXXjGUZ+bV4zz/2D7Ou7rme4LVBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHn/wAW/wDWeDv+wy3/AKQXdVbiwhvrSOTG1yv3h61c+LHM/g4f9Rl//SC7pmmH/QlHoTWczqoq8Pmcy0Vzp8+6MnHqvQ/UVbS8hlTMy+S/95RlT9R2qzqqNuVk6gkcVUi0+e74jQLnqTxUuVinBXInUPMAhVv9pTkVp2Fo8si44XuasW2jNbQED5nPUgVqaXEV+Vh0rNzuxxjpdlu2t1jjAAwBSyHaKlZgAapTyc+1IorXT5I+tWNJQFix5UcfWs65kwQB94nA+tatuY7W03O4AAyapIxqu2hPeSpGmep7VjSygZZjUNxqAuCWjBPYUyGOZ23HA+tKSLppRXmNmDTqNysI/wBTSwrCoAUbQO2KtiIkfM5/ClEaLztyfU1naxVxqsMfKvHqajjnCSEtyh4IqC+uhH8oIFVhcKFw3JbooqWxqPU0bq4XyGijYGRh8g70yztxbwqgJ4FZ1haMBunkk3seNvQDsK2IlKpkPkD2qo66sq6WgybgZHWsfT/32rMD1IOKv384WAsrqx7djTdIXbtdlG896T96St0KbtH1OltE2KBV0NgVTtzkDNTlwo461okZEVwx9azpzgE96uTyA8VmXkgSMnvUsZWugtxMIUceai7tp71g+ILo2WlXL/8ALbGxB/tHitUStE4dwGzzn0Ncxq4OreKUgDZgt1DsB03n/wCtSb5VqXBO9jR0O1Fnp0MZHzbcmtqA/KKqFcJkcjpx2qRJgFxWVJOzbNJvUnuGGDXO+IXxo12T3AH6iteaUtwKxfEsRl0iZVJzGQ5Hr7Vo9hR+JHDmNZo5IpBlXXBrvvCshk0uNHYOY/kJPf3rglOGrqPCV4Emltj0I3jPeu7B1NeU5cbTtaZoW4FrqgAGNsnb0z/9euq16ITaS+Bu8vDY9q5bWEWO5EyswLgDGM8iuq0q4F5pqiQqWKbGA9a7HpK5nio+0pKRH8FzmLxcc5/4nIx/4A2lej1558HovJbxjH/d1sD/AMkrSvQ65p/Ezlp/CrhRRRUlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwPxX/1/g3/ALDLf+kF3UFkwW125y244FXPidD9ovvBcWdu7WX5/wC3C8os7AQ3AQ5J6n6VlUfQ66HwsfDZIq+ZMoZzyM9qmjVRJkACnzvyahRvmrF6mi11LTvtwccVIdoXcByajCl0xSXDiOMJnJpAyOV8LnNUJ5goJY4AqW5mCpycCuW1fUlJZd4SNerH/PWririvY0IZ/tF4D/AD1pNT1DzG2IwEK9STwawF1BmH+jgeSOMg9f8ACoNTsrDX9LudNv08y3nXZLFuKnHUcjkdAa3jTtqzlnUTehuqecqSje3SrcV3JHgTDC/3h0ryhNG8XeDTu8O3x1/SE/5huoPiZB6Ry9/oePY0zU/jNpun6Q8y209vqkE0aXGl3sZSXYWAfb2PGSP1ApShcqNSx7Os4IyhLfSoJ7or94hRWFo2tWGr6ZBqWlXC/Z503oc/KR6ex7Yp82qW0U6DUA6ByAHIyvNc9SlJG0KkWSzwyXt6NpKwY+96/T/GtOG2hTjGD6mpbWGBkWWFtyMMgg5BFTFgGwfwrJRNHIYm1BjcCKlUgj5XCyDoezfWmMBtzVGaRXBUH5xyMVWxNupU1tP9MtvLG0yHDoOn1rc0+PgcVz6CSbVVLowVV4z6101thEHrRTW7ZUuhoRttFJI/FRLlqSQ4GO9aCIZHznmsu9kBkC596u3brHEW79BXManqCW0Mk0pwq5x6n0FTbUcdWQ69qpsoNsY3zycRoPX1+lGgaXJFbtNcbjczHc5ql4cspb68fVL5evEaHsK6wscccVz1Z30R0RViu0Tx8oPw7GoyTnmE59jVkzEdaRpWJ4xQqqE4lcLK33U2e561W1GFTaSQ5yXUg1elkYIT3rPmfIyTSlUvoCjbU86xg4qW2mkt7qG4iIDRkk5OOPSrd3pd7BEbiSA+WeTggkD3FZzAFWB6da6cPK0kxYmKnCSXY9B3pqGnkoQxYbl9jT9AvRBcCKQ7QRjA9a5Hw1qP2W4ELElGPyn0rptRtmjxdQkA9zjp717M49DzMLVVSPs31Oy+Fxze+NCP+g0v/pBaV3Vec/BiVpo/Fsj53HWFBz7WNoK9Grje5LXK7BRRRSEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHF/EU7dV8EH/AKjT/wDpBeVdEgaTI64waz/iUcaj4KP/AFGn/wDSC8qWOXEnt3rCp8R00l7rFm6mol+9Uj8saAAATWRstEK0pUcVTnmySWPApl1OI8ljXLa3rQXdHE2X6YHam7JXY0nJ2RJ4g1nYPLj5Y9B/U1wetT3DOkztuhHDD+771ekdpHLOSWPU0x1DqVYZUjBFcsq7ctNjshRUVruQWk00SB45GXII46YrSsruIYQr5bE5LDkE+p7/AI5rO2hPlHQdKRgMV9bDBwnSi4vWy17nx9THThWkprS707HVrfi3VC7LJG5wuPm3fTFcP8RfhhdePb+O7j8QxwRQKVhszZglc9fn3gt+X0FaVrdSW8mVOD69fzq+dVjZGcsQw6BfUdvrXBWoTpO0kd9GtGqrwdzkvAXgvWvA8lxZz6pbXml3B5gdGRkf++vUDPAI+h7YPT6zePBYIkMiHzH2rBcY2tj0P40+z8TiZHXUoEms84LScMn49RXO6hEuuXYufD90l35eVSwmO2Ut6r2brWVi09T0DwXO50lvLDwOszr5MhyOuePbmuhNyHIVwY5fQ9/pXL6LFJpel21jMDviXDq/UMeT+tacNz5kiJJlgSAK5JQ5nodaqW3NtZDIpX06mm+YkAOEGKyV8SaIkYI1K2CkEgbueuOR1zWRr/jTT7a2H9mvHeTv02n5V9z/AIVpRwWIrNKEHr5afeZ1sXQpp881p56/cbunXQuNRnUrhxg/UGukjTgACvIPAviS7vfFTQ6g6bZIyUCpt+YHP8s/lXr8L7hxTxOFqYSfsqu/kPC4mniqftaWxMSEXrUJYEnJwKlEZJyelRXM+FKrwornNtUZOry5cJnA6cetcYEOu6uqKD9hgbJPZmqXxFe3N9qh06zLBcfvXXrz2/Kt7TbUWVqkMMQGByScZrnrVVFWW51UqbtcuxKsaBFGFAwBSSSbRSKsh6yAfRf8aa8Z7yufyrlu+xtyrv8AmNX5zk0/pUALIvD/AJiojMx44NK/kPk7MfdSYBA71XjjMhyfuj9aGYu5UEZHX2qxbACID04q4u+hMouKuRSqJUKE8HgivOp4zDdSRHqrFa9FYbJM9jXD+IQo1iYoeCQT9cV00nYy3diraQsQrDHH4Yr0Hw5MNQ01o5D8y/I4/rXH2KHYgVxtYjjNdN4TYx6m6P8AKJRtA6DPavoqj5o8x8zSm6dTlOn+D0bQt4xjfll1sDP/AG5Wleh1w/wzG3UPGo9NaT/0gs67ivPluz0W7u4UUUUhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw/xM/5CHgr/sMv/wCkF5TwB3NM+Jpxf+Cyf+gy/wD6QXlRGYBuTWNRanVR+Euhc9BxUN04hjJY4FMk1GOGIs7BVUZJNcPr/iKW8do7clIume7VlKShuawhKo9CXXtY3O0UDZPdh2rmSCTk96dGM81MI+M1x1JubuzvhBQVkQbeKYwxVzaMcVBItZtGhWkHGajxmp8dqb5ZU4719Zklf2lB03vH8n/TPkM8w/s66qLaX5r+kQFCajFg7szwvsbv6H61d8sgZrV8MyBdVSKUAxzKYyCM+4/lXdjKKrU7PpqcOBruhUuuuhxupaJPdDa7mM/+On8q0PDWgQ6bOlxJOPtQ6SMuAo9F7D65J+lejT6VbEkCJQPSoP7Ltgpj8kAHuCcj6GvGVGdrX0PcdaDd7aldL4yAR3q+cF4D9GH496qXlytvGxgy8sh8uEerHj9M1UjRhNIke6OMEqOecZ/nXI+OYrmxSOWyufLZ8oBIflz179M8n3NTRoyrVFTjuxVpqlBzlsiLxLo7XItL+CVzHb5guWhHyRshxt7kE57jBzWcbfZ1P3hn8fajQNTvdOV5PNBvZdhkk3KwAVgwAA4xlR1qV74XEgefke3HGck/ieK+2ynD1aNK1Tbp/wAMfDZ1iKdaqvZPVb2/z/r1KEc82nahBeQt+9jcMp9SOx+vIr6E8J61a6pp0Fwg2iVc4PVT3FeB6pblbW2fORI5Ax6gDP6t+lXdE8RXOiXptYFzDhWkOScHHYfhXNnmW/W6aq0l7y/Ff8A7MhzL6vP2NZ2jLX0ff5n0VPLkYHArn/E2px6Xpktw/wAx6Kv94noKwT4tkg0qC6Biukk+Xyw3zofRh1Fc7f6he65MjXoWO3RtyQoOM+pPevg6qdJtS0Z97Qh7W0lsa3hVPMhlupW3Xcjln/H+ldOr/LzXGWFw1pOrr93ow9RXXREMuQcgjNcDd3c7Zx5SwG4zUU77QD60sayOmVXj3qtdllUCRSKLEXEdiw4qvqM/2KyeQYL9F+pq3GNyA9axvE7/ACwRepLH+VBUVd2Kvh24Yag6uxJlGST3IrpSmCSh257dq4/S/l1O3x/ex+ldmx+XNKyZVSTi9DK1e7+y27McM3QD1NcPcEvIWc5YnJNdJ4lkzJEn1auZlPzGuikrGbd0bOmgGEdicDPpzW5ZMLa7hlYnKuD16jpXPaZIFTbvPzHkCtmOMPIdq7uP4j0r6Kn71NX7Hydf3asrdz0L4bYOo+NCOn9sof8Ayn2ddtXn/wAI5TM3i92wT/bCDj2sLQV6BXC9z0Yu6TCiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOB+LEohm8HSMwULrLZJOB/x4Xdcxe69AmfKPmv7cD861vjzxp3hX/sM/wDtndV51XJiKjjKyPQwlNSg2+5cvtQnvGPmudvZR0FVkQufaliiLn2q7HGFFcTbbuzvSSVkNjjCrTiOKlC8UhFAyv0pjip2Xmo5BgUmMpMMGr0MKzRRyd+hqpKOauaW/wAsifjXp5NV5MRy/wAy/wCCeTnVH2mH5v5X/wAAmMK4xiqQkNrdxSjqjhvyNapGaztQjwc19dvoz5B6ao9HSATwiROQQCKpzo0T/MKb4UuzNpUQZuY/kP4dK3riBJx07V4c26cnFntwfPFSRwZixdTlxghj/Os/WNKj1K2aK4QNGexFdpd6WGJcDDdMjvWfLZtyJH4x2HNc3JNSvBnSqkbWkeHeMNFl8PPbtHIZbectiPAyuMfmOR1rGjv2O0JGzMeeeAD6k9/wr0f4jWDXWrWUYbaggJTPc7uf6Vyd5psdsEVQWIGWY+tfeZdVk6EeeV2fFZlThGrJxhZIp2m+SZN7FjnP0q9bPCrTSxztFdszBiwypQAAAe5+br7VZ8M2b3V9LBbwpLJJGURpDhYzxlz9B/Os7U9Nv9KZbbUomULnZIDlG57NXVOvTU/Zyep58MNVnF1YLTYuWt3JEwA/eKD0H3h9K6TSdRiuxsV13gdOh/L/AArhVd07lsfgRVlblZFy3Eo5Ei8H8fX+defmOU0MfD3lZ9H/AFuellmb18vmknePVP8ArQ9EAzXTaRN5unr/AHlG0/hXntlruwRx38TIWA2ydm96zfEGvapEz29u72tk54aI8yf8CHT6V8VHhzGOt7J2S730/wAz7epxBhHQ9rFtvtbU9vtHV4V2nOBg+1RaiFNuwcdq8U8EarLYan5hlfbkF8seRnB/mK9Y1CWXYdzZXFc2a5fLLqipSd7q99jTLMfHH0/axVrO1iWxO63zWF4gbN8g9EH8zXQ2o22o9xXM62c6i3soFeUerT3K2nj/AImVv/vV2Ehwn4VymljOpw+xJ/Q11Ux4b6AU0Kq9TkdfbN7j0UVgS/era1c7r+b24rGmHzVvTJ6GpoyB2UEdeOtdDChiQlzwemeTXP6MA8OMDg89ifxrc+YAByCBxgHP519BRd6cfQ+VxStWn6nXfBggx+LiowP7ZHH/AG42lejV5x8FiTF4uycn+2gM/wDblaV6PXHP4mdtP4F6BRRRUlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5f8AHo403wr/ANhn/wBs7qvPoV3tzXf/AB/40vwt/wBhr/2zuq4S16CuHFfEengvgfqW41CjgVMoqNakUVynaKaaRUgFBWmIgIqOUVYZajYcUhlGRadp7bbkD+8MU+UVXU7Jlb0INXh6nsqsZ9mjLEU/a0ZQ7pm3Ve8TdGTVimuMqRX3h8CXPBV1tupbdjw67h9RXfRj5R6V5PZzGy1OCboEcZ+nevWLVg0AI5xxXl4+HLJS7npYKfNDl7DmAzjtUM9qki4xzVjb0weaUdwetcCdtjtOP8R+GYtVgWOQujxndFLGcMh9v8K5MfDl2kLXWozyoe2zBP616y8eAWPIpNoZeBXZRx9ejHlhKyOWtg6NZ3qRucLYeHoNLhKWsOzd95jyW+pqWexjlhaG5iSWJuGR1yDXYywh0AIqpPZo3SoeJlJ80nqaxpRguWKsjxnxV4PgtI5LrTGaNF5aBuR/wE9R9K4ue2dCCyggda978RWinTrhcc7D/KvMZrSOdGwMOBkH1rb+28RhpRs7x7P/ADKhk2GxcJc0bS7o5m01CSBPKIWWAnJikGR+HcH6VfjaO5Vls2GGHzWsxzn/AHT3/nWbf2NyUMsLrzyFI7VnRS3EcoSeF1bsQMg/Q19jQqLEQUpKzZ8fiKEsLNxhK6Xyf9fgbltAFuY2jRo1cmIqxzhsf/qr1vR5zqGgWkp5coFb6jivJGvQY7ZTktG29nPUtx+gAFep+EEaKxurdukU7Y+h5FfNcV0U6VOfZtHucK1m6lWHozdj4h2+grldVOdQm9sfyrqv4TXK6jzfTH/ar4Y+4p7i6MudST2BNdNN91vrXO6EM6gfZD/MV0VxxCT9aaJq7nEXzb7udv8AaNZkv3qvTHc7n1JqjJ1reAM09EwY2DD5d3rwK3VZAoIzyOcDPHrXP6Nnc2Bk5HXpXQLKD8qMCAM9MV7uGd6SPl8erYiR1vwWO6Hxcf8AqMj/ANIrSvR682+CR3W/i48f8hodP+vK1r0muafxM6qXwL0CiiipLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyz9oD/kE+Fv8AsNf+2d1XCWp+QV3nx/8A+QV4W/7DX/tndV5/aE7a4sT8R6eC+B+ppR9KnUVXt+atLXIdguKKWimA1hxULCp24FQvSArSiqco5q9JVOYc1LKRqwNvhRvUVJVbT2zbKPQkVZr7rDT9pRhLukfB4qHs604dmzO1GPuK9C8LXhutJhYn5gu1vqOK4a8TdCT6Vu+BbsATW7H7pDgex4P9KjGQ5qd+w8JLlqW7naq3tgCkLHcSBmngZUgdD3pqDBGK8U9YGOQBTxwoFMcfN9acPug0wIyWIIphXpx1qbdk8dqXHegDC1pN8MqkcFSP0ryVfllI98V7TqUIaBmPUV41crsvZV9HI/WubFLRM9DAPWSMuQLDvQjLITx6qe9UZzGY2IGfQV0r2kV2gEgIYdGBwRVU6C6kFZ8qD3QE19Bl/EFGlSUK6d126niZnkFavUc6DVn36HJxwGRxlWwTjp19hXsPhS3uodMMt/j7ROwfGMYAGBmodJ8M2FjIJn3XM46NJ0H0FbrHNeZnWdf2glTpq0V33Z1ZPkyy+85yvJ/cl/XUXs1cnf8A/H3N/vGurH3T9K5O95upv98188fQ0y74fX/SpD/sgfrW5fHbbv8AQmsfw+P3kp+g/nWnrD7bKU/7JprcmpqziDyKpy/eq4elVJutbQ3KZp6FC0kVyyZOzBIHpWjv3D5lC45JznNTfD+ITT30Zxgxjg/WpdXszbXLo5BC/dQcZHrXtYR3ppHzmZQtVcjqPgdn7J4s3df7ZH/pFa16XXmfwNz9j8Wbhg/2yP8A0ita9MrGfxM0p/AvQKKKKksKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPLvj8M6X4WH/AFGv/bO6rgrUfJiu9+Pn/IN8K/8AYa/9s7quDtzXHifiPSwfwP1LsIwatLVWHrVodK5DtHUUUlADXqM1KaYRSAqyiqsozV6UcVTkHFSykT6YflkX0OavVnaacTOPUVo19flMubCx8r/mfG5tHlxUvl+QjDcpFVtIn+w61C7HCE7W+hq1WbqI2yAjvXotcyaZ51+VqS6Hrdu+6JcemDT8ADI9axvDN59q02BicsyhW/3hxWu5wdtfPzi4yaZ7kZKSTQ/hsZpAeSOwpvIUsTmkUFjwcc5xUFD5AAgK9TQAcA5603dk4x0p2eMDpTAq6iSLV8jtXjmrLs1a5H/TQ17LfPttHGM5FeP+IhjWZz64P6VjiF+7v5nZgX77XkMhPStJOYyPasy37VpR9BXmSPWR1Fowkt4z3wKlIxWNY3OyIDPSp5bv5MZqWjKxd8wYauXujm5lP+0a0jdYBrKc7nZvU1KNYKxp6K4RXPq39KsazNus3GevFZVrL5ake9LeTmSPb71SJktTKkGM1Tm61emHFUJutawBnYfDMf6beHvsX+ddB4thXfDcMuTjYcf1rnvhsStxeMB/Co/Wuw1SA3dq6dGPTvg16uFdkjxMfHmk0Q/BIYt/Fv8A2GR/6RWlek15v8FEeOHxekoAca1ggf8AXla16RSn8TM6fwL0CiiipLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDy74+/wDIL8K/9hr/ANs7qvPrdulegfH/AP5BXhb/ALDX/tndV51A1cmI+I9LB/A/U1bc9KtqeKz7dulXozXIzsRKKKPSipASmNT6aaBkTjiqsi1cYVWkHWkxohs/lu198itOsqM7bqM/7QrVr6bI5Xoyj2f6Hy+eRtWjLuv1Cqt/HviyOoq1TWG5SPWvaPEZp+Brso0tsT/tr/Wu64ZVbvXlekXH2LVI5G4AbB+lepWzB7Yc5PrXk46HLPm7np4OfNDl7Dk5zu5BppHOBxUkfD5PSkcZPBxzXEdgrbQCQOopEwFPOT1pjtxjHSmI21QTzk0gKt9MfJdfavLPFC41QN/eQGvTtQOQcV5z4sTbcQt7EfrU1leizpwjtVRmW56VpQnKisu3atG3bgV5Mj2UTiQocU4uWFOKgrQFwKlsEiJifWowKnKUm3AqUiiEcCo3OTUzDioXFUSyCboaz5epq9KeDVKTqa0gSztvhoh2Xj4yMqK7dlXDZyMmuO+Hq7NMmf8AvyY/IV08k+OM4HpXqUdII8bE61GS/DEKL/xrt6f20n/pBaV3NcJ8LTuu/GZ/6jS/+kFpXd0PczWwUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5b8f/APkFeFv+wz/7Z3Vebxda9I+P/wDyCvC3/Ya/9s7qvNoetcmI+I9LB/A/U0ber8VZ8Bq/EeK5WdhYHSikFLUABpppxppoAY1VZe9W26VUm60mNFRuJAfQ1sVjSferXQ5RT7CveyKX8SPp+p4GfR/hy9f0HUUUV9EfOmdfLtk3Cu/8G35u9MjD4LJ8jfh0/SuEvehrY8C3fl3ksJOA43Ae4/8ArVz4uHPT9DbCz5atu56BuG73pHbmgEA80hUqTmvDPYF+8pPtULkIhHXNSZ3YPYVWnb5jQBVuTnNcN4yT93E3o5H6V3M3SuP8aJix3ejg0T1pyRth3arE5KE9K07boKy4MVqW/SvJke2i9HyKkABqKI1OvSsihpWmOOKnxxUbjigCqwxUEnSrL1WlpiKkp61RkPzGrc/FUmOWrWBDPR/BcRGhRcfecn9a6WO1yvQmsvwggTRrNDjBjDEEetdHAADjOR616cNIo8Sq7zbKPwzXZqHjVcYxrSf+kFnXcVxnw8x/a3jfH/QZT/032ddnSYlsFFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8t/aA/wCQV4W/7DX/ALZ3VeaIcGvS/j//AMgrwt/2Gf8A2zuq8xWuSv8AEelg/gfqaMDdK0ITWVA3StCBq5mdaL6mlqNDUgNQMKQ0tBpARt0qpPVxulVZ+lJjRRk+9WtDzEn+6KypBWpb/wCoj+le1kb/AHk15HiZ6v3UH5klFITikr6Y+ZILwZWqVhctZX0Uy/wMD9R3q/OMoay5V5NFrqzJbs7o9fsZVuIFdGyGAYH2qaYkCuT8BX/mWpt5Gy0JwP8AdPT9a65xxk14Fan7Obie5Sn7SCkiBjlM1UY5arzqGTjiqMi/N9KyNCKQVzfi+PfpMx9AD+tdV5RKnisHxJHu025X/pm38qdrpouDtJPzPNrc84rXtvuisW2OcVs2p+UV5Ez3kXIqsrVaOrS1kUOqN6kqJ+tAEEgqtIMCrT1WmPBoAz7rpxVAn5jV25qpbIZbyKMclnC/ma6KexnI9k0VPJsLZB1WNR+laQJ3cHA9KrW6mIAZ4xirAbDf7Wa9O1keC3d3I/h0Q2q+NiOn9sx/+m+zrtK4r4cf8hPxtx/zGk/9ILOu1qGUtgooooGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlvx/wD+QV4W/wCwz/7Z3VeYV6n8d08zTvCyjqdYP/pFd15Z3rmrx1TPQwclyuJYgatGA1kxHkVoW7VyyR2mlGamFVojxU6msxklBpAaWkAxqrTdKsnpUEo4oY0UZBWhaHNsn0qhJ6Ves/8Aj2T8f516+Sfx5en6o8fPP4EfX9GSNQTQ9MzX058qEn3azphya0D901n3BxmmiWXfDd39j1aFmOEc+W30P/169TDAxLj05rxcuBznmvU/DV8L7TIJc5Yrhv8AeHBrgx9PaZ6GAqbwNTGATnNRGMu+eak/ioWQK1eUeiBKhSOprA1iPzIJl9VI/St8gckd6yNSQgMPWqjuB49CCshB7Gti1PGKzZ0KX06ejn+dXrU4xXk1FZ2PoIO6uacfarKVWi5FWk6VgWPqKQdal7VG/SgCs3Wqs3erT8E1WmPBoAzbjvT/AA7H5mvWg7CQH8uaiuj1q74SUHVkY/wgmuuhG8kjCs7QbPVAwwo9D61bTrn1rJjkQD5jnPSphdBF4b8M17Dpng3Lfw2OdS8bH/qNJ/6QWddtXB/CuQS3XjNwc51pf/SC0rvK5ZaNmq2CiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNvjZ/x7+Es9P7ZP8A6RXdeVXKeXK6+hIr1b42f6jwlj/oMn/0iu68y1Zdt2x/vAGivC+HUuz/ADRrg6lsQ4d4/k/+CUkPNaFs3Ss0cGr1qa85nsGrFU4qvDyBVgVkxjlNPFRjrUgpABqCXpU56VDL0pDRQlq9af8AHsn0qlNV20/49o/pXsZIv38vT9UeNnn8CPr+jJGqKpWqNutfTHyxHK+xTWdK2Tz0q9cruQ1myNg/N0qooiRXmbkiut+Hl+VnltGbAYb1+o61xzn5+lXNJuWtdQgnX/lm4Jx3HcUV6ftKbiVQqezqKR7MF6tUY4Y0lnOJIlZTuUjIPsafJwwNfNtWdj6Bakypnk1l6gv3q1A+OneqN8u5fehbgeR65H5Wt3I7Fs/nToO1WfGCeXrKtj7yD+tVbU5rzcQrTZ7mHd6aZpQGridKpwjGKtKelclzclpjd6dTHpgVZetVpjwasydapzng0IDNujya0fDAZTNInUACsy45NRxIWU/PIFzyoYgfpXr5ZQdaskump5mZ11QoOT66HVXOuW9qWEtyAw6IvzNn6Cs6XxJdXHy21uVH9+U4/SstI0iICIoB9qcOGwK+qjhILfU+TnjZvSOh6h8CZJZrDxU85DSHWeSBgf8AHla16dXl/wABOdN8Vf8AYZ/9s7WvUK+cxCSqyS7v8z26Dbpxb7IKKKKxNQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA83+Nf+o8I/wDYaP8A6RXdec66n7yNx3GK9G+NYzB4S/7DJ/8ASK7rgtVUNadsqc118nPhJrs7/dYwhU9njIN9dPvuYB4NXbU5xVJ6sWjYIrw2fSGzD0qwDVOFuKsqayYyUU9aiBp6nmkA49KgkNTN0qB+lIaKk/Srtp/x7x/SqM55q/a/8e6Y9K9nJP40vT9UeNnn8GPr+jHt2pjDintSV9KfLkTDIIrMvYtvNapFU75MpmnF2ZEloZLEdR0pgbYwIokBV9oxRsx161vbQyuek+CdUE1p5Dn54vXutdRgNya8a0jUptPu1njP3eCOxHcV6DZ+JbC5jj2z7JGOPLbqDXjYvCSU+aOzPYwmJjKPLJ6o6OSRUI5474qCeZGHFZN7qtrbxF5JAo6kk4rktT8a2sMjLbEztjI28D8TWFPDSnsjpnVjHdlbx0ytewMvUZU1mWh4FUr7VptXYyNCsaryMNnNPs5OBXm5jRlSqWaPXy6tGrSvF3sbsTZqzGaoQPkVZR68k9IujpTJKjWXjikZyelUIgmPWqc3Sr7IW6kCoXijXqc0IRjTLnheTSwj92tWbtkCkRryfSq0BzF7jg17+RS/fNeR4eexvQi/MeeOT0FJwWye3FKec0mOOTX1Z8kz0v4B/wDIM8U/9hn/ANs7WvUa8u+Af/IM8U/9hn/2zta9Rr5PE/xp+r/M+mofwo+i/IKKKKxNQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA81+NxxbeEsf9Bk/wDpFd1xBjMiupHUEc13HxtGbfwkP+o0f/SK7rkOnFevgEnSaff9Dycc2qqa7fqcrIMMQeopYDhhVq6VRcyq69GNJFbAtlTivmZrkk4vofYwlzxUl1Ldu3FXENV4rcryCDUyhgeAKxZZMKepqMAngsBTiq/xSflUgOZhjrVd3ycLyakdolHAJ+pqLeT91aLDIZYyVO/j2FXLP/j3X07VUnVmX5m49BVuzYGAAduK9bJmlXd+3+R5GdJvDq3dfqSt0pDTm6U2vpz5QaeRUcihlINSGkNAGLdQhJMkfSqrtg8YxW3dRB4z61jzRAZxW0XcyaIyRtFNVirHHQ0qqOh7UkhKEYAI9TVEjJ4Vcgklvqc1H9jHByBVtcEZPGaY5Kj1FNO2wmr6sjhjChlGOmKnt4lfBzhqrrnceat2yBweoOa8HP4q0J+p9Fw9N3nDpoX4ICOBKPyq0kKj7zFv0qnFE46SfpVhU5+dmavl2fTlgMg+7inckZxTEKgcDFDPSuFgfPrioZEB6804nNLnIpXGVmjHpgVnzr5Uuf4T1rVYVXuIg6nitqFaVGopx3RlWoxrQdOWzKZ9u9B5AFMjz909VqSvvcPXjXpqpHqfBYihLD1HTl0PSfgH/wAgzxT/ANhn/wBs7WvUa8u+AX/IL8U/9hr/ANs7WvUa+bxH8Wfq/wAz3qH8KPogooorE1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDG8UeGtL8UWlvba1DNLFbzC4iMNzLbukmxkyHjZW+67DGcc1z/wDwqrwp/wA8dY/8Hl9/8eoopqTWzE4p7ojb4S+EHbLWuqsfU63fH/2tQPhJ4QHS11Qf9xu+/wDj1FFS0nqylJrRMcPhP4SHS31Yf9xu+/8Aj1H/AAqjwl/z76t/4PL7/wCPUUUcq7D55dw/4VP4S/599W/8Hl9/8eo/4VP4S/599W/8Hl9/8eooo5V2Dnl3D/hU/hL/AJ99W/8AB5ff/HqX/hVHhP8A54av/wCDy+/+PUUUcq7Bzy7iH4T+Ej1t9W/8Hl9/8epV+FHhNfuwauB7a5ff/HqKKEuV3QpNyVmL/wAKq8Kf88dY/wDB5ff/AB6j/hVXhT/njq//AIPL7/49RRV88u5HJHsJ/wAKp8Kf88dX/wDB5ff/AB6j/hVPhT/nhq//AIPL7/49RRRzy7hyR7B/wqnwn/zw1f8A8Hl9/wDHqYfhH4PPW01Q/wDcavv/AI9RRT9pLuHJHsNHwh8Gj/lz1P8A8HV7/wDHqU/CLwcetnqZ/wC41e//AB6iij2k+4vZx7B/wqHwd/z56n/4Or3/AOPUh+EPg09bPU//AAdXv/x6iij2k+7D2cewf8Kh8G9fsWp/+Dq9/wDj1KPhH4PX7tpqg+mtXv8A8eooqZScvi1KilD4dB//AAqbwiP+XbVv/B3ff/HqP+FT+Ev+ffVv/B5ff/HqKKjlXYvnl3D/AIVR4S/599W/8Hl9/wDHqP8AhU/hL/n31b/weX3/AMeooo5V2Dnl3D/hU/hL/n31b/weX3/x6j/hU/hL/n31b/weX3/x6iijlXYOeXcP+FT+Ev8An31b/wAHd9/8epP+FTeEf+fbVv8Awd33/wAeooo5V2Dnl3G/8Ki8HZz9k1PPr/bV7/8AHqP+FR+D/wDn01T/AMHV9/8AHqKK0jJxVk7ESipO8tTpPCvhjSfCtlcWuh28sMNxMbiXzbiWdnkKqmS0jM33UUYzjitqiipvfVj2CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Insert the needle in the proximal tibia on the flat surface located distal and medial to the tibial tuberosity. Direct the needle caudad (away from growth plate) at a 10 to 15 degree angle. Use downward pressure from the heel of the hand, and a twisting motion until resistance decreases. See text for details.",
"    <br>",
"     (B) Marrow can sometimes be aspirated.",
"     <br>",
"      (C) The needle will flush easily when it is in the marrow cavity and should stand without support.",
"      <br>",
"       Once successful placement is established, immobilize the leg and secure the needle.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39190=[""].join("\n");
var outline_f38_17_39190=null;
var title_f38_17_39191="External beam radiotherapy in the treatment of thyroid cancer";
var content_f38_17_39191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   External beam radiotherapy in the treatment of thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/17/39191/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39191/contributors\">",
"     James D Brierley, MB, BS, FRCP, FRCR, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/17/39191/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39191/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/17/39191/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39191/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39191/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/17/39191/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiotherapy (EBRT) has been used in patients with all types of thyroid epithelial cancer, medullary thyroid cancer, and thyroid lymphoma. It can be given as primary therapy to treat unresectable cancer, as adjuvant therapy after surgical resection, and as palliative therapy for symptomatic recurrent cancer. EBRT can be given alone or in combination with surgery or chemotherapy.",
"   </p>",
"   <p>",
"    The use of EBRT in the treatment of thyroid cancer will be reviewed here. Other aspects of thyroid cancer management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41064?source=see_link\">",
"     \"Surgical treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WELL-DIFFERENTIATED THYROID CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the primary treatment of patients with differentiated thyroid cancer, followed by radioiodine and then thyroxine (T4) therapy. However, not all patients have resectable disease. For those with residual tumor after surgery, radioiodine therapy is unlikely to eradicate the tumor unless the absorbed dose of radiation is high, ie, at least 100 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/1\">",
"     1",
"    </a>",
"    ]. In one study, as an example, a single dose of radioiodine producing an absorbed dose over 80 Gy resulted in destruction of tumor in cervical lymph nodes in only 74 percent of patients with small-volume disease (less than 2 grams) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/2\">",
"     2",
"    </a>",
"    ]. Further radiation in the form of EBRT can improve local control.",
"   </p>",
"   <p>",
"    The efficacy of EBRT in controlling residual disease has been illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from Hong Kong of 842 patients, 126 of whom had gross residual disease, the 69 patients who had EBRT had better local regional control at 10 years compared with those who did not have EBRT (56 percent versus 24 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The complete remission rate in patients with palpable disease may be as high as 78 percent with an actuarial five-year relapse free rate of 62 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 88 patients with well-differentiated thyroid cancer that had been incompletely resected, the five-year survival was 77 percent with EBRT compared with 38 percent after surgery alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that patients who have macroscopic residual disease after thyroidectomy be treated with radioiodine followed by EBRT to the thyroid bed and known sites of disease. If thyroidectomy is not possible, EBRT alone is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with well-differentiated thyroid cancer have resectable tumors, and the results of surgery, radioiodine therapy, and T4 therapy are excellent. However, there is a subgroup of patients whose outcome is poor, namely older patients with extrathyroidal cancer that may not concentrate radioiodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one series of 65 patients in whom the disease recurred after surgical and radioiodine therapy, 62 percent had no tumor uptake of radioiodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of adjuvant (postoperative) EBRT in patients with well-differentiated thyroid cancer has been studied only retrospectively, and many of the studies included patients at low risk of recurrence who were unlikely to benefit from the therapy. Those who are most likely to benefit are probably patients with evidence of extrathyroidal extension at the time of surgery.",
"   </p>",
"   <p>",
"    Several reports have described either no benefit or even a deleterious effect of adjuvant EBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In contrast, other studies have suggested an improvement in local control with EBRT (",
"    <a class=\"graphic graphic_table graphicRef60357 \" href=\"mobipreview.htm?40/16/41228\">",
"     table 1",
"    </a>",
"    ). As an example, in an update of a previous report from a single institution, of 154 patients with well-differentiated thyroid cancer over age 45 years with microscopic residual papillary cancer after surgery, 90 patients received external radiation and 64 did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/12\">",
"     12",
"    </a>",
"    ]. The cause-specific survival was 100 percent at 10 years in patients given EBRT, compared with 95.3 percent if EBRT was not prescribed. The local relapse-free rate was greater in patients who received EBRT (94.2 percent) than in those who did not (83.9 percent) (",
"    <a class=\"graphic graphic_figure graphicRef79096 \" href=\"mobipreview.htm?30/23/31102\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Neither the extent of surgery nor radioiodine therapy had any effect on cause-specific survival or local recurrence rate. There was no demonstrable benefit from EBRT in the 52 patients with follicular cancer who had microscopic residual disease after surgery.",
"   </p>",
"   <p>",
"    There were higher 10-year cause-specific survival (81 percent versus 65 percent) and local-regional relapse-free rates (86 percent versus 66 percent) among patients over age 60 with extrathyroidal extension, but no gross residual disease, who were treated with external beam radiation when compared with those who did not receive radiation.",
"   </p>",
"   <p>",
"    All of these studies (",
"    <a class=\"graphic graphic_table graphicRef60357 \" href=\"mobipreview.htm?40/16/41228\">",
"     table 1",
"    </a>",
"    ) are retrospective and consequently flawed, and not all patients had radioactive iodine in addition to external radiation. However, in one study of 137 patients over age 40 with extrathyroidal extension of their cancers, all of whom had total thyroidectomy and radioiodine and T4 therapy, 85 patients received EBRT (50 to 60 Gy) to the thyroid bed and cervical and upper mediastinal lymph nodes. The patients in the radiotherapy group had fewer local and regional recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon this evidence, the American Thyroid Association guidelines recommend that: \"The use of EBRT should be considered in patients over age 45 with grossly visible extrathyroidal extension at the time of surgery and a high likelihood of microscopic residual disease, and for those patients with gross residual tumor in whom further surgery or radioactive iodine would likely be ineffective\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the wider acceptance of a role for EBRT in high-risk thyroid cancer, three leading cancer centers have published their experience of EBRT in high-risk patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Memorial Sloan-Kettering Cancer Center reported on 76 patients with advanced or recurrent nonanaplastic thyroid cancer, including 12 patients with medullary thyroid cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/15\">",
"       15",
"      </a>",
"      ]. The four-year locoregional control rate was 72 percent, and the overall survival at four years was 55 percent. They concluded that EBRT was effective for locoregional control with acceptable toxicity.",
"     </li>",
"     <li>",
"      The MD Anderson group reported on 131 patients with high-risk or recurrent disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/16\">",
"       16",
"      </a>",
"      ]. For patients with only microscopic residual disease who were treated postoperatively, the four-year regional control rate was 86 percent and four-year cause-specific survival, 82 percent. Patients with gross residual disease had a locoregional control rate of 22 percent. They concluded that postoperative EBRT provides durable locoregional control, but only if the tumor is reduced to microscopic residual disease.",
"     </li>",
"     <li>",
"      The Christie Hospital group reported on 49 patients with similar results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/17\">",
"       17",
"      </a>",
"      ]. The five-year locoregional control was 89.1 percent for patients with clear or microscopic margins and 69.2 percent if there was macroscopic residue or inoperable disease, and the five-year cause-specific survivals were 91.4 percent and 58.3 percent respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;All these reports suggest that for patients at high risk of recurrence, EBRT is beneficial, but defining patients at risk and determining the population for whom EBRT should be offered remain controversial.",
"   </p>",
"   <p>",
"    We currently recommend EBRT in addition to radioiodine ablation for older patients (age 50 or older) who have gross extrathyroid extension (T4 disease) at the time of surgery which is resected, but who have microscopic residual disease.",
"   </p>",
"   <p>",
"    We also consider EBRT in selected younger patients with T4b or extensive T4a disease and poor histological features (insular or poor differentiation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/6\">",
"     6",
"    </a>",
"    ]. Lymph node involvement by itself is not an indication for external radiotherapy because regional control is usually achieved with surgery and radioiodine. However, EBRT is probably of value in patients who have extracapsular extension of their lymph node disease and are at high risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also recommend EBRT in patients with recurrence in their thyroid bed or repeated cervical nodal recurrence despite adequate surgery and radioiodine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiation protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with well-differentiated thyroid cancer, we usually treat the thyroid bed alone, from the hyoid to just below the suprasternal notch. The clinical target volume (CTV) is defined to cover thyroid bed, jugular, and posterior cervical lymph nodes within the limits defined above, including level III, IV, VI, and partially level V nodal regions (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"mobipreview.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ), and this volume is adjusted according to the surgical and pathology findings.",
"   </p>",
"   <p>",
"    Although some groups give more extensive nodal irradiation, we typically only treat the whole cervical and upper mediastinal lymph node chain in differentiated thyroid cancer that persists after neck dissection and radioiodine therapy or has extensive nodal extracapsular extension.",
"   </p>",
"   <p>",
"    Modern radiation therapy (RT) techniques, such as three dimensional conformal radiotherapy (3D-CRT) or intensity modulate radiation therapy (IMRT), can allow for more accurate RT delivery, allowing more normal tissue to be spared, and potentially reducing acute and late toxicity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58544 \" href=\"mobipreview.htm?38/49/39703\">",
"     image 1",
"    </a>",
"    ). These advantages are due to the fact that IMRT utilizes variable, computer-controlled intensities within each RT beam, in contrast to the uniform doses within conventionally planned two-dimensional EBRT or 3D-CRT planning and delivery techniques. The advantages of IMRT are particularly evident when the target volumes have complex shapes, concave regions, or are adjacent to many critical normal structures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of IMRT were shown in a series from MD Anderson, in which IMRT was associated with less frequent late morbidity than was conventionally planned two-dimensional EBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/16\">",
"     16",
"    </a>",
"    ]. IMRT is becoming increasingly available and will likely become the standard for care in many radiation oncology centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/6,15,16,19\">",
"     6,15,16,19",
"    </a>",
"    ]. Typically, we prescribe 66 Gy in 33 fractions to the site of gross residual disease or area of high concern for microscopic residual disease, ie, the tracheoesophageal groove, concurrently with 56 Gy in 33 fractions to the rest of the CTV as described above.",
"   </p>",
"   <p>",
"    Well-planned radiotherapy treatment regimens rarely have serious long-term complications. However, acute toxicity occurs and may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate skin erythema",
"     </li>",
"     <li>",
"      Dry desquamation and, rarely, moist desquamation",
"     </li>",
"     <li>",
"      Mucositis of the esophagus, trachea, and larynx, which may require a soft diet and analgesics, may develop towards the end of radiation therapy; this will subside within two to four weeks after the end of treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common manifestations of late toxicity are skin telangiectasias and skin pigmentation. The development of esophageal stenosis is rare and tracheal stenosis is extremely rare.",
"   </p>",
"   <p>",
"    EBRT does not preclude future surgical intervention if required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best therapy for patients with metastatic well-differentiated thyroid cancer, radioiodine, is less effective in patients with bone metastases. In one series, as an example, the 10-year survival rate was 54 percent for patients with lung metastases, but there were no survivors among patients with bone metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/20\">",
"     20",
"    </a>",
"    ]. In another report of 214 patients with distant metastases, the metastases took up radioiodine in 60 percent of those with bone involvement, but only 3 percent of these patients achieved complete remission after radioiodine therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these disappointing results of radioiodine therapy in patients with bone metastases, an aggressive surgical approach has been recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/22\">",
"     22",
"    </a>",
"    ]. However, not all bone metastases are amenable to surgical resection.",
"   </p>",
"   <p>",
"    We therefore recommend EBRT in addition to radioiodine therapy for patients with unresectable bone metastases or multiple bone metastases. For solitary metastases, we usually give 50 Gy in 25 fractions, but we lower the dose to 40 Gy in 20 fractions in patients with spinal bone metastases in addition to radioactive iodine, to ensure that the dose to the spinal cord is safe (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61712 \" href=\"mobipreview.htm?1/53/1873\">",
"     image 2",
"    </a>",
"    ). All patients with painful bone metastases should be referred for EBRT to aid pain control. Issues related to the use of bone modifying agents for patients with bone metastases are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANAPLASTIC THYROID CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaplastic thyroid cancer is one of the most lethal of all cancers, and therapy has little effect on outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23721?source=see_link\">",
"     \"Anaplastic thyroid cancer\"",
"    </a>",
"    .) Although complete surgical resection gives the best chance of cure, this is rarely possible (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79632 \" href=\"mobipreview.htm?32/14/33007\">",
"     image 3",
"    </a>",
"    ). The main goal of local therapy in patients with anaplastic thyroid cancer is to prevent death from uncontrolled disease in the neck. Anaplastic cancers do not concentrate radioiodine; as a result, EBRT is given with the aim of local control. However, the prognosis remains poor.",
"   </p>",
"   <p>",
"    In a group of 134 patients with anaplastic cancer, 98 percent had extrathyroidal extension at the time of presentation, with a survival of only three months. Neither the completeness of resection nor the use of concurrent chemoradiation had an effect on survival. There was, however, a modest improvement in survival (three months versus five months) in patients given EBRT compared with those who did not receive EBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a smaller study of 33 patients (with a median survival of 3.8 months), a subgroup of eight patients had either no or minimal macroscopic disease after surgery and received subsequent EBRT plus adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/24\">",
"     24",
"    </a>",
"    ]. Four of these eight patients survived longer than two years.",
"   </p>",
"   <p>",
"    Thus, it appears that there is a small group of patients who have limited or no extrathyroid extension who benefit from an aggressive approach of surgery followed by postoperative therapy. Two studies have shown encouraging results with combined chemoradiotherapy (EBRT plus taxane-based chemotherapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23721?source=see_link&amp;anchor=H17#H17\">",
"     \"Anaplastic thyroid cancer\", section on 'Combined modality therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small series of six patients, there was a 33 percent response rate with locoregional disease, including one complete response in one patient with an 8 cm tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report on 10 patients treated with concurrent chemotherapy and radiation, the median survival was 44 months with a 60 percent survival at two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hyperfractionated radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term toxicity to normal tissues depends in part upon the size of each treatment fraction as well as the total radiation dose. Decreasing the size of each radiation fraction should permit higher total doses without increasing late morbidity. Hyperfractionation administers multiple daily treatments with smaller than conventional fraction sizes given over approximately the same treatment duration. This strategy, which enables high \"radical\" doses (&gt;40 Gy) to be delivered over a short time with acceptable toxicity, appears to be associated with improved local control of disease in patients with anaplastic thyroid cancer. In a retrospective study of 47 patients who underwent hyperfractionated RT, the six-month progression-free rate was significantly higher with radical compared with palliative (defined as &le;40 Gy) RT (94 and 65 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/27\">",
"     27",
"    </a>",
"    ]. There was also a trend towards improved survival with twice-daily compared with once-daily fractionation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Radiation protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiation fields in patients with anaplastic thyroid cancer are usually tailored to include the thyroid bed and the adjacent lymph nodes. No attempt is made to treat the entire neck or mediastinum unless disease is documented in these sites. In patients with good-performance status and no evidence of metastatic disease, we give 60 Gy in 40 fractions, two fractions a day for four weeks.",
"   </p>",
"   <p>",
"    We treat with EBRT alone so that the dose does not need to be decreased to account for chemotherapy toxicity; however, in other centers hyperfractionated RT with concurrent chemotherapy, such as taxanes, is a standard approach.",
"   </p>",
"   <p>",
"    In patients with poor performance status or known metastatic disease, we give palliative EBRT only, 20 Gy in five fractions, with the option of a second course four weeks later for patients who respond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDULLARY THYROID CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best treatment for patients with medullary cancer is thyroidectomy and lymphadenectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/23/38263?source=see_link\">",
"     \"Medullary thyroid cancer: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EBRT may be useful both for primary therapy if resection is incomplete and for adjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If complete surgical resection is not possible, we recommend EBRT because local control can be achieved in some patients. In a report of 21 patients with macroscopic residual disease after surgery, who were treated with conventional fractionation EBRT, the local relapse-free rate was 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the benefit of adjuvant RT in patients with medullary cancer are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/28-34\">",
"     28-34",
"    </a>",
"    ]. A significantly lower survival was reported in a series of 15 patients who received RT, as compared with 29 patients matched for age, extent of disease, and surgery who did not receive radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/29\">",
"     29",
"    </a>",
"    ]. However, other studies suggest a benefit from radiation therapy in terms of local control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/28,30-32,34\">",
"     28,30-32,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 51 patients with persistently elevated calcitonin and no evidence of distant disease, the local relapse rate was significantly lower in those who were treated with radiation therapy (29 versus 59 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/34\">",
"       34",
"      </a>",
"      ]. There was no difference in 10-year survival between the two groups (72 versus 60 percent).",
"     </li>",
"     <li>",
"      A later study of 34 patients with stage IVa-c cancer treated with external radiation showed a five-year locoregional control rate of 87 percent and 10-year cause-specific survival of 56 percent, which confirms a role for external radiation in locoregional control in high-risk patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adjuvant EBRT has not been associated with a survival benefit, presumably because of microscopic disease beyond the neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/28,32-34\">",
"     28,32-34",
"    </a>",
"    ]. Nevertheless, local and regional control is still important because of the morbidity of locally recurrent disease. EBRT is not a substitute for appropriate surgical resection but seems to be beneficial in minimizing local recurrences in patients with extensive extrathyroid extension and is probably indicated for this purpose (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58544 \" href=\"mobipreview.htm?38/49/39703\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiation protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with medullary cancer, radiation therapy is usually given using IMRT planning and delivery, with a minimum of 56 Gy in 33 fractions to the cervical lymph nodes, and 66 Gy in 33 fractions to areas of potential residual disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THYROID LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid lymphomas are rare, accounting for less than 1 percent of all malignant thyroid tumors. Most have aggressive histology, usually diffuse large B-cell lymphoma, followed by mucosa associated lymphoid tissue lymphoma (MALT lymphoma), also termed marginal zone lymphoma, an indolent lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35974?source=see_link\">",
"     \"Thyroid lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although surgical debulking has been advocated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], the main role for surgery in this disease is to obtain tissue for histological diagnosis. Patients with thyroid lymphomas should be staged like any other patient with lymphoma. In those with stage I or limited stage II disease (ie, disease confined to the neck), the choice is between EBRT alone for indolent lymphoma or combined EBRT and chemotherapy for aggressive histologies. The rate of local control with 35 to 40 Gy given in four weeks is excellent.",
"   </p>",
"   <p>",
"    In one series of 39 patients, almost all of whom were treated with EBRT alone or in combination with chemotherapy, five-year actuarial survival and cause-specific survival rates were 64 and 73 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39191/abstract/37\">",
"     37",
"    </a>",
"    ]. Although the patients treated by combined EBRT and chemotherapy had less favorable disease, the cause-specific survival rate at five years was 82 percent for those treated with combined therapy as compared with 63 percent for those treated with radiotherapy alone, a difference that did not achieve statistical significance. Radiation therapy (RT) alone is adequate treatment for localized indolent lymphomas, such as MALT lymphoma or follicular lymphoma. MALT lymphomas have excellent outcomes with moderate dose RT, and relapse is very uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend combined therapy for all patients with aggressive histology thyroid lymphoma. Chemotherapy, when given before RT, usually results in rapid tumor regression. The standard regimen for diffuse large B-cell lymphoma consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (R CHOP), given every three weeks for three to six cycles. We usually give three courses of R CHOP followed four weeks later by EBRT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35974?source=see_link\">",
"     \"Thyroid lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiation protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total dose of 35 Gy is given in 20 fractions over four weeks to encompass the thyroid, neck nodes bilaterally, and superior mediastinal nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3109212\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiotherapy (EBRT) has been used in patients with all types of thyroid epithelial cancer, medullary thyroid cancer, and thyroid lymphoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with well-differentiated or medullary thyroid cancer, who have gross residual disease after attempted surgery, radiation therapy is of value in controlling local disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Well-differentiated thyroid cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Medullary thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with differentiated thyroid cancer without gross residual disease but who are at high risk for recurrence (over age 45 with grossly visible extrathyroidal extension at the time of surgery and a high likelihood of microscopic residual disease), radiation therapy improves locoregional control. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Well-differentiated thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with medullary thyroid cancer and extensive extrathyroid extension and extensive nodal disease, adjuvant radiation therapy is beneficial in minimizing local recurrences, but not survival. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Medullary thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with anaplastic thyroid cancer, radiation therapy is often used in combination with chemotherapy, especially taxanes, for local control. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Anaplastic thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective treatment of thyroid lymphoma depends upon the tumor type and extent of disease. The standard approach for patients with aggressive thyroid lymphoma is combined therapy with chemotherapy followed by radiation therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Thyroid lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/1\">",
"      O'Connell ME, A'Hern RP, Harmer CL. Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. Eur J Cancer 1994; 30A:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/2\">",
"      Maxon, HRd, Englaro, EE, Thomas, SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients [see comments]. J Nucl Med 1992; 33:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/3\">",
"      Chow SM, Law SC, Mendenhall WM, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/4\">",
"      Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/5\">",
"      Wu XL, Hu YH, Li QH, et al. Value of postoperative radiotherapy for thyroid cancer. Head Neck Surg 1987; 10:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/6\">",
"      Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/7\">",
"      Andersen PE, Kinsella J, Loree TR, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995; 170:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/8\">",
"      Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996; 78:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/9\">",
"      Mazzaferri EL. Papillary and follicular thyroid cancer: a selective approach to diagnosis and treatment. Annu Rev Med 1981; 32:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/10\">",
"      Lin JD, Tsang NM, Huang MJ, Weng HF. Results of external beam radiotherapy in patients with well differentiated thyroid carcinoma. Jpn J Clin Oncol 1997; 27:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/11\">",
"      Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/12\">",
"      Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 2005; 63:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/13\">",
"      Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996; 77:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/14\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/15\">",
"      Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2009; 73:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/16\">",
"      Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2009; 74:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/17\">",
"      Azrif M, Slevin NJ, Sykes AJ, et al. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Radiother Oncol 2008; 89:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/18\">",
"      Ito, Y, Hirokawa, M, Jikuzono, T, et al. Extranodal Tumor Extension to Adjacent Organs Predicts a Worse Cause-specific Survival in Patients with Papillary Thyroid Carcinoma. World J Surg 2007; 31:1196.",
"     </a>",
"    </li>",
"    <li>",
"     Cancer Care Ontario. Radiation Therapy Evidence-based Series (EBS). file://www.cancercare.on.ca/toolbox/qualityguidelines/clin-program/radther/ (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/20\">",
"      Brown AP, Greening WP, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/21\">",
"      Casara D, Rubello D, Saladini G, et al. Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients. Tumori 1991; 77:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/22\">",
"      Proye CA, Dromer DH, Carnaille BM, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 1992; 16:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/23\">",
"      McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/24\">",
"      Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001; 91:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/25\">",
"      Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010; 95:E54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/26\">",
"      Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011; 21:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/27\">",
"      Wang Y, Tsang R, Asa S, et al. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006; 107:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/28\">",
"      Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/29\">",
"      Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988; 67:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/30\">",
"      Nguyen TD, Chassard JL, Lagarde P, et al. Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes--the Radiotherapy Cooperative Group. Radiother Oncol 1992; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/31\">",
"      Mak, A, Morrison, W, Garden, A, et al. The value of postoperative radiotherapy for regional medullary carcinoma of the thyroid. Int J Radiat Oncol Biol Phys 1994; 30 (Suppl):234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/32\">",
"      Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. Head Neck 2008; 30:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/33\">",
"      Martinez SR, Beal SH, Chen A, et al. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 2010; 102:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/34\">",
"      Fersht N, Vini L, A'Hern R, Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 2001; 11:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/35\">",
"      Rosen IB, Sutcliffe SB, Gospodarowicz MK, et al. The role of surgery in the management of thyroid lymphoma. Surgery 1988; 104:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/36\">",
"      Klyachkin ML, Schwartz RW, Cibull M, et al. Thyroid lymphoma: is there a role for surgery? Am Surg 1998; 64:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39191/abstract/37\">",
"      Tsang RW, Gospodarowicz MK, Sutcliffe SB, et al. Non-Hodgkin's lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess Margaret Hospital Lymphoma Group. Int J Radiat Oncol Biol Phys 1993; 27:599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2192 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39191=[""].join("\n");
var outline_f38_17_39191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3109212\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WELL-DIFFERENTIATED THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiation protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANAPLASTIC THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hyperfractionated radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Radiation protocol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDULLARY THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiation protocol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THYROID LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiation protocol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3109212\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2192|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/49/39703\" title=\"diagnostic image 1\">",
"      XRT variable dose neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/53/1873\" title=\"diagnostic image 2\">",
"      Thyroid cancer spine MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/14/33007\" title=\"diagnostic image 3\">",
"      Anaplastic thyroid cancer CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2192|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/23/31102\" title=\"figure 1\">",
"      XRT thyroid cancer survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/16/41228\" title=\"table 1\">",
"      Recurrent post XRT thyroid cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23721?source=related_link\">",
"      Anaplastic thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/23/38263?source=related_link\">",
"      Medullary thyroid cancer: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35974?source=related_link\">",
"      Thyroid lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_17_39192="Immunohistol kidney Alport";
var content_f38_17_39192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Immunohistological analysis of the renal distribution of type IV collagen chains",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The analysis was carried out in (",
"    <strong>",
"     A-D",
"    </strong>",
"    ) control, X-linked (",
"    <strong>",
"     E,F",
"    </strong>",
"    ) male and (",
"    <strong>",
"     G,H",
"    </strong>",
"    ) female Alport syndrome patients, and (",
"    <strong>",
"     I-L",
"    </strong>",
"    ) patients with autosomal recessive Alport syndrome, using antibodies to &alpha;1(IV) (",
"    <strong>",
"     A,E,I",
"    </strong>",
"    ), &alpha;3(IV) (",
"    <strong>",
"     B,F,J",
"    </strong>",
"    ), or &alpha;5(IV) (",
"    <strong>",
"     C,G,K,L",
"    </strong>",
"    ) chains. Double labeling was made with anti-&alpha;2(IV) in red, and anti-&alpha;5(IV) in green (",
"    <strong>",
"     D,H",
"    </strong>",
"    ). In control kidney, the &alpha;1(IV) chain is present in the mesangial matrix, Bowman's capsule, and the extraglomerular basement membranes (",
"    <strong>",
"     A",
"    </strong>",
"    ). The &alpha;3(IV) and &alpha;5(IV) chains are distributed within the GBM (",
"    <strong>",
"     B",
"    </strong>",
"    and",
"    <strong>",
"     C",
"    </strong>",
"    , respectively). The Bowman's capsule is strongly &alpha;5(IV)-positive (",
"    <strong>",
"     C",
"    </strong>",
"    ). In X-linked Alport syndrome, no &alpha;3(IV) expression was detected in a male patient (id for &alpha;4-&alpha;5) (",
"    <strong>",
"     F",
"    </strong>",
"    ), whereas the distribution is segmental in a female patient (",
"    <strong>",
"     G",
"    </strong>",
"    ). In autosomal recessive Alport syndrome, no &alpha;3(IV)-&alpha;5(IV) labeling is detected in the GBM (",
"    <strong>",
"     J",
"    </strong>",
"    ) whereas &alpha;5(IV) is expressed in Bowman's capsule (",
"    <strong>",
"     K",
"    </strong>",
"    ) and the basement membranes of the collecting ducts (",
"    <strong>",
"     L",
"    </strong>",
"    ). In both types of Alport syndrome, &alpha;1(IV) is diffusely expressed in the GBM (",
"    <strong>",
"     E,I",
"    </strong>",
"    ).",
"    <div class=\"footnotes\">",
"     GBM: glomerular basement membrane.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 2008; 1:24. Copyright &copy;2008 Macmillan Publishers Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39192=[""].join("\n");
var outline_f38_17_39192=null;
var title_f38_17_39193="Vascular structures 1";
var content_f38_17_39193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=21\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=21\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 642px\">",
"   <div class=\"ttl\">",
"    Vascular structures most commonly seen in melanocytic tumors",
"    <sup>",
"     [1-3]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 622px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377.",
"       </li>",
"       <li>",
"        Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part I. Melanocytic skin tumors. J Am Acad Dermatol 2010; 63:361.",
"       </li>",
"       <li>",
"        Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485",
"       </li>",
"       <li>",
"        Ka VS, Clark-Loeser L, Marghoob AA. Vascular pattern in seborrheic keratoses and melanoma. Dermatol Surg 2004; 30:75.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39193=[""].join("\n");
var outline_f38_17_39193=null;
var title_f38_17_39194="Secondary involvement of the central nervous system by non-Hodgkin lymphoma";
var content_f38_17_39194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     Andrew D Norden, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     Ephraim Hochberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     Fred H Hochberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/17/39194/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/17/39194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic non-Hodgkin lymphoma (NHL) may involve the nervous system at every level, including peripheral nerve, spinal nerve root, spinal cord, meninges, and brain. Such involvement may include direct invasion or compression of these structures, as well as non-invasive paraneoplastic effects of NHL. Whereas involvement of the central nervous system (CNS) complicates the course of a significant minority of patients, peripheral nervous system involvement is rare. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHL can involve the CNS either as the sole area of disease (ie, primary CNS lymphoma) or as secondary spread of systemic disease. Secondary involvement of the CNS by NHL can present in many ways and rapid control of CNS involvement is necessary to prevent neurologic morbidity and preserve quality of life. As such, clinicians must keep this entity high on their differential diagnosis in patients with NHL presenting with neurologic complaints.",
"   </p>",
"   <p>",
"    The most common manifestations of NHL involvement of the CNS include leptomeningeal metastasis, epidural spinal cord compression, and parenchymal infiltration. These entities will be discussed here. Primary CNS lymphoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=see_link\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=see_link\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the cellular or molecular interactions that facilitate trafficking of lymphoma cells to the CNS. Lymphoma cells are thought to enter the CNS by hematogenous spread, direct extension from adjacent bone metastases, or by centripetal growth along neurovascular bundles. It has also been hypothesized that lymphoma cells could spread from retroperitoneal lymph nodes or bone marrow to the leptomeninges via the intervertebral venous plexus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/1\">",
"     1",
"    </a>",
"    ], although confirmatory evidence for this mode of spread is lacking.",
"   </p>",
"   <p>",
"    Most episodes of CNS involvement by non-Hodgkin lymphoma (NHL) occur in the setting of relapsed disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/2\">",
"     2",
"    </a>",
"    ]; however, a significant percentage may have had subclinical CNS involvement at the time of diagnosis. This is suggested by the high rate of CNS involvement within six months of initial therapy in many patients with aggressive NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, late CNS recurrences of NHL may represent second primary tumors. Support for this hypothesis comes from molecular studies in which immunoglobulin heavy chain (IgH) rearrangement analysis suggested a separate clonal origin for some CNS tumors arising more than three years after the initial diagnosis of NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most data on the mechanism of spread of NHL to the CNS come from studies of varieties of T cell lymphoma with an unusually high rate of extranodal involvement. These malignancies typically express CD56, which is also known as the neural cell adhesion molecule (NCAM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/5\">",
"     5",
"    </a>",
"    ]. NCAM is a member of the immunoglobulin superfamily of cell adhesion molecules; it exhibits homophilic (like-to-like) binding which allows NCAM molecules to facilitate adhesion among neighboring cells with surface NCAM expression. NCAM is naturally expressed on multiple cell types in the brain, spinal cord, muscle, and hematopoietic tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/5\">",
"     5",
"    </a>",
"    ]. As such, expression of NCAM may allow these tumor cells to interact with cells in the CNS that also express NCAM. In a series of 46 patients with T-cell lymphoma evaluated during a 12-year period, 24 percent of the tumors were NCAM-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/6\">",
"     6",
"    </a>",
"    ]. Of these, 36 percent had CNS involvement, compared with 3 percent of NCAM-negative tumors. NCAM-positive tumors had a clear predilection for widespread extra-nodal involvement, with a median survival less than half that of NCAM-negative tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clues surrounding the migration of NHL to the CNS may also be found by examining the molecular phenotype of normal lymphocytes that migrate to the CNS and how this phenotype differs from that of lymphocytes that do not travel to the CNS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, a study of T lymphocyte trafficking into the subarachnoid space of healthy individuals found that P- and E-selectin expression on endothelial cells in the CNS may be a crucial discrepancy between these lymphocytes and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/8\">",
"     8",
"    </a>",
"    ]. Whether these data also apply to neoplastic lymphocytes traveling to the healthy CNS is unclear.",
"   </p>",
"   <p>",
"    B lymphocytes may also enter the brain even under normal circumstances, although the molecular mechanisms that make this possible have not been fully described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/9\">",
"     9",
"    </a>",
"    ]. In primary central nervous system lymphoma (PCNSL), a B cell-attracting chemokine, CXCL13, may play an important role in lymphocyte retention within the CNS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/10\">",
"     10",
"    </a>",
"    ]. A subset of patients with PCNSL may have occult systemic disease at presentation that eludes detection by routine staging techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/11\">",
"     11",
"    </a>",
"    ]. This patient population may provide insight into the mechanisms by which lymphoma cells home to the CNS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171056704\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS disease is found in a minority of patients at the time of NHL diagnosis, the exact percentage of which differs by histologic subtype. The majority of cases of CNS involvement by NHL occur in the setting of relapsed disease.",
"   </p>",
"   <p>",
"    The frequency of CNS involvement in systemic NHL varies depending at least partially upon the aggressiveness of the NHL subtype. As an example, 2 to 10 percent of patients with aggressive subtypes of systemic NHL (eg, diffuse large B cell lymphoma) will experience direct involvement of the CNS at some time during their course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/3,12-18\">",
"     3,12-18",
"    </a>",
"    ]. The incidence is much higher in highly aggressive NHL (eg, Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia,",
"    </span>",
"    lymphoblastic lymphoma) and lower in indolent NHL (eg, follicular lymphoma). Peripheral nervous system (PNS) involvement by lymphoma is rare.",
"   </p>",
"   <p>",
"    It is unknown whether the risk of CNS relapse has changed as initial treatment of these diseases has evolved. However, two retrospective studies have suggested that the incidence may be lower among patients with B cell NHL treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    -containing therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to histologic subtype, risk factors for invasion of the neuraxis by NHL include the primary site of disease and the extent of bulky disease (",
"    <a class=\"graphic graphic_table graphicRef54470 \" href=\"mobipreview.htm?12/35/12859\">",
"     table 1",
"    </a>",
"    ). These issues are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histologic subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic subtype of lymphoma is the major risk factor for nervous system involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. The incidence of CNS relapse without CNS prophylaxis ranges from less than 3 percent in patients with indolent subtypes of lymphoma to 50 percent in some patients with highly aggressive NHL subtypes, such as Burkitt lymphoma or lymphoblastic lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/21\">",
"     21",
"    </a>",
"    ]. Although histologic subtype is an indicator of risk for CNS involvement, nearly every lymphoma subtype has been reported to invade the nervous system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single-center retrospective study of 2514 consecutive patients with newly diagnosed NHL with a median follow-up of 94 months reported that 106 patients (4.2 percent) developed CNS disease either during (36 patients) or after (70 patients) primary treatment, with a median time to diagnosis of CNS involvement of 10 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/16\">",
"       16",
"      </a>",
"      ]. Of the 1163 patients with low grade histology, 33 (2.8 percent) developed CNS involvement (",
"      <a class=\"graphic graphic_table graphicRef59978 \" href=\"mobipreview.htm?41/26/42412\">",
"       table 2",
"      </a>",
"      ). Of the 1220 patients with aggressive NHL, 53 (4.3 percent) developed CNS involvement, 35 of which occurred during the first year after NHL diagnosis. This rate has never been confirmed in a prospectively gathered cohort.",
"     </li>",
"     <li>",
"      In a retrospective study of 498 patients with NHL, 30 developed secondary CNS disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/13\">",
"       13",
"      </a>",
"      ]. Twenty-six of the 30 had aggressive or highly aggressive disease. As examples, the risk of CNS recurrence was 23 percent for the highly aggressive variant lymphoblastic lymphoma and only 1.4 percent for those with indolent lymphoma.",
"     </li>",
"     <li>",
"      Mantle cell lymphoma (MCL), which can behave as either an indolent or an aggressive NHL variant, has an unusually high risk of CNS involvement, approaching 4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. An important factor may be the increased frequency of advanced disease at the time of diagnosis of MCL, when compared with other indolent NHL variants. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other prognostic factors'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A single institution retrospective review of 250 patients with peripheral T cell NHL from the United States reported a CNS relapse rate of 2.4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In comparison, a second retrospective study of 228 patients from Korea with primary",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell NHL reported a rate of CNS involvement of 8.8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/25\">",
"       25",
"      </a>",
"      ]. The higher rate in this population likely reflects the predilection of",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma for involvement of the hard palate and nose, with venous drainage to the cavernous sinuses.",
"     </li>",
"     <li>",
"      Although the indolent T-cell lymphoma mycosis fungoides (MF) primarily involves the skin, autopsy and clinical studies have demonstrated nervous system involvement indistinguishable from that caused by other lymphomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary site",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is clear that the rate of CNS involvement differs based upon the primary site of disease, there is controversy regarding which primary sites of disease should be considered high risk. Most studies have noted a high rate of CNS involvement with lymphomatous involvement of the testes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18,28,29\">",
"     18,28,29",
"    </a>",
"    ]. In addition, an increased risk of CNS disease has been associated with lymphomatous involvement of the paranasal sinuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18,30,31\">",
"     18,30,31",
"    </a>",
"    ] and retroperitoneal lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. An association between CNS involvement and other sites of primary NHL is more controversial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of CNS relapse among 1386 patients with newly diagnosed aggressive NHL treated on prospective trials of chemotherapy in Germany reported that 2.2 percent of patients developed CNS relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18\">",
"       18",
"      </a>",
"      ]. When compared with patients without these sites of involvement, the probability of developing CNS relapse by six years was increased in patients with involvement of the testes (22 versus 2 percent),",
"      <span class=\"nowrap\">",
"       orbit/sinus",
"      </span>",
"      (33 versus 2 percent), liver, bladder, adrenals, or kidney. Unlike other studies, this analysis did not find an increased risk associated with bone marrow involvement. While these primary sites of disease were associated with increased risk of subsequent CNS involvement, only elevated serum LDH and involvement of &gt;1 extranodal site were independent risk factors for CNS involvement on multivariate analysis.",
"     </li>",
"     <li>",
"      Several retrospective studies have noted an increased risk of CNS disease among patients with bone and bone marrow involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/14,33,34\">",
"       14,33,34",
"      </a>",
"      ], while others have not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several studies have noted an increased risk of CNS relapse among patients with primary testicular lymphoma in both young and older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18,28,29\">",
"       18,28,29",
"      </a>",
"      ]. As an example, one review found that 13 of 62 such patients (21 percent) experienced CNS relapse, with 8 of the 13 recurrences isolated to the CNS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/28\">",
"       28",
"      </a>",
"      ]. Late CNS recurrences were also common, with one patient developing CNS recurrence 13 years after entering remission.",
"     </li>",
"     <li>",
"      Several studies have noted an increased rate of CNS involvement in patients with primary breast lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/35-37\">",
"       35-37",
"      </a>",
"      ] and primary mediastinal large B cell lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/38\">",
"       38",
"      </a>",
"      ]. Whether this risk exceeds the risk in the entire diffuse large B cell lymphoma (DLBCL) population is uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. An international retrospective analysis of 204 patients with primary diffuse large B cell lymphoma of the breast, only 8 of whom received CNS prophylaxis, reported CNS relapse in 5 percent after a median follow-up of 5.5 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although primary cutaneous lymphoma is often cited as a risk factor for CNS recurrence, this did not appear to be the case in a large series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravascular lymphoma is an uncommon form of diffuse large B cell lymphoma that has a rate of CNS involvement that approaches 40 percent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13511?source=see_link\">",
"       \"Intravascular large cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other important risk factors for nervous system involvement include advanced stage disease (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"     table 3",
"    </a>",
"    ), increased serum LDH level, involvement of more than one extranodal site, and a high International Prognostic Index (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective Norwegian study of 2514 patients with NHL, of whom 106 (4.2 percent) developed neuraxis involvement, identified the following independent risk factors (ie, Hollender criteria): age &gt;60 years, LDH &ge; 450",
"      <span class=\"nowrap\">",
"       U/l,",
"      </span>",
"      albumin &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      retroperitoneal lymph node involvement, and involvement of &gt;1 extranodal site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/16\">",
"       16",
"      </a>",
"      ]. Notably, if four or five of these risk factors were present, the risk of CNS recurrence was &gt;25 percent at five years.",
"     </li>",
"     <li>",
"      A similar evaluation of 1371 French patients with aggressive lymphoma found that elevated LDH and presence of more than one extranodal site were independent risk factors for CNS relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/44\">",
"       44",
"      </a>",
"      ]. A retrospective evaluation of 605 patients with diffuse large B cell and immunoblastic lymphoma, 24 of whom (4 percent) developed CNS recurrence, found the same two risk factors on multivariate analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A series of 1693 aggressive NHL patients treated on a variety of modern German chemotherapy protocols found a low incidence of CNS relapse (2.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18\">",
"       18",
"      </a>",
"      ]. On multivariate analysis, only elevated serum LDH and involvement of &gt;1 extranodal site were independent risk factors for CNS involvement.",
"     </li>",
"     <li>",
"      In a study of 399 elderly patients with DLBCL treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CHOP) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus CHOP (R-CHOP) without CNS prophylaxis, 20 patients (5 percent) developed CNS involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/23\">",
"       23",
"      </a>",
"      ]. Only the age-adjusted IPI predicted CNS recurrence (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"       table 4",
"      </a>",
"      ). There was no apparent impact of rituximab on the risk of developing CNS disease.",
"     </li>",
"     <li>",
"      In another retrospective study, nine patients with CNS involvement were identified from a cohort of 175 with aggressive NHL. All had achieved complete response (CR), and the CNS was the sole site of relapse. For these patients, CNS relapse was predicted by the presence of stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      disease (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"       table 3",
"      </a>",
"      ), B symptoms, bone marrow involvement, elevated serum lactate dehydrogenase (LDH), and high or high-intermediate risk according to the International Prognostic Index (IPI) (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"       table 4",
"      </a>",
"      ). However, on multivariate analysis, only the presence of stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      disease predicted an increased risk of CNS relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"       \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A retrospective study of 795 patients with DLBCL treated with R-CHOP reported that relapse in the CNS occurred in 9 of the 67 patients (13 percent) with DLBCL (concordant) bone marrow involvement; 4 of the 58 patients (7 percent) with small B cell lymphoma (discordant) bone marrow involvement; and 16 of the 670 (2 percent) with no evidence of lymphoma in the bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/45\">",
"       45",
"      </a>",
"      ]. Concordant bone marrow involvement, but not discordant bone marrow involvement, was an independent predictor of CNS relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LEPTOMENINGEAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptomeningeal metastasis (LM), or lymphomatous meningitis, is a common nervous system complication of NHL. Of 30 NHL patients with CNS involvement in one study, 27 had evidence of leptomeningeal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/13\">",
"     13",
"    </a>",
"    ]. Approximately one-quarter patients with LM involvement will also have intraparenchymal brain lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LM occurs in as many as 8 percent of patients with NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12\">",
"     12",
"    </a>",
"    ]; conversely, patients with NHL represent one quarter of all patients with LM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/47\">",
"     47",
"    </a>",
"    ]. Other neoplasms with a predilection for the subarachnoid space include leukemia, melanoma, breast cancer, and lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24329?source=see_link\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptomeningeal metastasis (LM) typically presents within the first year of diagnosis of NHL. In a large review of NHL patients with CNS disease, a median duration of eight months passed between systemic disease and CNS infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the 20 patients with LM, 9 had LM as the initial manifestation of their disease.",
"   </p>",
"   <p>",
"    Patients with LM commonly present with cranial nerve deficits, radicular pain, vague back or neck pain, mental status changes, focal weakness or sensory loss,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    headache. Dysfunction at multiple levels of the neuraxis is common. Seizures are unusual but have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12,14,47\">",
"     12,14,47",
"    </a>",
"    ], possibly as a result of small cortical tumor deposits or vascular lesions in continuity with subarachnoid disease. Patients may also present with neurologic syndromes, such as the syndrome of inappropriate antidiuretic hormone (SIADH) or hypothalamic dysfunction, due to infiltration of specific areas of the brain.",
"   </p>",
"   <p>",
"    Cranial nerve palsy is among the most common finding, developing in up to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. One or several nerves may be affected, with a predilection for cranial nerves II, III, V, VI, and VII [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12,48\">",
"     12,48",
"    </a>",
"    ]. Hydrocephalus with nausea, vomiting, and papilledema may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because lymphoma cells in the subarachnoid space have easy access to every portion of the CNS, LM may present with a multitude of signs and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/50\">",
"     50",
"    </a>",
"    ], often lacking classical features of neck rigidity or headache. For this reason, one must have a high index of suspicion for LM when evaluating lymphoma patients. As an example, one case report described hyperventilation as the initial manifestation of LM in a patient with a B cell lymphoma in leukemic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6052480\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging with gadolinium-enhanced magnetic resonance imaging (MRI) is a critical part of the diagnostic evaluation of a patient with suspected leptomeningeal metastasis (LM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Patients with contraindications to MRI may be evaluated with contrast-enhanced cranial computed tomography. While characteristic findings on imaging can suggest the diagnosis, confirmation of the diagnosis by cerebrospinal fluid analysis or brain biopsy is usually necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings may be seen on MRI of the brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal cord:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enhancement and enlargement of one or more cranial nerves due to tumor infiltration is extremely suggestive of LM (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69226 \" href=\"mobipreview.htm?23/55/24434\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Communicating hydrocephalus, leptomeningeal enhancement, or nerve root thickening are more commonly seen, yet less specific for LM (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66435 \" href=\"mobipreview.htm?3/60/4033\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60419 \" href=\"mobipreview.htm?9/15/9457\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58262 \" href=\"mobipreview.htm?15/60/16322\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Spinal MRI may show intradural enhancing nodules, especially at the level of the cauda equina; linear enhancement of the leptomeninges is a suggestive finding. Other processes including neurosarcoidosis, chronic meningitis, and Guillain-Barre syndrome may mimic LM on spinal MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine lumbar puncture (LP) may cause meningeal irritation adequate to produce leptomeningeal enhancement on spine and brain MRI. This is particularly common in patients who have had multiple or high-volume LPs and may have low cerebrospinal fluid pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/54\">",
"     54",
"    </a>",
"    ]. As such, neuroimaging should be performed prior to LP so as to avoid confusion in the interpretation of imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6053884\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic findings of leptomeningeal metastasis (LM) on lumbar puncture and cerebrospinal fluid (CSF) analysis include a high opening pressure, low glucose concentration, high protein concentration, lymphocytic pleocytosis, and positive cytology and flow cytometry for malignant cells. Although most patients do not have all of these features, an entirely normal CSF examination is uncommon. In particular, the combination of a high protein concentration and lymphocytic pleocytosis is often found without other abnormalities.",
"   </p>",
"   <p>",
"    The site of CSF sampling may affect the ability to detect LM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Many patients with suspected LM have Ommaya reservoirs in place that allow for rapid, safe access to ventricular CSF. In one study in which CSF was concurrently sampled from ventricular and lumbar sites, there was a 32 percent discordance rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/56\">",
"     56",
"    </a>",
"    ]. For patients with known radiographic disease involving the spinal cord or spinal nerve roots, the diagnostic yield of CSF obtained by LP was higher. Conversely, for patients with known intracranial leptomeningeal disease, the yield of CSF obtained via the Ommaya reservoir was higher. Accordingly, CSF sampling from both sites should be performed when feasible.",
"   </p>",
"   <p>",
"    The CSF sample should be evaluated for cell counts, protein and glucose levels, cytology, flow cytometry, and immunoglobulin heavy chain gene rearrangement studies. Flow cytometry may detect cases of LM not found by cytology, and cytology may find cases not identified by flow cytometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of molecules present in CSF have been studied as possible diagnostic markers for LM. Examples include B2-microglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/59\">",
"     59",
"    </a>",
"    ], D-dimer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/60\">",
"     60",
"    </a>",
"    ], and soluble CD27 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/61\">",
"     61",
"    </a>",
"    ]. None of these has proven adequately reliable for routine use. Other common but insensitive nonspecific laboratory findings include elevated CSF protein and decreased CSF glucose concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6054638\">",
"    <span class=\"h3\">",
"     CSF cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomorphologic examination by light microscopy of a cytospin preparation of cerebrospinal fluid (CSF) is the standard method for determining the presence of leukemic cells in the CSF. However, false negatives and false positives can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Because specificity of the technique is substantially greater than sensitivity, false negative results are more common than false positive results. A number of shortcomings of cytologic evaluation may preclude rapid diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cell count in the CSF sample may be inadequate to permit positive identification of malignant cells.",
"     </li>",
"     <li>",
"      Infectious causes of atypical lymphocytosis (eg, viral illnesses, Borrelia burgdorferi) may lead to false positive cytologic diagnoses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cellular atypia is common in immunosuppressed patients, increasing diagnostic confusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytologic analysis requires fresh CSF and adequate preservation of cell structure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple lumbar punctures (LPs) may be required in order to make the diagnosis of LM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/63\">",
"     63",
"    </a>",
"    ]. In a study of 15 patients with cytology-proven LM, a single LP was adequate for diagnosis in only 60 percent of cases. A second LP detected an additional 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/47\">",
"     47",
"    </a>",
"    ]. Other studies have demonstrated that serial LPs increase the sensitivity of CSF cytology for the diagnosis of LM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]; accordingly, most authorities recommend two or three negative LPs when ruling out LM if suspected clinically.",
"   </p>",
"   <p>",
"    Even when three CSF samples are obtained under optimal circumstances, countless retrospective and anecdotal reports in the literature confirm that cytologic diagnosis may be problematic. Specific guidelines for minimizing false negative results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24329?source=see_link&amp;anchor=H7301492#H7301492\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\", section on 'Cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6054645\">",
"    <span class=\"h3\">",
"     Molecular techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular techniques including immunocytochemistry, flow cytometry, and polymerase chain reaction can increase the sensitivity of cerebrospinal fluid (CSF) analysis for NHL involvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunocytochemistry uses a variety of monoclonal antibodies directed against known cell surface markers and is able to distinguish between lymphomatous and reactive cellular infiltrates. In such cases the immunophenotype of the abnormal CSF cells may be compared with that of the patient's primary tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/68\">",
"       68",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Immunophenotype'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flow cytometry is a related technique in which clonal populations of B lymphocytes are separated from reactive cells on the basis of size, granularity, and surface antigen expression (",
"      <a class=\"graphic graphic_figure graphicRef67324 \" href=\"mobipreview.htm?6/18/6432\">",
"       figure 1",
"      </a>",
"      ). Flow cytometry can detect populations of neoplastic cells comprising as few as 0.2 percent of CSF lymphocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. There is also a substantial improvement in sensitivity (43 to 50 percent) when flow cytometry is combined with conventional cytology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/57,58,69,71-73\">",
"       57,58,69,71-73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymerase chain reaction (PCR) relies on the clonal rearrangement of IgH genes during B cell development to identify malignant cells (",
"      <a class=\"graphic graphic_figure graphicRef81109 \" href=\"mobipreview.htm?34/25/35230\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. As an example, in one study of patients with known CNS lymphoma, five of seven specimens suspicious but non-diagnostic by conventional cytology were positive by PCR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/74\">",
"       74",
"      </a>",
"      ]. Of 13 specimens that were negative by cytology, 5 were positive by PCR.",
"     </li>",
"     <li>",
"      A single-cell PCR technique designed to detect monoclonality on the basis of IgH rearrangement may be more sensitive and specific than standard PCR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/76\">",
"       76",
"      </a>",
"      ]. However, the primers utilized span only 70 percent of the potential sites of rearrangement; thus, a 30 percent false negative rate exists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/77\">",
"       77",
"      </a>",
"      ]. Less experience exists with PCR detection of clonal T cell populations. Comparison of the PCR band size from the CSF with a PCR band from peripheral blood or a lymph node can reduce the false positive rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evaluation and Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of leptomeningeal metastases (LM) is made based upon the pathologic evaluation of a sample of cerebrospinal fluid (CSF) interpreted within the clinical context. A careful history and physical examination should evaluate for multifocal involvement. Patients suspected of having LM should be evaluated promptly with neuroimaging and CSF analysis. Radiographic evaluation with MRI of the brain and spine should be performed prior to lumbar puncture (LP) or ventricular tap, because the latter procedures can cause iatrogenic meningeal irritation and enhancement on imaging. Patients with an Ommaya reservoir in place should have CSF samples collected from both the Ommaya reservoir (ie, ventricular tap) and lumbar space (ie, LP). A positive CSF cytology establishes the diagnosis of LM. (See",
"    <a class=\"local\" href=\"#H6052480\">",
"     'Neuroimaging'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6053447\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While leptomeningeal disease must be managed to prevent neurologic morbidity and preserve quality of life, the survival of patients with leptomeningeal metastases (LM) depends largely on the extent to which the underlying systemic disease is controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/67,78\">",
"     67,78",
"    </a>",
"    ]. Thus, an effective treatment for LM must address both meningeal and systemic components of the disease.",
"   </p>",
"   <p>",
"    Treatment options for patients with documented LM include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High-dose intravenous (IV) chemotherapy",
"     </li>",
"     <li>",
"      Intrathecal (IT) chemotherapy",
"     </li>",
"     <li>",
"      Radiation therapy (RT) to sites of radiographically apparent symptomatic disease",
"     </li>",
"     <li>",
"      High-dose chemotherapy with hematopoietic cell rescue",
"     </li>",
"     <li>",
"      High-dose corticosteroids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal treatment of LM is unknown and there is variation in clinical practice. Patients should be encouraged to participate in clinical trials, when available. The majority of information regarding treatment comes from retrospective analyses. Very few controlled studies have been performed. A choice among these modalities must take into consideration the patient&rsquo;s functional status, burden of disease, and the therapy&rsquo;s side effect profile. Details of typical dosing schedules and information about monitoring response to therapy are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our general approach depends upon the site of disease and patient-related factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with LM, we suggest the use of high-dose intravenous chemotherapy rather than intrathecal chemotherapy or radiation therapy. This preference places a high value on our clinical experience with high-dose intravenous chemotherapy and the avoidance of lumbar puncture or Ommaya reservoir placement and access. Alternatively, some clinicians place an Ommaya reservoir for patients with documented CSF involvement to allow for the direct administration of chemotherapy into the CSF in addition to systemic chemotherapy.",
"     </li>",
"     <li>",
"      Radiation therapy is usually reserved for patients who have failed intravenous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intrathecal chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those who have a functional status that limits their ability to receive intravenous or intrathecal chemotherapy. Select patients who attain a complete response may be considered for high-dose chemotherapy with hematopoietic cell rescue in the setting of a trial.",
"     </li>",
"     <li>",
"      High-dose corticosteroids can be used for temporary symptomatic relief and may be used in conjunction with radiation therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of the large case series have included patients managed over a period of many years with a variety of treatment protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In these studies, reported survival has been poor, with a median time from diagnosis of CNS relapse to death of approximately four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12-15,18,48\">",
"     12-15,18,48",
"    </a>",
"    ]; no patients were alive after 26 months of follow-up.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 24 patients with CNS relapse, the treatment protocols and responses were as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/17\">",
"       17",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with LM and no focal deficits received IT",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , MTX, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      twice a week. All patients showed a decrease in the number of neoplastic cells in the CSF, but only one of six had symptomatic improvement.",
"     </li>",
"     <li>",
"      Patients with focal deficits or brain parenchymal disease received whole brain radiation therapy (WBRT) or spinal radiation. Symptomatic improvement was noted in six of nine patients, but responses were transient. Five patients had progression of CNS disease, and four patients had systemic recurrence.",
"     </li>",
"     <li>",
"      Five patients received systemic chemotherapy, which was combined with IT chemotherapy in two patients. CNS disease responded transiently in three patients. One patient had a durable remission and remained alive at the time of publication.",
"     </li>",
"     <li>",
"      Overall, median survival after CNS recurrence was 88 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another study examined the treatment of 170 patients with CNS involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/15\">",
"       15",
"      </a>",
"      ]. They were treated as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with established CNS involvement received CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) or \"CHOP-like\" chemotherapy (",
"      <a class=\"graphic graphic_table graphicRef66136 \" href=\"mobipreview.htm?0/54/876\">",
"       table 5",
"      </a>",
"      ) with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IT MTX.",
"     </li>",
"     <li>",
"      From 1990 on, patients &lt;60 years of age with chemosensitive disease were also offered high-dose chemotherapy with autologous hematopoietic cell transplantation (HCT).",
"     </li>",
"     <li>",
"      All patients with spine or brain parenchymal disease received RT.",
"     </li>",
"     <li>",
"      Overall, median survival after CNS recurrence was 2.6 months.",
"      <br/>",
"      <br/>",
"      Although 158 of 170 patients died during the study period, patients treated with high-dose chemotherapy and autologous HCT had better outcomes. All eight achieved a CR, and five (63 percent) were alive and disease-free at the end of the study period. In contrast, only 28 of 132 (21 percent) of those treated with combination chemotherapy and radiotherapy achieved a CR, and only 7 (25 percent) remained disease free.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A third multicenter retrospective study reported the outcomes of 113 patients with isolated CNS relapse of systemic NHL of which 83 percent had diffuse large B-cell lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/79\">",
"       79",
"      </a>",
"      ]. Median overall survival from the time of brain relapse was 1.6 years. In a multivariate model, treatment with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -based regimen resulted in significantly longer median overall survival (2.6 versus 0.6 years) compared with regimens that did not contain methotrexate. There was no significant benefit to the addition of whole brain radiation therapy in this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21866970\">",
"    <span class=\"h3\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose systemic therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ) allows for the uniform distribution of chemotherapy throughout the neuraxis and optimal penetration of brain tissue remote from CSF spaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. High dose systemic methotrexate (MTX) is commonly used for the treatment of primary CNS lymphoma and appears to have efficacy in secondary involvement of the CNS with NHL. However, high-dose systemic therapy carries with it the risk of systemic toxicity that local treatment with intrathecal (IT) chemotherapy or radiation therapy largely avoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Methotrexate-based induction chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small feasibility study evaluated 23 patients with first CNS relapse of NHL treated with high-dose IV MTX (3.5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue and IT",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    50 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/83\">",
"     83",
"    </a>",
"    ]. Patients with adequate bone marrow reserve also received oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every patient showed a partial or complete CNS response, while only 47 percent showed a systemic response.",
"     </li>",
"     <li>",
"      Despite excellent initial CNS response, durable responses were rare, and the prognosis remained extremely poor, with a median survival of six months and one and two-year survivals of 32 and 15 percent, respectively.",
"     </li>",
"     <li>",
"      Approximately equal numbers of CNS and systemic relapses were observed, with an overall relapse rate of 96 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective study of 20 patients with CNS relapse of NHL evaluated the use of intravenous MTX (4",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (1.5 to 2",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/84\">",
"     84",
"    </a>",
"    ]. The overall response rate was 90 percent with 60 percent achieving a complete response or unconfirmed complete response. At a median follow-up of 14.9 months, the median time to neurologic progression was 8.9 months and the median overall survival was not reached.",
"   </p>",
"   <p>",
"    The ideal dose of MTX to control CNS disease is unknown. Our own approach is to provide higher-dose IV MTX (8",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over four hours) such as that commonly used for primary CNS lymphoma. We administer MTX every 14 days with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue until the patient achieves a complete response or treatment failure. No data have yet been obtained to prove the superiority or inferiority of this approach. Alternative regimens include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or the combination of methotrexate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    used for primary CNS lymphoma. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=see_link&amp;anchor=H23594407#H23594407\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Choice of regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    must be performed at a center that has expertise in its use and appropriate laboratory support for the measurement of methotrexate levels. Adjustment for renal dysfunction is necessary. Further information on the use of methotrexate for the treatment of LM is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H575191885\">",
"    <span class=\"h4\">",
"     Is there a role for rituximab?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is incorporated into the standard therapy of most CD20 positive non-Hodgkin lymphomas (NHL). CD20 is expressed by most B cells but not neurons or glial cells. However, the role of rituximab in the treatment of CNS involvement by B cell NHL is less clear, largely because of the unknown ability of rituximab to cross the blood-brain-barrier. Case reports and single-arm prospective trials have included rituximab into the treatment of newly diagnosed or relapsed primary CNS lymphoma, and suggest that it can cross the blood-brain-barrier and has activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/85-89\">",
"     85-89",
"    </a>",
"    ]. If a regimen that incorporates rituximab is used, clinicians must be aware that rituximab therapy imposes a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103009612\">",
"    <span class=\"h3\">",
"     Intrathecal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal (IT) chemotherapy is able to achieve high drug levels in the cerebrospinal fluid (CSF) while avoiding much of the systemic toxicity seen with high dose intravenous chemotherapy. Intravenous administration of most chemotherapy drugs is only able to achieve a CSF to serum drug concentration ratio &lt;10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/82\">",
"     82",
"    </a>",
"    ]. Because the volume of distribution in the CSF is much smaller than that of plasma, relatively small IT doses are adequate. In addition, the clearance half-lives for most chemotherapeutic drugs are longer in CSF than in plasma. Thus, the IT route affords prolonged drug exposure at high concentrations, with minimal systemic toxicity.",
"   </p>",
"   <p>",
"    Options for IT administration include lumbar puncture (LP) and Ommaya reservoir instillation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration via LP is inconvenient for patients, often requires multiple injections each week, and is associated with a significant rate of inadvertent drug injection into the epidural space or soft tissues. Even when IT administration via LP is successful, the agent may fail to reach the brain parenchyma in cytotoxic concentrations.",
"     </li>",
"     <li>",
"      Ommaya reservoir instillation circumvents the problems of LP administration at the expense of the requirement for surgical placement of a reservoir, which has a 4 to 11 percent complication rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/90\">",
"       90",
"      </a>",
"      ]. Placement of an Ommaya reservoir may not be practical in patients with a poor prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103009619\">",
"    <span class=\"h4\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal treatments with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    have demonstrated activity against NHL in the CNS. Randomized trials are needed to determine the appropriate schedule, dosing, and efficacy of both intrathecal (IT) and systemic treatment.",
"   </p>",
"   <p>",
"    In the first randomized controlled trial performed in leptomeningeal metastases (LM), 28 patients were randomly assigned to receive IT injections of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    or a slow-release liposomal formulation of the same drug (DepoCyt) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/91\">",
"     91",
"    </a>",
"    ]. When compared with conventional cytarabine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A significantly greater cytologic response rate (71 versus 15 percent)",
"     </li>",
"     <li>",
"      A trend towards improved median time to neurologic progression (78 versus 42 days)",
"     </li>",
"     <li>",
"      A trend towards increased median survival (100 versus 63 days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary practical advantage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    , which may translate into improved quality of life, is that its long half-life permits infrequent injections with even distribution throughout the entire CSF space, although this benefit may be partially offset by an increased incidence of chemical meningitis. On the basis of this study, liposomal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    was approved by the FDA as therapy for meningeal lymphoma in 1999. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Liposomal cytarabine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H30#H30\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Intrathecal liposomal cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A subsequent retrospective analysis of 55 patients with LM who received a median of four cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    reported complete and partial neurologic responses in 27 and 12 patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/92\">",
"     92",
"    </a>",
"    ]. Of those responding, neurologic progression occurred at a median time of 105.5 days. Headache was the most common side effect.",
"   </p>",
"   <p>",
"    The ideal schedule of IT administration is unknown. If conventional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , MTX, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    are used, they are typically administered twice per week until the CSF clears, and then weekly thereafter for another one to two months. The usual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/53/34645?source=see_link\">",
"     liposomal cytarabine",
"    </a>",
"    regimen is 50 mg IT every two weeks, with the frequency of administration decreasing in responding patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Liposomal cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103009652\">",
"    <span class=\"h4\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been incorporated into the initial treatment of many subtypes of B cell NHL. CD20 is expressed by most B cells but not neurons or glial cells. Intravenous (IV) rituximab achieves CNS concentrations that much lower than that of matched serum. In comparison, intrathecal (IT) rituximab may achieve higher CNS concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A German group reported results of IT",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in two patients with NHL, one with leptomeningeal (LM) spread from Burkitt lymphoma and another with parenchymal brain metastasis from diffuse large B cell lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/94\">",
"       94",
"      </a>",
"      ]. The patient with LM showed total clearing of lymphoma cells from the CSF for four weeks, while the patient with a parenchymal metastasis showed only a minor response.",
"     </li>",
"     <li>",
"      A larger phase I dose-escalation study was performed in 10 patients with recurrent CNS NHL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/95\">",
"       95",
"      </a>",
"      ]. The maximally-tolerated IT dose was 25 mg, with rapid craniospinal axis distribution and achievement of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      concentrations within the ventricles that were similar to peak serum levels achieved after standard IV rituximab. Cytologic responses, complete responses, and improvement in intraocular NHL were noted in six, four, and two patients, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These highly preliminary results suggest that IT",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may have a role in secondary CNS NHL. Additional investigation will determine whether IT rituximab is superior to currently available treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most types of NHL are sensitive to radiation therapy (RT), but cranial irradiation is associated with both short and long-term side effects that limit its use. In addition, RT is localized therapy. Effective treatment for leptomeningeal metastasis must address both meningeal and systemic components of the disease. RT remains an option for the palliative treatment of patients who are not candidates for high dose systemic chemotherapy. In addition, RT is commonly administered in conjunction with chemotherapy for patients with radiographically visible, symptomatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Brain metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Chemotherapy has limited penetration into bulky disease. As an example, in one study only one of 11 patients (9 percent) with parenchymal brain involvement achieved a complete response (CR) with chemotherapy alone versus a 33 percent CR rate in patients with leptomeningeal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/83\">",
"     83",
"    </a>",
"    ]. Involved-field RT allows for the treatment of bulky disease that would not usually respond to chemotherapy. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Brain metastases'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    Although one would prefer to treat the full extent of leptomeningeal disease, craniospinal irradiation is associated with significant neurologic and bone marrow toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/96\">",
"     96",
"    </a>",
"    ]. The latter may mandate cessation of RT and may make additional chemotherapy unsafe. Involved-field RT avoids the toxicity of craniospinal irradiation. With this approach, daily fractions of 2 to 4 Gy to a total dose of 20 to 40 Gy are administered to areas that are symptomatic or involved according to imaging studies.",
"   </p>",
"   <p>",
"    Immediate complications from radiation are few and include headaches, hair loss, and cutaneous irritation. In patients with significant mass effect, corticosteroids should be administered to avoid cerebral edema and symptomatic elevation of intracranial pressure. Acute symptoms of confusion, caused by XRT-induced brain edema, are usually mild and transient. Occasionally, it may be necessary to temporarily increase the dose of corticosteroids to reduce the resulting edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Corticosteroids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intrathecal radiation with radioactive nuclides or radiolabeled monoclonal antibodies has been evaluated in only a limited number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1782453\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids are commonly used in combination with chemotherapy for the treatment of NHL. They can result in temporary reversal of neurologic deficits from leptomeningeal metastasis (LM) due to NHL. In addition, they may improve headache and radicular pain more effectively than analgesics.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is the most commonly used preparation, and is often given at a starting dose of 4 mg PO four times per day. If radiation treatment is contemplated, some radiation oncologists prefer to continue corticosteroids until the radiation course has been completed. The dose can then be tapered.",
"   </p>",
"   <p>",
"    Because treatment with corticosteroids may delay or interfere with diagnosis and alter the histopathology of the tumor, it is important that they not be used before pathological confirmation of biopsy results. If necessary, patients with symptomatic edema or increased intracranial pressure can be initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1782427\">",
"    <span class=\"h3\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with secondary involvement of the CNS by NHL are at risk for seizures, but prophylactic anticonvulsants may not reduce the frequency of subsequent seizures, and have deleterious interactions with cytotoxic drugs and corticosteroids. As with other brain tumors, we reserve the use of anticonvulsants for patients with documented seizure activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link&amp;anchor=H4#H4\">",
"     \"Seizures in patients with primary and metastatic brain tumors\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17393200\">",
"    <span class=\"h3\">",
"     High-dose chemotherapy with stem cell rescue",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the efficacy of high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) in patients with secondary involvement of the CNS by NHL. The following is a survey of studies that have reported on the outcomes with this approach:",
"   </p>",
"   <p>",
"    In a series of 13 patients treated with a conditioning regimen including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , intrathecal (IT)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , IT",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , or both, as well as CNS radiotherapy, excellent outcomes were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/97\">",
"     97",
"    </a>",
"    ]. Actuarial five-year event-free (EFS) and overall (OS) survivals were 46 and 41 percent, respectively, with median EFS and OS of 2.2 and 1.5 years, respectively. There was only a single CNS relapse, occurring 11 years post-transplant. Despite treatment-related toxicities and white matter abnormalities on imaging, seven patients surveyed one year after transplant reported good quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/97\">",
"     97",
"    </a>",
"    ]. Two of three patients treated with autologous HCT in another study achieved a prolonged complete response (CR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Almost all patients who have had durable responses to this regimen had achieved CR in the CNS prior to transplant, while those whose CNS disease remained uncontrolled at the time of HCT had poor outcomes. A retrospective analysis from the European Bone Marrow Transplant Lymphoma Registry also suggested that the presence of CNS disease before HCT but not at the time of transplant did not adversely affect the outcome of HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/98\">",
"     98",
"    </a>",
"    ]. Larger trials are necessary to clarify the role of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SPINAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;NHL may involve the vertebral body, the epidural space, and rarely, the spinal cord itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Epidural spinal cord compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural spinal cord compression (ESCC) is a common neurologic complication of many cancers that can cause irreversible loss of motor, sensory,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autonomic function. Most cases develop when a solid tumor invades a vertebral body and then encroaches upon the spinal cord from its anterior aspect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHL is unique in that it often reaches the cord via the vertebral foramina without first causing bony destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. In one study, for example, 16 of 18 patients presenting with ESCC as the first manifestation of NHL had no evidence of vertebral body involvement on radiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/101\">",
"     101",
"    </a>",
"    ]. Presumably, NHL first involves the paraspinal soft tissues and then invades via the vertebral foramen.",
"   </p>",
"   <p>",
"    ESCC occurs in 0.1 to 6.5 percent of NHL patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12,101-103\">",
"     12,101-103",
"    </a>",
"    ], either at the time of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/1\">",
"     1",
"    </a>",
"    ] or as the initial manifestation of NHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/104\">",
"     104",
"    </a>",
"    ]. Details regarding the clinical manifestations, diagnosis, and treatment of ESCC are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two unique aspects of ESCC due to NHL deserve mention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although radical surgical resection is often recommended as initial therapy for ESCC arising from solid tumors, NHL tends to be radiosensitive and is unlikely to be cured by surgical resection. Accordingly, a surgical approach is best reserved for lymphomatous ESCC that has failed to respond to radiation and chemotherapy. However, when NHL presents initially as ESCC, surgical decompression, or a biopsy from the involved area, may provide crucial interim relief as well as a tissue diagnosis.",
"     </li>",
"     <li>",
"      Although radiation therapy may provide local relief of ESCC, patients with ESCC due to lymphoma require systemic treatment of the lymphoma with multiagent chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      for CD20 positive disease.",
"     </li>",
"     <li>",
"      Although the median survival following the diagnosis of ESCC from any cause is approximately six months, the subset of NHL patients who present with ESCC may have a better prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12,101\">",
"       12,101",
"      </a>",
"      ]. As an example, one study reported that 50 percent of 18 such patients were alive more than three years after this presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intramedullary metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramedullary metastases (IM) may develop when a tumor in the subarachnoid space grows along nerve roots into the spinal cord or when there is direct hematogenous tumor spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/105\">",
"     105",
"    </a>",
"    ]. IM are sufficiently rare that their prevalence is difficult to estimate. In the largest published review of 79 cases of IM, 6 (7.6 percent) were caused by malignant lymphoma. Lung cancer and breast cancer were the most common primary tumors reported to produce IM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/106\">",
"     106",
"    </a>",
"    ]. Although classic neurologic teaching suggests that IM are more likely than epidural metastases to present with a hemicord (Brown-S&eacute;quard) syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/105\">",
"     105",
"    </a>",
"    ], this has only rarely been reported in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical presenting features of IM include pain, weakness, spasticity, sensory loss, and bowel or bladder dysfunction. These symptoms and signs clearly point to spinal cord disease but are inadequate to distinguish between intramedullary and extramedullary processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/106\">",
"     106",
"    </a>",
"    ]. Myelography is a poor test for the diagnosis of intramedullary lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/106\">",
"     106",
"    </a>",
"    ], but gadolinium-enhanced magnetic resonance imaging (MRI) easily makes the diagnosis in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard treatment of IM includes corticosteroids and radiation therapy, which may stabilize neurologic function for a short period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/105\">",
"     105",
"    </a>",
"    ]. Prognosis is poor, as most patients with IM present in the setting of widespread metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     BRAIN METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenchymal involvement of the brain by NHL is distinctly less common than either leptomeningeal metastases or epidural spinal cord compression. In a series of 592 patients with NHL, only 1.4 percent developed cerebral metastases, representing only 16 percent of the patients who developed CNS involvement of any sort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms and signs depend on the number and location of brain metastases. Presenting complaints include seizures, focal motor or sensory deficits, cranial nerve deficits, or depressed level of consciousness due to elevated intracranial pressure.",
"   </p>",
"   <p>",
"    Gadolinium-enhanced magnetic resonance imaging (MRI) is the optimal neuroimaging modality for NHL patients presenting with signs and symptoms suggestive of brain metastasis. Surgical biopsy is often necessary to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/99\">",
"     99",
"    </a>",
"    ]. There are no known imaging features that allow NHL metastases to be distinguished from primary brain tumors or metastases from other primary tumors with a high degree of certainty (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62013 \" href=\"mobipreview.htm?35/56/36737\">",
"     image 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As for other brain metastases, treatment usually includes corticosteroids to reduce swelling and radiation therapy. There may be a role for high-dose systemic chemotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) in selected patients with good performance status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the rarity of this presentation, very little information is available to guide therapeutic decision-making. However, since brain metastases from NHL often develop in the setting of widespread disease, systemic chemotherapy is usually necessary. Consideration should clearly be given to regimens which include agents that penetrate the blood-brain barrier, such as high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Surgery is not generally considered, except in the setting of radiation-resistant disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17393438\">",
"    <span class=\"h2\">",
"     Who should receive prophylaxis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the poor outcomes of patients who develop secondary involvement of the CNS by NHL, attempts have been made to prevent its development by administering prophylaxis to patients at high risk. There is no consensus regarding which risk factors should be used to identify patients who need prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/108\">",
"     108",
"    </a>",
"    ]. Patients should be encouraged to participate in clinical trials, when available.",
"   </p>",
"   <p>",
"    In general, the need for CNS prophylaxis is determined based upon the aggressiveness of the NHL subtype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indolent NHL &mdash; Most authors agree that indolent NHL (eg, follicular lymphoma) has a very low risk of CNS involvement and does not warrant prophylactic therapy.",
"     </li>",
"     <li>",
"      Highly aggressive NHL &mdash; The propensity for highly aggressive NHL (eg, lymphoblastic",
"      <span class=\"nowrap\">",
"       lymphoma/acute",
"      </span>",
"      lymphoblastic leukemia, Burkitt lymphoma) to involve the CNS is well-established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/13,16\">",
"       13,16",
"      </a>",
"      ]. Intrathecal (IT) chemotherapy and high doses of MTX, with or without the addition of cranial irradiation, are standard components of treatment for such NHL variants, and the likelihood of CNS recurrence is thought to have been reduced by such measures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aggressive NHL &mdash; Patients with aggressive NHL (eg, diffuse large B cell lymphoma) have a risk of CNS recurrence of approximately 5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/13,14,17,32,33\">",
"       13,14,17,32,33",
"      </a>",
"      ]. Factors such as International Prognostic Index, the number and location of extranodal sites of disease, and serum LDH may be used to identify a group of patients with aggressive NHL who are at particularly high risk for CNS recurrence and might therefore benefit from prophylactic treatment (",
"      <a class=\"graphic graphic_table graphicRef54470 \" href=\"mobipreview.htm?12/35/12859\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/110,111\">",
"       110,111",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H171056704\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CNS prophylaxis is most likely to benefit patients who achieve systemic complete response (CR). In patients who fail to achieve CR, CNS recurrence is generally an expression of end-stage disease.",
"   </p>",
"   <p>",
"    CNS prophylaxis should be routinely incorporated into the treatment of patients with highly aggressive subtypes of NHL such as lymphoblastic",
"    <span class=\"nowrap\">",
"     lymphoma/acute",
"    </span>",
"    lymphoblastic leukemia, Burkitt",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia,",
"    </span>",
"    and intravascular lymphoma. CNS prophylaxis is",
"    <strong>",
"     not",
"    </strong>",
"    indicated for patients with indolent forms of NHL such as follicular lymphoma. For patients with aggressive subtypes of NHL, we suggest the administration of CNS prophylaxis for patients with the following high risk features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An elevated serum lactate dehydrogenase level and involvement of &gt;1 extranodal site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Four or more of the following risk factors: elevated serum lactate dehydrogenase, serum albumin &lt;35",
"      <span class=\"nowrap\">",
"       g/l,",
"      </span>",
"      &lt;60 years of age, retroperitoneal lymph node involvement and involvement of more than one extranodal site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymphomatous involvement of the testes, orbit, or paranasal sinus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Concordant bone marrow involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are offered as general guidelines. The decision to administer CNS prophylaxis in the setting of aggressive NHL should be decided on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17393445\">",
"    <span class=\"h2\">",
"     What prophylaxis should be used?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision is made to administer CNS prophylaxis in a patient at high risk for CNS relapse, a choice must be made regarding the chemotherapy agent to be used and the route of administration. The efficacy of CNS prophylaxis has never been directly tested, but retrospective comparisons are available with mixed results. Randomized trials to determine the appropriate schedule, dosing, and efficacy of both intrathecal (IT) and systemic prophylaxis are needed in order to settle this issue.",
"   </p>",
"   <p>",
"    The following is a survey of studies that have investigated CNS prophylaxis in NHL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Japanese group analyzed 68 patients with aggressive NHL who had achieved CR after therapy with a MACOP-B like regimen and then received either IT MTX with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      or no CNS prophylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/112\">",
"       112",
"      </a>",
"      ]. CNS relapse occurred in none of the 29 patients who received prophylaxis, compared with 6 of 39 patients (15 percent) who did not receive prophylaxis. Five-year overall survival (80 versus 58 percent) and recurrence-free survival (85 versus 51 percent) were significantly longer for the group that received prophylaxis. On multivariate analysis, lack of CNS prophylaxis was the strongest independent predictor of CNS recurrence.",
"     </li>",
"     <li>",
"      In an uncontrolled study, 51 patients with diffuse large B cell lymphoma (DLBCL) involving sites associated with high risk of CNS relapse received IT prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      in some cases) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/113\">",
"       113",
"      </a>",
"      ]. The CNS relapse rate was 1.1 percent, which is substantially lower than the expected relapse rate based on other reports.",
"     </li>",
"     <li>",
"      A single institution retrospective study of 65 patients with newly diagnosed DLBCL and risk factors for CNS recurrence evaluated the use of R-CHOP-based chemotherapy plus concurrent CNS prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (3.5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/114\">",
"       114",
"      </a>",
"      ]. Risk factors for CNS recurrence included two or more extranodal sites; elevated LDH; or involvement of high risk sites such as the bone marrow, testes, or paranasal sinuses. A complete response was attained in 86 percent. After a median follow-up of 33 months, rates of progression-free and overall survival at three years were 76 and 78 percent, respectively. Two patients (3 percent) developed CNS recurrence, both of whom had bone marrow involvement at the time of diagnosis. Non-CNS relapse occurred in 11 patients.",
"     </li>",
"     <li>",
"      A non-randomized study of 974 patients with aggressive subtypes of NHL who achieved a CR and received CNS prophylaxis with IT and intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , isolated CNS relapse occurred in 1.6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/44\">",
"       44",
"      </a>",
"      ], substantially lower than the historical value of 5 percent noted above.",
"     </li>",
"     <li>",
"      An Australian group retrospectively studied 27 patients who had received IT prophylaxis for B cell malignancies. Six patients with DLBCL suffered secondary CNS relapse despite the use of IT prophylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of 515 patients with relapsed aggressive NHL found that CNS relapse rates were not significantly different in patients who had received or had not received any type of CNS prophylaxis (radiation or IT chemotherapy) (5.2 versus 3.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/17/39194/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients at high risk of CNS relapse, we suggest the use of systemic intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (3500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue for CNS prophylaxis rather than intrathecal therapy. Intravenous methotrexate is administered as an inpatient on day 15 of alternating cycles of chemotherapy (ie, cycles 2, 4, and 6). This preference is based upon our clinical experience with systemic intravenous methotrexate and the avoidance of central nervous system access. Intrathecal chemotherapy is an acceptable alternative for patients who cannot tolerate systemic therapy. The administration of high-dose methotrexate must be performed at a center that has expertise in its use and appropriate laboratory support for the measurement of methotrexate levels. Adjustment for renal dysfunction is necessary. Further information on the use of methotrexate for the treatment of LM is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1782397\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic non-Hodgkin lymphoma (NHL) may involve the nervous system at every level, including peripheral nerve, spinal nerve root, spinal cord, meninges, and brain. Such involvement may include direct invasion or compression of these structures, as well as non-invasive paraneoplastic effects of NHL. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central nervous system (CNS) disease is found in a minority of patients at the time of NHL diagnosis, the exact percentage of which differs by histologic subtype. The majority of cases of CNS involvement by NHL occur in the setting of relapsed disease. (See",
"      <a class=\"local\" href=\"#H171056704\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leptomeningeal metastasis (LM), or lymphomatous meningitis, is the most common nervous system complication of NHL. Patients with LM commonly present with radicular pain, vague back or neck pain, mental status changes, cranial nerve deficits, focal weakness or sensory loss,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      headache. Dysfunction at multiple levels of the neuraxis is common. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of leptomeningeal metastases (LM) is made based upon the pathologic evaluation of a sample of cerebrospinal fluid (CSF) interpreted within the clinical context. A careful history and physical examination should evaluate for multifocal involvement. Patients suspected of having LM should be evaluated promptly with neuroimaging and CSF analysis. Radiographic evaluation with MRI of the brain and spine should be performed prior to lumbar puncture (LP) or ventricular tap, because the latter procedures can cause iatrogenic meningeal irritation and enhancement on imaging. Patients with an Ommaya reservoir in place should have CSF samples collected from both the Ommaya reservoir (ie, ventricular tap) and lumbar space (ie, LP). The CSF sample should be evaluated for cell counts, protein and glucose levels, cytology, flow cytometry, and immunoglobulin heavy chain gene rearrangement studies. Flow cytometry may detect cases of LM not found by cytology, and cytology may find cases not identified by flow cytometry. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation and Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6052480\">",
"       'Neuroimaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6053884\">",
"       'Lumbar puncture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While leptomeningeal disease must be managed to prevent neurologic morbidity and preserve quality of life, the survival of patients with leptomeningeal metastases (LM) depends largely on the extent to which the underlying systemic disease is controlled. Thus, an effective treatment for LM must address both meningeal and systemic components of the disease. (See",
"      <a class=\"local\" href=\"#H6053447\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment of LM is unknown and there is variation in clinical practice. Patients should be encouraged to participate in clinical trials, when available. Outside of a clinical trial, our general approach depends upon the site of disease and patient-related factors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For most patients with LM, we suggest the use of high-dose intravenous chemotherapy rather than intrathecal chemotherapy or radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference places a high value on our clinical experience with high-dose intravenous chemotherapy and the avoidance of lumbar puncture or Ommaya reservoir placement and access. (See",
"      <a class=\"local\" href=\"#H103009619\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation therapy is usually reserved for patients who have failed intravenous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intrathecal chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those who have a functional status that limits their ability to receive intravenous or intrathecal chemotherapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Select patients who attain a complete response may be considered for high-dose chemotherapy with hematopoietic cell rescue in the setting of a trial. (See",
"      <a class=\"local\" href=\"#H17393200\">",
"       'High-dose chemotherapy with stem cell rescue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-dose corticosteroids can be used for temporary symptomatic relief and may be used in conjunction with radiation therapy. (See",
"      <a class=\"local\" href=\"#H1782453\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CNS prophylaxis should be routinely incorporated into the treatment of patients with highly aggressive subtypes of NHL such as lymphoblastic",
"      <span class=\"nowrap\">",
"       lymphoma/acute",
"      </span>",
"      lymphoblastic leukemia, Burkitt",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia,",
"      </span>",
"      and intravascular lymphoma. CNS prophylaxis is",
"      <strong>",
"       not",
"      </strong>",
"      indicated for patients with indolent forms of NHL such as follicular lymphoma. For patients with aggressive subtypes of NHL, we suggest the administration of CNS prophylaxis for patients with high risk features (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17393438\">",
"       'Who should receive prophylaxis?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients at high risk of CNS relapse, we suggest the use of systemic intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (3500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue for CNS prophylaxis rather than intrathecal therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17393445\">",
"       'What prophylaxis should be used?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/1\">",
"      Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkin's lymphomas. Cancer 1980; 45:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/2\">",
"      Gleissner B, Chamberlain M. Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 2007; 84:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/3\">",
"      Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol 2009; 27:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/4\">",
"      Lossos A, Ashhab Y, Sverdlin E, et al. Late-delayed cerebral involvement in systemic non-Hodgkin lymphoma: a second primary tumor or a tardy recurrence? Cancer 2004; 101:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/5\">",
"      Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/6\">",
"      Kern WF, Spier CM, Hanneman EH, et al. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood 1992; 79:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/7\">",
"      Engelhardt B, Martin-Simonet MT, Rott LS, et al. Adhesion molecule phenotype of T lymphocytes in inflamed CNS. J Neuroimmunol 1998; 84:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/8\">",
"      Kivis&auml;kk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A 2003; 100:8389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/9\">",
"      Anthony IC, Crawford DH, Bell JE. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 2003; 126:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/10\">",
"      Smith JR, Braziel RM, Paoletti S, et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/11\">",
"      Jahnke K, Hummel M, Korfel A, et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 2006; 24:4754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/12\">",
"      Mead GM, Kennedy P, Smith JL, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases. Q J Med 1986; 60:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/13\">",
"      Hoerni-Simon G, Suchaud JP, Eghbali H, et al. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients. Oncology 1987; 44:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/14\">",
"      Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999; 32:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/15\">",
"      Hollender A, Kvaloy S, Lote K, et al. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000; 36:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/16\">",
"      Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/17\">",
"      van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/18\">",
"      Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/19\">",
"      Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113:3896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/20\">",
"      Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/21\">",
"      Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/22\">",
"      Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/23\">",
"      Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/24\">",
"      Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood 2010; 115:5427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/25\">",
"      Yi JH, Kim JH, Baek KK, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol 2011; 22:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/26\">",
"      Rappaport H, Thomas LB. Mycosis fungoides: the pathology of extracutaneous involvement. Cancer 1974; 34:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/27\">",
"      Hallahan D, Griem M, Griem S, et al. Mycosis fungoides involving the central nervous system. J Clin Oncol 1986; 4:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/28\">",
"      Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000; 88:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/29\">",
"      Bj&ouml;rkholm M, Hagberg H, Holte H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007; 18:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/30\">",
"      Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990; 8:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/31\">",
"      MacKintosh FR, Colby TV, Podolsky WJ, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982; 49:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/32\">",
"      McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 2005; 131:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/33\">",
"      Bos GM, van Putten WL, van der Holt B, et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/34\">",
"      Keldsen N, Michalski W, Bentzen SM, et al. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. Acta Oncol 1996; 35:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/35\">",
"      Au WY, Chan AC, Chow LW, Liang R. Lymphoma of the breast in Hong Kong Chinese. Hematol Oncol 1997; 15:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/36\">",
"      Yamazaki H, Hanada M, Kitada M, et al. Four cases of central nervous system involvement of breast malignant lymphoma. Jpn J Clin Oncol 2003; 33:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/37\">",
"      Ribrag V, Bibeau F, El Weshi A, et al. Primary breast lymphoma: a report of 20 cases. Br J Haematol 2001; 115:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/38\">",
"      Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/39\">",
"      Gholam D, Bibeau F, El Weshi A, et al. Primary breast lymphoma. Leuk Lymphoma 2003; 44:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/40\">",
"      Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML, et al. Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews. Ann Hematol 2003; 82:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/41\">",
"      Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. J Surg Oncol 2002; 80:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/42\">",
"      Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008; 19:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/43\">",
"      Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer 2000; 89:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/44\">",
"      Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/45\">",
"      Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011; 29:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/46\">",
"      Ferreri AJ, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol 2009; 27:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/47\">",
"      Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 9:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/48\">",
"      Yoshida S, Morii K, Watanabe M, Saito T. Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 2000; 53:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/49\">",
"      Allen C, Bell J, McNaughton H, Warlow C. Papilloedema and lymphocytic meningitis in a 68 year old man. J Neurol Neurosurg Psychiatry 1995; 58:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/50\">",
"      DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/51\">",
"      Karp G, Nahum K. Hyperventilation as the initial manifestation of lymphomatous meningitis. J Neurooncol 1992; 13:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/52\">",
"      Schuknecht B, Huber P, B&uuml;ller B, Nadjmi M. Spinal leptomeningeal neoplastic disease. Evaluation by MR, myelography and CT myelography. Eur Neurol 1992; 32:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/53\">",
"      Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 2011; 32:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/54\">",
"      Su CS, Lan MY, Chang YY, et al. Clinical features, neuroimaging and treatment of spontaneous intracranial hypotension and magnetic resonance imaging evidence of blind epidural blood patch. Eur Neurol 2009; 61:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/55\">",
"      Schiff D, Feske SK, Wen PY. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med 1993; 153:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/56\">",
"      Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 2001; 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/57\">",
"      Finn WG, Peterson LC, James C, Goolsby CL. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol 1998; 110:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/58\">",
"      Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007; 68:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/59\">",
"      Jeffery GM, Frampton CM, Legge HM, Hart DN. Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancy. Pathology 1990; 22:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/60\">",
"      Eclache V, Vu T, Le Roux G. D-dimer levels in the cerebrospinal fluid: a marker of central nervous system involvement in neoplastic disease. Nouv Rev Fr Hematol 1994; 36:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/61\">",
"      van den Bent MJ, Lamers CH, van 't Veer MB, et al. Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies. Ann Hematol 2002; 81:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/62\">",
"      Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/63\">",
"      Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/64\">",
"      Garc&iacute;a-Monc&oacute; JC, G&oacute;mez Beldarrain M, Benach JL, et al. Borrelia meningitis mimicking meningeal lymphoma. Neurology 1994; 44:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/65\">",
"      Bigner SH. Cerebrospinal fluid (CSF) cytology: current status and diagnostic applications. J Neuropathol Exp Neurol 1992; 51:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/66\">",
"      Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/67\">",
"      Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/68\">",
"      Tani E, Costa I, Svedmyr E, Skoog L. Diagnosis of lymphoma, leukemia, and metastatic tumor involvement of the cerebrospinal fluid by cytology and immunocytochemistry. Diagn Cytopathol 1995; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/69\">",
"      Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/70\">",
"      Quijano S, L&oacute;pez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009; 27:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/71\">",
"      French CA, Dorfman DM, Shaheen G, Cibas ES. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol 2000; 23:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/72\">",
"      Roma AA, Garcia A, Avagnina A, et al. Lymphoid and myeloid neoplasms involving cerebrospinal fluid: comparison of morphologic examination and immunophenotyping by flow cytometry. Diagn Cytopathol 2002; 27:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/73\">",
"      Benevolo G, Stacchini A, Spina M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 2012; 120:3222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/74\">",
"      Rhodes CH, Glantz MJ, Glantz L, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996; 77:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/75\">",
"      Gleissner B, Siehl J, Korfel A, et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002; 58:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/76\">",
"      Hug A, Storch-Hagenlocher B, Haas J, et al. Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins. J Neurol Sci 2004; 219:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/77\">",
"      Gong JZ, Zheng S, Chiarle R, et al. Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. Am J Pathol 1999; 155:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/78\">",
"      Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/79\">",
"      Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2008; 111:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/80\">",
"      Lopez JA, Nassif E, Vannicola P, et al. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 1985; 3:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/81\">",
"      Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/82\">",
"      Blaney SM, Balis FM, Poplack DG. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park) 1991; 5:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/83\">",
"      Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002; 43:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/84\">",
"      Fischer L, Korfel A, Kiewe P, et al. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol 2009; 88:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/85\">",
"      Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/86\">",
"      Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/87\">",
"      Wong ET. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2005; 64:934; author reply 934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/88\">",
"      Santisteban M, Nieto Y, De la Cruz S, et al. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clin Transl Oncol 2007; 9:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/89\">",
"      Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011; 76:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/90\">",
"      Berweiler U, Krone A, Tonn JC. Reservoir systems for intraventricular chemotherapy. J Neurooncol 1998; 38:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/91\">",
"      Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/92\">",
"      Garcia-Marco JA, Panizo C, Garcia ES, et al. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 2009; 115:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/93\">",
"      Perissinotti AJ, Reeves DJ. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother 2010; 44:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/94\">",
"      Schulz H, Pels H, Schmidt-Wolf I, et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/95\">",
"      Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/96\">",
"      Hanssens PE, Lagerwaard FJ, Levendag PC. Principles of radiotherapy of neoplastic meningosis. J Neurooncol 1998; 38:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/97\">",
"      Alvarnas JC, Negrin RS, Horning SJ, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/98\">",
"      Williams CD, Pearce R, Taghipour G, et al. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 1994; 12:2415.",
"     </a>",
"    </li>",
"    <li>",
"     Giglio P, Gilbert MR. Neurological complications of non-Hodgkin's lymphoma. In: Lymphoma of the Nervous System, Batchelor TT (Ed), Butterworth Heinemann, Amsterdam 2004. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/100\">",
"      Oviatt DL, Kirshner HS, Stein RS. Successful chemotherapeutic treatment of epidural compression in non-Hodgkin's lymphoma. Cancer 1982; 49:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/101\">",
"      Perry JR, Deodhare SS, Bilbao JM, et al. The significance of spinal cord compression as the initial manifestation of lymphoma. Neurosurgery 1993; 32:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/102\">",
"      Herman TS, Hammond N, Jones SE, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer 1979; 43:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/103\">",
"      Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/104\">",
"      Mohammed WA, Doshi R. Spinal epidural malignant lymphoma presenting with spinal cord compression. Clin Neuropathol 1995; 14:237.",
"     </a>",
"    </li>",
"    <li>",
"     Schiff D, Wen P. Nervous system metastases. In: Neurology in Clinical Practice, Walter GB, Daroff RB, Fenichel GM, Jankovic J (Eds), Butterworth Heinemann, Philadelphia 2004. p.1441.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/106\">",
"      Edelson RN, Deck MD, Posner JB. Intramedullary spinal cord metastases. Clinical and radiographic findings in nine cases. Neurology 1972; 22:1222.",
"     </a>",
"    </li>",
"    <li>",
"     Posner JB. Neurologic Complications of Cancer, F.A. Davis Company, Philadelphia 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/108\">",
"      Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011; 12:1258.",
"     </a>",
"    </li>",
"    <li>",
"     Lister A, Abrey LE, Sandlund JT. Central nervous system lymphoma. Hematology (Am Soc Hematol Educ Program) 2002; 283.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/110\">",
"      Cheung CW, Burton C, Smith P, et al. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2005; 131:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/111\">",
"      Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012; 23:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/112\">",
"      Tomita N, Kodama F, Kanamori H, et al. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer 2002; 95:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/113\">",
"      Arkenau HT, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007; 18:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/114\">",
"      Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010; 116:4283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/17/39194/abstract/115\">",
"      Chua SL, Seymour JF, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43:1783.",
"     </a>",
"    </li>",
"    <li>",
"     Bernstein SH, Unger J, LeBlanc M, Fisher RI. Central nervous system (CNS) relapse in aggressive non-Hodgkins lymphoma: Does CNS prophylaxis work? (abstract) Blood 2007; 110: abstract 520.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4720 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-82E6EA8F2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39194=[""].join("\n");
var outline_f38_17_39194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1782397\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H171056704\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histologic subtype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LEPTOMENINGEAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6052480\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6053884\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6054638\">",
"      - CSF cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6054645\">",
"      - Molecular techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evaluation and Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6053447\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21866970\">",
"      - Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H575191885\">",
"      Is there a role for rituximab?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103009612\">",
"      - Intrathecal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103009619\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103009652\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1782453\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1782427\">",
"      - Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17393200\">",
"      - High-dose chemotherapy with stem cell rescue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SPINAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Epidural spinal cord compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intramedullary metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      BRAIN METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17393438\">",
"      Who should receive prophylaxis?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17393445\">",
"      What prophylaxis should be used?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1782397\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4720\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4720|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/55/24434\" title=\"diagnostic image 1\">",
"      Cranial nerve lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/60/4033\" title=\"diagnostic image 2\">",
"      Leptomeningeal lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/15/9457\" title=\"diagnostic image 3\">",
"      Nerve root lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/60/16322\" title=\"diagnostic image 4\">",
"      Cauda equina lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/56/36737\" title=\"diagnostic image 5\">",
"      Thalamic lesion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4720|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/18/6432\" title=\"figure 1\">",
"      CNS lymphoma flow study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/25/35230\" title=\"figure 2\">",
"      CNS lymphoma PCR study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4720|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/35/12859\" title=\"table 1\">",
"      Risk neuraxis involvement NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/26/42412\" title=\"table 2\">",
"      Classification of NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37819\" title=\"table 3\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17757\" title=\"table 4\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/54/876\" title=\"table 5\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=related_link\">",
"      Treatment and prognosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_17_39195="Relative contraindications to exercise testing";
var content_f38_17_39195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative contraindications to exercise testing*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Severe arterial hypertension (ie, diastolic blood pressure &gt;110 mmHg or systolic blood pressure &gt;200 mmHg at rest)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left main coronary stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate stenotic valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolyte abnormalities (hypokalemia, hypomagnesemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High degree atrioventricular block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tachyarrhythmias or bradyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertrophic cardiomyopathy or other forms of outflow tract obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled metabolic disease (eg, diabetes, thyrotoxicosis, or myxedema)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic infectious disease (eg, mononucleosis, hepatitis, AIDS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mental or physical impairment leading to inability to exercise adequately",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromuscular, musculoskeletal, or rheumatoid disorders that are exacerbated by exercise",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Relative contraindications can be superceded if benefits outweigh risks of exercise. In some instances, these individuals can be exercised with caution and/or using low-level end points, especially if they are asymptomatic at rest.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39195=[""].join("\n");
var outline_f38_17_39195=null;
var title_f38_17_39196="CAILS";
var content_f38_17_39196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composite Assessment of Index Lesion Severity for Mycosis Fungoides and Sezary Syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Clinical sign and degree or size (scale of 0 to 8)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Index lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1",
"       </td>",
"       <td class=\"subtitle2\">",
"        2",
"       </td>",
"       <td class=\"subtitle2\">",
"        3",
"       </td>",
"       <td class=\"subtitle2\">",
"        4",
"       </td>",
"       <td class=\"subtitle2\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scaling",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plaque elevation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypo- or hyperpigmentation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Lesion size*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td align=\"right\">",
"        <strong>",
"         Subtotal:",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"right\">",
"        <strong>",
"         Total (sum of subtotals):",
"        </strong>",
"       </td>",
"       <td colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Composite Assessment of Index Lesion Severity cannot be used as skin assessment in global response score. Suggestions for improvement include using actual size of lesion versus categorical score for size and eliminating pigmentation as a clinical parameter.",
"    <div class=\"footnotes\">",
"     * Lesion size (cm",
"     <sup>",
"      2",
"     </sup>",
"     ): 0: no measurable area; 1: &gt;0 to &le;4; 2: &gt;4 to &le;10; 3: &gt;10 to &le;16; 4: &gt;16 to &le;25; 5: &gt;25 to &le;35; 6: &gt;35 to &le;45; 7: &gt;45 to &le;55; 8: &gt;55 to &le;70; 9: &gt;70 to &le;90; 10: &gt;90 to &le;110; 11: &gt;110 to &le;130; 12: &gt;130 to &le;155; 13: &gt;155 to &le;180; 14: &gt;180 to &le;210; 15: &gt;210 to &le;240; 16: &gt;240 to &le;270; 17: &gt;270 to &le;300; 18: &gt;300.",
"    </div>",
"    <div class=\"reference\">",
"     From: Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol; 29(18), 2011:2598-2607. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39196=[""].join("\n");
var outline_f38_17_39196=null;
var title_f38_17_39197="Ischemic events with asymptomatic bruits";
var content_f38_17_39197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Cerebral ischemia events with asymptomatic carotid artery bruits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 265px; background-image: url(data:image/gif;base64,R0lGODlh0wEJAeYAAP///4CAgP+AgICZ/4CzmQAAAMwzM0BAQMDAwAAz//LNzeaZmf8AAABmM//AwEBm/9lmZsDN//9AQFBQUNDQ0ECMZnBwcPDw8MDZzaCgoCAgILCwsBAQEDAwMHCN/xBwQP8gIPnm5uDg4GBgYKDGsyB5Tc9AQP+goP/g4JCQkP8QEFBz//Dz///Q0ODs5iBN/+/AwODm/9Dj2aCz/xBA/1CWc/zz8/8wMLDA//bZ2dxzc+yzs/9QUDCDWXCpjdZZWWCggLDQwGCA/9+AgP9gYOKNjf/w8P9wcJCm/zBZ//D28/+QkNDZ//+wsJC8pummptJNTb9AQL+Mv7+AgICZjIBZv0BzWQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADTAQkBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3ujggB8vII7/b3+Irx8wcB+f8AAcoLSLAgu4EGEyoUh3Chw4fYGkKcSNGZxIoYMxK7qLGjR10cP4ocCSskyZMoTZlMybIlp5UuY8qUBHOmzZuIauLciVMnz58xfQIdilIo0aMfjSJdilEp06cPnUKdalAq1av/rGI1iOIQCgdgwQIwEtZBC0EoBAjoCuArqxYS/05A07qVIIMbS9gKEsCgb18ADvwykCBIhQQJKgRJIOJoMKe0Dub66+hAreXLmDNr3sy5s+fPoEOLHk2ac2RELY6AuJu3LdgjDEAAvgv2bGCwDBw0UaG3UBMeix2ciL0WwInDS/aeWLLYyNgji88CaEFEAo8TkJ8fFqCMLj4BEkqLH0++vPnzoE8rOrGa+6DVcgMbJtK1BYMmTRi0AKHWunRBw/EggICwGZYaA0fwwEByfd2wGmM3qCBAhCigcJcARPAQGHcgSKhad5NppFZd06nGml7DyTYdEeDdJYiDINxwggrDHXcDIUtcKBcAjgGgAn98EeaYEYPZdwQA+S1hH/8IRyxBFgPcqaACi70Z4909I9Z1oiHwGfKXIC1EBiQDAPBVSIsI8kgYj0AKIFePg204G3dNIEYblNPxsBpvyVxpT5ZbnVCWA2zxpWKZAkrQ4yACgGDEcCgQcSgASxwhHAM8sEmoggIIxx2chP3ogIJhEtGEA1LKGZcDiv5nZYgZAYqVYH1xZ4QK9w3SxGqYOjfIrXIZoSCNhOzaFw/O8aWfEUTgKqGagjjWwg2xyYUCtXeFiaeC1YLokawk/uTnO+CGu9O47pRr7k3otqPuuhOJkEIAKVwgyAUZBJCBvYe0y8678D50QAEEdyBIBwUMbHC/sGIEcMALbXDBBRoUgMD/BgVMAMAEBWzA8LfuQaxRxSIEUIA/Jk+2jzz9TFQZZuGJrFEKBVgAQMo3nyzIygG0DBF4makn80QWFDCCIDTbXHQKH/8c8tAacawBPSIUoAECJDf90MNQO0Tw1/5kULEGGeTUsEJcd82Sv+SkrbY5GdQDwAYeg8L2OG6/TY7PFhwQyt3i5K03OAh8/bXGdp+dz8uXxTw4OxQcwIEGBxwwAQV/K/5deJgJ/bg6cZcCuDaCf14OBRNUfoDNiRtUuunjVPy1360X9Drs4WQsuuZYPo17OxOwPsro2dz+uzcjcKC68J4Qj43xx3Mz8OyZu+579C05fw302GdzQd+o1/2J//axMI7eZo53rw7HFo+A+Pi8LwP0+aapv04BKRwQD+3wU8O9/QnpmP4sV71p/A+ABUne5ApQttpJ44AIDMgFOMYB5jUvfsqAYAT/sQF/lAxzDoyGBjeIj6kJgoAhhMYISWgPiwmiZwV84PVYiBENjGBiHThaCp+xQhq2w2Rfk1v/DDhDH1IkA5YT3xBlaMSOZKCBw8NgMnrYxHSkbnf+K2IVFyI2BHgRhEsUoRa3mJDpEYx/F8wiGSuSr3lAMY1EXGNFLoAAOvIrjCocoxwDkgGCIaADFnyJFJFBxT2KQwMduBoMN8EznzHRkF5DgP76xolGDvIYhYTkN2zYgQBUMP+GYtRkxL7GARGAMo+iXAgF6GXKU/JQj6m0RwdT0ModOiOTsdRG0QjGATDCsRjmQx8sc8mOjF2MA+/7JTHm1xnPERMfHZDbIvEoDFw+cxx9Y1k/3rgJ8o3CmtcMhxmpp8xhgDOc36CAF9eJAF9285K5OCc6M+JNUchznhWpZyjuic+J6BMU/OxnVOCJi4AKFBsIGIEQy1nNYR70HhQ4ozs18c9PGPSh14gHNylK0FtcFKPQ+N4BwufKYHwUpM5gX0KT2YmKPiKYnEkfSv+BP/1Nk6GyYKZnnDnTFm5ggCwVZEEd2tOAKLBiG33nUIuKkQkW4JMljcVJmTrQpVJ1Inz/C6pSPUrUq76jZJSTRwfQ2NKOnmKqXo1G4QynM1tKtatpZQcdc/hFUbjUEWiNazTUWVe3wiKvenXGLs8Y1b/CNbDqUN7JNBDIrdoCsIhdhsUKcIEAaJWjVo0sQQQ4gbE+op2DwJe+7liIuzYCsppFhgUCgDEGNmKVCRsEwhRmtsymliAUmCgipkc7jGmMY3WzpG1vi4/KSaJwtMMZzgAgXK4SVyBkbQRyX6iz5ZbWrKZA7XOHUbTlwSO2AEgaAJamtVpoF4FMQMIAZsACQbBgButtbyFYEIH61le+AIhBBJjgXvVGwL0RwG8qPPCAT4wzuoegAM2ieYGqXS1rhjAt/yPOC8AEWDgBBQZAEjCcgCQYIgIXtvB/AcCCDWd4BS8QQgL4O4AXOOIBCegEfGUxznqIzWpJvRl2S0HhmERgAEAOspCHTOQiG3nIIzbEDPJrYQDgIAErAMAKEoCD+dZ3BhaOgSA8YOEMJ2AAAPhyDGhQ5UOwgMAPGEAEXvDl/0ZgBQ/wQHvhi4MVrIC/ToYzEtyLZjDPGABIeECctewLl8JUMzLF3gDSfORGO/rISf4wl8E8gC8DoNJgPoSKhSAIEFc6wzSQcwKQIIQH4EDQZR7EC2gwAA+8YAY0wPAMnrwCLkcZxi/YsItpzWUPAGDVrXYxjAGgYg8MIAmR3oVLdf9aP/sBWRYzgLGvMX3pNl840zHIMolf4AEQZ9gDNEgCDUD8ZA9wWcA0oIEQBqDlYUv5yy2Osbs3/O72ihsA6V53u2M85RWoGRjLPqyiMy0LGEcACQnwNZeRQN/6EnrTnQ4xhgWhXxaUGsT1TUCkmYDiBNAgBu6GsZABEHJ5x5jkMeY4mz8+bItvmMqYCN3clFhWVfQYKc9+RQSS0OosZ/sFa04AoQkBYqED+OAdxnPEmZDtGWB56CSfQQRgzAQY4yC9UI4ADjhdckB/mdZRn/qKhy0EJERg4ZjgG4Ixm4qbHyXnrojBy19Q5hmw+dWHkPaHJ06IB3AaAOBOeCGmnAD/vOMg1nuON5RRLgh3B34F7SU83oc9gFiH+hJrNdxlMxFwOcIdKpGbXOUuV9h9Cjx6n5+KzKNo89MfL/VQucC85JFjzu/YEm4nCuyfcuDSY+LQiW7i7plSgGj2lZqcYLZaeOrD4S+lk1g0fS6djxQLTI32vr9E7qdC/aP03q+Z2D5Uuk8Uvh4fp4w4NKJdj0DyD0WkJAV/IpS/GeZ7nuBUUan7sn8I8YvM/UBRU/vDf4bgfxADgD8hQJK0eZhgFQaoDT/2aBI4gRRYgRKYZltxVK4lf4jwgNmwaBYYgiI4go2WbLFHQY3lWJDggdiAgExFWnaFXSx4DS5YVAfQAfvC/3qSMIPWUIM9NVgKRYBnwn4T4YM9dQE/BV7IN2FECBFGiFIUYH0Eo0NLuAg8WA1PCFIDw1i6pYKPcIWUEIEkOIYhiIHPlQI0x4H914S+AIJk+IYUaILbxX/BFHzQkIVziAomM142Y1xqyGz21wx4mIcqUQAAYFx+WIWEAIaZMIiESAp7iIhrRwnNZYVsOAyO+Ih2xVZKmAmVqAiMiAmZqDYYQAAEEASD4AJOcIqpaIouIAgugAGsIAMVQAKnAESGM4kNOEiheAmjKDIuIAMAgAENUIwNQAAA4AIf8AE90AA+IAgfUAEV8AGCUAFA4AgNUAGc4AIEIIvP4BO9+GEUaP+GLVGKpniO6JiO6riO7KiO3pgIGAAEx5iMskgC2QgAPtAATgAAH9AASkCMGACQQfABr3gIQVAD1ogB9lgCBPCKJCCN+wgABEACTmCNSgAASuAD1iiMACADQFABNUAC3CiLGSmNyNgnvHiJsuCGEiiHJEEAFdCOMjmTM/mOhaAEJFACDQAENkkCNfABqFgBDSCLQokBMtAAQRAEDSADDAmTNcCRgmCPNUAAU5mP0SgD+egDNaCPAFCMPaCT19gDH0AAYukCLtAAPUAAQFADxIiMJTCWPlAC3sKEzPCLHmGKstCPPlCQhOADYmmLRQkAgfmVJdADJPAB9viQPUAIToD/lhMpCPfIj015j/eoBNl4lM+olE5wlCXgA07wj/O4jEDQkHNpiXWJf0eBl7FAAG8JBHxJCMUIAFuJis3IkTIgi5MpkQ1QCDBZjM8YmQ3QlI8JnBXQlsM4j0EwjWhpnDJQAzpJkCh5WioZC3bZEaopCw+ZjbJIlVQZnAAglUopl4TAmjjZAC4ABOIpCE7gAwrZADXQlSWAAS6wld1IAshInJKJAVt5m0AQBBiwjMZZixgglFD5KtJ5mk9xnbNwnvsYBDp5mYLgA/3YAwWqBIiJkVt5oYPgoMVYAxdJAMUoA0oABP04ll2pjSfakc1YArboAs2Ilrc5j1sZnLYYnYQA/3zTmQpiGGTkiBQKSkMXQX+BuAssGWQu+RM/ykJBmqOwUJ0nkaQktKSCiJpTAaUbJKUIuhVWGkFYugxO+pInaURdOgw4QGQ9ShVbikBjGgzlRmRHGgrmSJNyOqd0Wqd2eqd4GpNVtKbA0GqyAJN4GqiCOqiEKqg2CaQNE4pfOglpqonDwKe/4KerGaaOaqOMwqREB4dHBmNLBguNWqkAl6iYOghFqqlEZghxWqh0qqegaql7MaqCsKiKAKiqWqeH2qobIaqiIKuJ8Km4eg6Qugm8igi++qvlEKyaIKupio6saqzvgKyDsKMWeKacQKvu6Kz2AK2xymgi+KaXUKzYqv8O2nppVEoKy7qOzRquWaGrizCsh2Ct7Xir6pqt7KoI7moI4Dqv+XARUlAFj0atpJCv+koOXrQI/Oqvj+atgnCug5quA9sOFMABvNSFOjaEmwCvhSqvD2tFHeNbiTCujyCwG6sQBCMIJVtbi6iSIjuyBnGyJzsI89Az/RCzURAFMXuzOJuzN2sFVqCzPvuzQBu0Qju0RFu0Rnu0SJu0Sru0TGu0C9USLmuIhBCzlXOzUzAFTTsPVEAFOFu1WUu0Xvu1Qhu2Ygu0ZFu2Onu2aJuzaru2XXt7EAFcHouyegi3k1BReGu3kZC3qiBh5xCxE/uxeksTgwsJfFu3iJu4iiv/EwWrCC51uLdYuI/wT5AbuVDxuJLrCJUbfSqRuY2AuVDRuKgguqZAuqVguqSAuqKguqv7tKfruiwbu7I7u7SLFasUABR7DCJQR4Nwu7UnDKIVALUEAHQEu8SgYKMVWm0EQBijARWThseAhAgjRIaTgsKAi6U0CCPwssiQi4IAuAegAQCEMLlVfM2QeUJUNhEltciAAKbEMZPRWuyLDGVTNVJbMbmLO1H7DAPztA7WDNtbNhfAAUDEDAhQNP4QUc6rO/azv87Qv4UAXMwQUQvTWQDAvfQ7MDZTONGEML/7ORI7MU/Fvy50LwPzwcGQARzQAfzCic3QvxHlN9aFPdsr/w9G0wxzhT+YIwKzJQ/DWww0U0H6wlxe5EfJ8EcBsEum9LzTaz9OlTEw2L7em3lGjAzfZ7Lzaww8TDAaUDcUgDAcgMK1O8ZkXMZmfMZonMZqvMZs3MZu/MZwbERexC/q9MOOEDliHMcTQTBMY7/wZDL1UDieq8fvwMXjRTCTkT8TUDf6kj83JAIDMwJxUzPZ9L0jYDl5TMj5YDUds0D+UDQWIMEFUzEjQAEVA0hrJTkMVDWdtH+aDBEJMwEcQMA6s8LEqzuxdQGxBcjMpTMYg7tWYwH18sqwfAAYs1o6A16xpcwy7EKC3Mv+8FMSuzDEvBCxVUc4A1wmwzTMnDMBUP/E/iDICbUBCDDL1ew1/IMzTgVV3SwCFTMBzyzIW1x8+XvO9nzP+JzP+rzP/NzP/vzPAB3QAj3QBF3QBq3HNqAACq0AOSAIIfAECwADg/DQEQ0MCm0Dg5DQITAICrAAFe0LOeDROzDRED3SGa0AG10MGk0IK00IF41ACmAAMm0AEAAAIWACJvADBlAENo3TOs3TvbADMq0AgqAAOmAAC1DUM43UvrDUPJ0DPk3TRX3USU0MRs3UU43VgiDUBkDUARMCEV0EEFDVJ73QCl0IMf0DCt3QRWAATwAAJmAANtDWbx3XGD0KYA0DYk3WgpDQZu3VhHDTQy0IM13VIUDUQl3/06WQ13tdCH5t1oYw0jkg0wCwADsNAJSN2TLN16nA2GPt2H8N2INQ2KO92RMd110NMTFN03Ft0kq91AaA1gZgAhAwBBsNAamN2wqg2wDA26Ow2hDQ2i4N27FdCBBw3KktCJbN1zugAyYg0aUA3MLN0cSNCCFgAFAAAFBtAEft2svdCtJtAK4NAKu91Ifw3YOA3r2N3KJtLjGd1DCg1Y2QA0OwALj9A72d213N274tCu8NAPHN2YvwBCYQAv2t3gBQBD9gAuPt30wd4JNw1BIdAj8ABXE9BOkt36nw3xAeCQiO3gRu4MkNL//934OQA8ed4op9CJQt4QCg0zng4jBO/wolLt8oruIrLgi4vdRejeCEXdw0ztQmLgg3ruKGYAO4bdJHrQA2AAXJ7eOoUON8XeQpft7yjd47PtPtTSJSHtge/eWcvQA6YN9SLdQ6EN/ZbeZoHt1CLt9gDeacnQMKrdNPgNEKMAQGMARELeZijt2m0OUTDeecTeE07dEhgOdDAANxvdF3nudb/udtztdvDuaG0Oh6XtSITtRyrgB0ftfrAuiOAANOzt13XQRx/QMNneCnnuq/HemT4NuwDeCjDgGs3upJPeSNUN5DbQNHbQA/AN2xvgqg7gjBHuw6PuIHnezKvuzM3uzO/uzQHu3SPu3UXu3Wfu3Ynu3avu3cLgMzgQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of ischemic events in 500 patients with asymptomatic carotid artery bruits according to the severity of carotid artery stenosis on initial Doppler ultrasonography. Patients with &ge;75 percent stenosis were at significantly increased risk (P &lt;0.0001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. N Engl J Med 1986; 315:860.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39197=[""].join("\n");
var outline_f38_17_39197=null;
var title_f38_17_39198="Contents: Gram positive cocci";
var content_f38_17_39198=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gram positive cocci",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gram positive cocci",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Enterococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/35/36406\">",
"           Epidemiology and pathogenesis of and risk factors for surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/4/27721\">",
"           Epidemiology, prevention and control of vancomycin-resistant enterococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/56/26506\">",
"           Mechanisms of antibiotic resistance in enterococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/48/20229\">",
"           Microbiology of enterococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/62/14314\">",
"           Treatment of enterococcal infections",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Group A Streptococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/20/23879\">",
"           Clinical manifestations and diagnosis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/8/8327\">",
"           Epidemiology and pathogenesis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/29/6616\">",
"           Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/35/42551\">",
"           Group A streptococcal (Streptococcus pyogenes) bacteremia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/14/41193\">",
"           Group A streptococcus: Virulence factors and pathogenic mechanisms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/2/44070\">",
"           Treatment and prevention of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/20/8519\">",
"           Treatment of streptococcal toxic shock syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Group B Streptococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/57/19354\">",
"           Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/3/43062\">",
"           Group B streptococcal infection in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/4/36936\">",
"           Group B streptococcal infections in nonpregnant adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/25/9621\">",
"           Group B streptococcus: Virulence factors and pathogenic mechanisms",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other Streptococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/33/22041\">",
"           Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/28/27080\">",
"           Group C and group G streptococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/41/34456\">",
"           Infections due to the Streptococcus anginosus group",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/14/29926\">",
"           Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pneumococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/36/38473\">",
"           Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/26/26026\">",
"           Diagnostic approach to community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/49/31514\">",
"           Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/37/601\">",
"           Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/29/7642\">",
"           Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/38/23143\">",
"           Microbiology and pathogenesis of Streptococcus pneumoniae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/4/13386\">",
"           Pneumococcal pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/5/81\">",
"           Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/18/3369\">",
"           Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/15/19704\">",
"           Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/24/24969\">",
"           Treatment of community-acquired pneumonia in adults in the outpatient setting",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Staphylococcus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/37/33365\">",
"           Botryomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/53/8026\">",
"           Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/13/15575\">",
"           Microbiology of methicillin-resistant Staphylococcus aureus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/28/9672\">",
"           Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/59/17338\">",
"           Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/58/31654\">",
"           Rapid detection of methicillin-resistant Staphylococcus aureus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/52/8010\">",
"           Staphylococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/3/12344\">",
"           Staphylococcus lugdunensis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/16/23815\">",
"           Treatment of infections due to coagulase-negative staphylococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/48/21258\">",
"           Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/7/4216\">",
"           Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/2/16425\">",
"           Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/51/40758\">",
"           Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-A5751E2720-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f38_17_39198=[""].join("\n");
var outline_f38_17_39198=null;
var title_f38_17_39199="Tonsillar hypertrophy OSA";
var content_f38_17_39199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tonsillar hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tonsillar hypertrophy in a child with obstructive sleep apnea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_17_39199=[""].join("\n");
var outline_f38_17_39199=null;
